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A B S T R A C T
Background
Mosquitoes become infected with Plasmodiumwhen they ingest gametocyte-stage parasites from an infected person’s blood. Plasmodium
falciparum gametocytes are sensitive to the drug primaquine (PQ) and other 8-aminoquinolines (8AQ); these drugs could prevent
parasite transmission from infected people to mosquitoes, and consequently reduce the incidence of malaria. However, PQ will not
directly benefit the individual, and could be harmful to those with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
In 2010, The World Health Organization (WHO) recommended a single dose of PQ at 0.75 mg/kg, alongside treatment for P.
falciparum malaria to reduce transmission in areas approaching malaria elimination. In 2013 the WHO revised this to 0.25 mg/kg due
to concerns about safety.
Objectives
To assess whether giving PQ or an alternative 8AQ alongside treatment for P. falciparum malaria reduces malaria transmission, and to
estimate the frequency of severe or haematological adverse events when PQ is given for this purpose.
Search methods
We searched the following databases up to 10 Feb 2014 for trials: the Cochrane Infectious Diseases Group Specialized Register; the
Cochrane Central Register of Controlled Trials (CENTRAL), published in The Cochrane Library; MEDLINE; EMBASE; LILACS;
metaRegister of Controlled Trials (mRCT); and the WHO trials search portal using ’malaria*’, ’falciparum’, and ’primaquine’ as
search terms. In addition, we searched conference proceedings and reference lists of included studies, and contacted researchers and
organizations.
Selection criteria
Randomized controlled trials (RCTs) or quasi-RCTs comparing PQ (or alternative 8AQ) given as a single dose or short course alongside
treatment for P. falciparum malaria with malaria treatment given without PQ/8AQ in adults or children.
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Data collection and analysis
Two authors independently screened all abstracts, applied inclusion criteria, and extracted data. We sought evidence of an impact
on transmission (community incidence), infectiousness (mosquitoes infected from humans) and potential infectiousness (gametocyte
measures). We calculated the area under the curve (AUC) for gametocyte density over time for comparisons for which data were
available. We sought data on haematological and other adverse effects, as well as secondary outcomes of asexual clearance time and
recrudescence. We stratified by whether the malaria treatment regimen included an artemisinin derivative or not; by PQ dose category
(low < 0.4 mg/kg; medium ≥ 0.4 to < 0.6 mg/kg; high ≥ 0.6 mg/kg); and by PQ schedules. We used the GRADE approach to assess
evidence quality.
Main results
We included 17 RCTs and one quasi-RCT. Eight studies tested for G6PD status: six then excluded participants with G6PD deficiency,
one included only those with G6PD deficiency, and one included all irrespective of status. The remaining ten trials either did not
report on whether they tested (8), or reported that they did not test (2). Nine trials included study arms with artemisinin-based malaria
treatment regimens, and eleven included study arms with non-artemisinin-based treatments.
Only two trials evaluated PQ given at low doses (0.25 mg/kg in one and 0.1 mg/kg in the other).
PQ with artemisinin-based treatments: No trials evaluated effects on malaria transmission directly (incidence, prevalence, or ento-
mological inoculation rate), and none evaluated infectiousness to mosquitoes. For potential infectiousness, the proportion of people
with detectable gametocytaemia on day eight was reduced by around two thirds with high dose PQ category (RR 0.29, 95% CI 0.22
to 0.37, seven trials, 1380 participants, high quality evidence), and with medium dose PQ category (RR 0.34, 95% CI 0.19 to 0.59,
two trials, 269 participants, high quality evidence), but the trial evaluating low dose PQ category (0.1 mg/kg) did not demonstrate
an effect (RR 0.67, 95% CI 0.44 to 1.02, one trial, 223 participants, low quality evidence). Reductions in log(10)AUC estimates for
gametocytaemia on days 1 to 43 with medium and high doses ranged from 24.3% to 87.5%. For haemolysis, one trial reported percent
change in mean haemoglobin against baseline, and did not detect a difference between the two arms (very low quality evidence).
PQ with non-artemisinin treatments: No trials assessed effects on malaria transmission directly. Two small trials from the same
laboratory evaluated infectiousness to mosquitoes, and report that infectivity was eliminated on day 8 in 15/15 patients receiving high
dose PQ compared to 1/15 in the control group (low quality evidence). For potential infectiousness, the proportion of people with
detectable gametocytaemia on day 8 was reduced by around half with high dose PQ category (RR 0.44, 95% CI 0.27 to 0.70, three
trials, 206 participants, high quality evidence), and by around a third with medium dose category (RR 0.62, 0.50 to 0.76, two trials, 283
participants, high quality evidence), but the single trial using low dose PQ category did not demonstrate a difference between groups
(one trial, 59 participants, very low quality evidence). Reduction in log(10)AUC for gametocytaemia days 1 to 43 were 24.3% and
27.1% for two arms in one trial giving medium dose PQ. No trials systematically sought evidence of haemolysis.
Two trials evaluated the 8AQ bulaquine, and suggest the effects may be greater than PQ, but the small number of participants (n =
112) preclude a definite conclusion.
Authors’ conclusions
In individual patients, PQ added to malaria treatments reduces gametocyte prevalence when given in doses greater than 0.4 mg/kg.
Whether this translates into preventing people transmitting malaria to mosquitoes has rarely been tested in controlled trials, but there
appeared to be a strong reduction in infectiousness in the two small studies that evaluated this. No included trials evaluated whether
this policy has an impact on community malaria transmission either in low-endemic settings approaching elimination, or in highly-
endemic settings where many people are infected but have no symptoms and are unlikely to be treated.
For the currently recommended low dose regimen, there is little direct evidence to be confident that the effect of reduction in gametocyte
prevalence is preserved.
Most trials excluded people with G6PD deficiency, and thus there is little reliable evidence from controlled trials of the safety of PQ
in single dose or short course.
P L A I N L A N G U A G E S U M M A R Y
A single dose of primaquine added to malaria treatment to prevent malaria transmission
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We conducted a review of the effects of adding a single dose (or short course) of primaquine to malaria treatment with the aim of
reducing the transmission of malaria. We included 17 randomized controlled trials and one quasi-randomized controlled trial.
What is primaquine and how might it reduce transmission
Primaquine is an antimalarial drug which does not cure malaria illness, but is known to kill the gametocyte stage of the malaria parasite
which infects mosquitoes when they bite humans. Primaquine is also known to have potentially serious side effects in people with
an enzyme deficiency common in many malaria endemic settings (glucose-6-phosphate dehydrogenase (G6PD) deficiency). In these
people, high doses of primaquine given over several days sometimes destroys red blood cells, causing anaemia and, in some cases,
possibly life-threatening effects.
The World Health Organization (WHO) recommends adding a single dose of primaquine to malaria treatment with the intention of
reducing malaria transmission and to contribute to malaria elimination. This recommendation was made in 2010, but in 2013 the
WHO amended its recommendation from a dose of 0.75 mg/kg to 0.25 mg/kg due to concerns about safety, and indirect evidence
suggesting this was as effective as the higher dose.This review examines the evidence of benefits and harms of using primaquine in this
way, and looks for evidence that primaquine will reduce malaria transmission in communities.
What the research says
We did not find any studies that tested whether primaquine added tomalaria treatment reduces the community transmission of malaria.
When added to current treatments for malaria (artemisinin-based combination therapy), we found no studies evaluating the effects of
primaquine on the number of mosquitoes infected. However, primaquine does reduce the duration of infectiousness (the period that
gametocytes are detected circulating in the blood) when given at doses of 0.4 mg/kg or above (high quality evidence). We only found one
study using 0.1 mg/kg but this study did not conclusively show that primaquine was still effective at this dose (low quality evidence).
When added to older treatments for malaria, two studies showed that primaquine at doses of 0.75 mg/kg reduced the number of
mosquitoes infected after biting humans (low quality evidence). Doses above 0.4 mg/kg reduced the duration of detectable gametocytes
(high quality evidence), but in a single study of the currently recommended 0.25 mg/kg no effect was demonstrated (very low quality
evidence).
Some studies excluded patients with G6PD deficiency, some included them, and some did not comment. Overall the safety of PQ
given as a single dose was poorly evaluated across all studies, so these data do not demonstrate whether the drug is safe or potentially
harmful at this dosing level.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
PQ for reducing P. falciparum transmission with artemisinin-based treatments
Patient or population: People with symptomatic malaria
Settings: Malaria-endemic areas
Intervention: Single dose or short course PQ plus malaria treatment including an artemisinin derivative
Control: Malaria treatment including an artemisinin derivative, without PQ
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control PQ
Malaria incidence, preva-
lence or EIR
- - - 0 trials -
People infectious to
mosquitoes
- - - 0 trials -
Participants with gameto-
cytes on microscopy or PCR
1
(day 8)
Dose <0.4 mg/kg RR 0.67
(0.44 to 1.02)
223
(1 trial)
⊕⊕©© 2,3,4
low
34 per 100 23 per 100
(15 to 35)
Dose 0.4 to 0.6 mg/kg RR 0.34
(0.19 to 0.59)
269
(2 trials)
⊕⊕⊕© 4,5,6
high
32 per 100 11 per 100
(6 to 19)
Dose >0.6 mg/kg RR 0.29
(0.22 to 0.37)
1380
(7 trials7)
⊕⊕⊕©
high 8,9
30 per 100 9 per 100
(7 to 11)
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Mean percent change in hae-
moglobin10
The mean percent drop in Hb
from baseline in the control
group was
15%
The mean percent drop in Hb
from baseline in the interven-
tion groups was 3% lower
(from 10% lower to 4% higher)
101
(1 trials)
⊕©©©
very low 10,11
*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk
in the comparison group and the relative effect of the intervention (and its 95% CI).
PQ: Primaquine; CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 AUC estimates (log(10)AUC for day 1 to 43) are included as footnotes for each dosing strata.
2 No serious risk of bias: Includes one trial with no risk of bias detected.
3 Downgraded by 2 for very serious imprecision: One small trial with CIs that include 50% reduction and no effect.
4 There was no log(10)AUC day 1 to 43 % reduction data for this dose.
Not downgraded on imprecision. Although one trial has few events, effect size is consistent with the second trial.
6 Log(10)AUC day 1 to 43 % reduction: 24.3% and 27.1% (one trial, two comparisons).
7 Includes seven trials, with 11 comparisons: one trial included five separate comparisons with AS-AQ, DHAP, AS-MQ, and AL (Smithuis
2010).
8 No serious inconsistency: whilst there is marked quantitative heterogeneity, the studies with no demonstrable effect had few events.
Not downgraded.
9 Log(10)AUC day 1 to 43 % reduction: range from 21.1% to 87.5%. We included four trials with 12 comparisons. We excluded one trial
as high risk of bias (Vasquez 2009) due to small sample size and large difference in baseline gametocyte count in the two groups.
10 Shekalaghe 2007 reported relative decrease in haemoglobin against baseline in both groups at day 8, 15, 29 and 43 in all participants
irrespective of G6PD status. The comparison between those receiving PQ and those not did not demonstrate a difference at any time
point. We presented day 43 in this table.
11 Downgraded by 2 for very serious indirectness: the percentage of people with large drops in haemoglobin, not the mean change in
the population, is the important safety outcome; and the estimates are averages in a small population (N = 99) that includes people with
normal G6PD function so unlikely to detect effects in a small subgroup with a relatively uncommon adverse event.
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B A C K G R O U N D
Malaria is a febrile illness due to infection with the plasmodium
parasite, and is transmitted between humans via mosquitoes. Of
the five plasmodium species known to cause illness in humans, P.
falciparum is the most common, especially in sub-Saharan Africa,
and causes themajority of severe illness and deaths. The clinical ill-
ness develops due to the presence of asexual stage parasites (sporo-
zoites) in the persons bloodstream, but transmission tomosquitoes
is via the sexual stage parasites (gametocytes), which develop from
sporozoites at some point after infection.
Artemisinin-based combination therapies (ACTs) are currently
recommended worldwide as the primary treatment for symp-
tomatic P. falciparum malaria (WHO 2010). The artemisinin-
derivatives treat the clinical illness by rapidly reducing the num-
ber of circulating sporozoites, which also reduces the potential for
sporozoites to develop into gametocytes for onward transmission.
The artemisinin-derivatives have been shown to kill early devel-
oping gametocytes, but they have no direct effects on mature ga-
metocytes (Price 1996; Chotivanich 2006; Okell 2008a; Okell
2008b). The partner drugs in ACTs (mefloquine, amodiaquine,
piperaquine, lumefantrine and sulfadoxine-pyrimethamine) are
schizonticides with variable effects on gametocytes, and none ade-
quately targetsmature gametocytes (Drakeley 2006; Barnes 2008).
In untreated infection, gametocytes can remain present formonths
as successive new generations are produced, and even follow-
ing treatment they may persist for several weeks (Smalley 1977;
Eichner 2001; Bousema 2010).
The mean circulation time of a mature P. falciparum gametocyte
in humans has been estimated by microscopy or polymerase chain
reaction (PCR) to be between 3.4 to 6.5 days (Smalley 1977;
Eichner 2001; Bousema 2010). The minimum number of game-
tocytes required for transmission from an infected person to a
mosquito has been estimated to be in the range of 100 to 300 per
µL blood (Carter 1988), and the percentage of bites on humans
that result in mosquito infection ranges between 0.3% and 46%,
although most estimates are in the range of 1% to 10% (Graves
1988; Killeen 2006; Churcher 2013).
After uptake of a P. falciparum-infected blood-meal by the
mosquito, gametocytes mature into male and female gametes.
When fertilized, diploid oocysts develop on the mosquito’s stom-
ach wall and subsequently mature into sporozoites that migrate
to the salivary glands, ready to be released when biting the
next human. The median number of oocysts formed in wild
caught infected mosquitoes is two to three (Rosenberg 2008).
Each oocyst develops thousands of sporozoites, but only about
20% are thought to reach the mosquito salivary glands, and fewer
than 25 sporozoites on average are ejected during mosquito blood-
feeding (Rosenberg 1990; Rosenberg 2008).
Description of the intervention
Primaquine (PQ) is the only drug in common use which is
known to kill mature P. falciparum gametocytes (Burgess 1961;
Pukrittayakamee 2004; Chotivanich 2006), and with the recent
emphasis on malaria elimination, there has been a renewed inter-
est and emerging literature on PQ’s potential value in reducing
malaria transmission (White 2012; WHO 2012b; White 2013).
PQ is an 8-aminoquinolone whose pharmacokinetic mode of ac-
tion is not well understood, but it is known to be rapidly metab-
olized, with a half-life of six hours (White 1992). PQ does not
directly affect the asexual stages of P. falciparum which cause the
clinical illness (Arnold 1955; Pukrittayakamee 2004), and does
not appear to affect the early or maturing gametocytes (Bhasin
1984; White 2008). Consequently, a combination of PQ and an
artemisinin-derivative (as part of ACT) would target all stages of
the gametocyte and have the greatest potential for reducing on-
ward transmission to mosquitoes (White 2013; WHO 2012b).
One of the constraints to widespread use of PQ is that the drug
is known to cause haemolysis in people with glucose-6-phosphate
dehydrogenase (G6PD) deficiency. The deficiency is X-linked and
expression highly variable with a wide variety of variants and levels
of G6PD deficit (Howes 2013). PQ is a haemolytic trigger, and
can cause a haemolytic anaemia that occasionally is serious with
haemoglobinaemia and renal failure. The effect depends on the
degree of enzyme deficiency, the dose of PQ, and the pattern of
the exposure. These occasional, but clearly serious, adverse effects
have led to a reputation of being “unsafe” although little is known
about haemolysis at low doses of PQ.
The WHO 2010 Guidelines for the Treatment of Malaria recom-
mended adding a single dose of PQ at 0.75 mg/kg to treatment for
uncomplicated P. falciparum malaria in people who are not G6PD
deficient with the goal of reducing transmission at the community
level (WHO 2010). However, since testing for G6PD deficiency
was rarely done, and due to the concerns about the safety of this
single dose, the WHO convened a special expert review group in
2012 to reconsider this recommendation (WHO 2012a). The ex-
pert group concluded that 1) G6PD testing should be done more
widely; 2) Countries already implementing single dose PQ should
reduce the dose to 0.25 mg/kg in G6PD deficient patients; and 3)
Countries not currently implementing single dose PQ but which
are targeting malaria elimination, or are threatened by artemisinin
resistance, should add 0.25 mg/kg PQ to treatment for uncom-
plicated P. falciparum malaria (White 2012; WHO 2012b).
How the intervention might work
A single dose of PQ could contribute to reducing malaria trans-
mission through its effects on mature gametocytes, and it is rea-
sonable to assume that reducing the density and duration of ga-
metocytes in the blood of infected patients will reduce the dura-
tion of potential infectiousness to mosquitoes at the level of the
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individual (see Figure 1). However, any subsequent effects on the
number of mosquitoes infected (infectiousness), or the number of
new malaria infections in the community (transmission) are im-
possible to predict without measuring these effects using reliable
methods.
Figure 1. Review logic framework: The potential points in the Plasmodium parasite life cycle that could be
impacted by primaquine and the outcomes used to measure impact
Infectiousness to mosquitoes can be measured directly by allowing
mosquitoes to feed on infected individuals who have been treated
with and without PQ (Killeen 2006; Bousema 2012), or esti-
mated indirectly by measuring the infection rates of wild-caught
mosquitoes (Graves 1990; Lines 1991).
Community level transmission can be measured through large
cluster-randomized trials, or less reliably through controlled be-
fore and after studies. Within any community there are people
who are carriers of P. falciparum gametocytes but who do not seek
treatment (Bousema 2011). This is most apparent in areas of high
endemicity, where much of the adult population has acquired im-
munity, and low level parasitemias do not produce symptoms.
This reservoir of gametocytes in untreated adults will continue to
facilitate community level transmission and may dilute any pos-
sible effect of PQ. Indeed, these dilutional effects may even be
important in low transmission settings.
Recently, with the move toward a target of elimination, some pol-
icy makers are considering mass treatment strategies (von Seidlein
2003; Sturrock 2013) to reduce transmission or contain outbreaks
once transmission is reduced to low levels. In this instance, it seems
more likely that a higher proportion of the population with game-
tocytes will be detected or treated, or both, and that this could be
effective in reducing or interrupting transmission. This policy is
being considered in countrieswith lower intensity transmission, on
islands or at the northern and southern fringes of malaria distribu-
tion, or both (GMAP 2008; Mendis 2009). Effective antimalarial
drugs are likely to play a large role in this new strategy. One ques-
tion in this effort is whether there is a role for PQ given in addition
to curative antimalarial drugs, including artemisinin combination
therapies (ACTs), to further reduce the infection transmissibility
(White 2008).
The transmission blocking potential of PQhas also been suggested
as a strategy to reduce the spread of artemisinin resistant parasites
in Southeast Asia (Breman 2012).
Why it is important to do this review
PQ could play a role in the next phase of P. falciparum malaria
control, particularly malaria elimination and possibly eradication.
Whether elimination or eradication can be accomplished, or at
the very least, the efficiency with which PQ is deployed, depends
on getting the details right on dose, timing and the situation in
which it is used. Best use must be made of existing data and op-
portunities for filling in missing information (and not duplicating
what already is known) should be created and moved on quickly.
This review is intended to clarify what is and is not known, and
to identify which missing pieces are critical to defining effective
uses of PQ.
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O B J E C T I V E S
1. To assess whether giving PQ or other 8AQ in addition to treat-
ment for P. falciparum infection reduces:
• malaria transmission intensity;
• infectiousness of infected people to mosquitoes;
• potential infectiousness (gametocyte prevalence and density
over time).
2. To compare the effects of different 8AQs.
3. To determine whether the effects of PQ or other 8AQ differ if
the primary treatment drug is artemisinin based or another anti-
malarial.
4. To estimate the frequency of severe or haematological adverse
events associated with single dose or short course PQ when it has
been used for this purpose.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) or quasi-RCTs including in-
dividual- or cluster-RCTs. Cluster-RCTs must have had at least
two clusters per arm.
Types of participants
Adults or children with P. falciparum infection or a mixed infec-
tion of P. falciparum and other Plasmodium species. For individ-
ual RCTs, eligible studies must have diagnosed patients by blood
slide, rapid diagnostic test, or other valid molecular method; for
cluster-RCTs, diagnosis could have been by clinical judgment if
that was standard in the trial area at the time of the trial.
Types of interventions
Intervention
A single dose or short course (up to seven days) of PQ or other 8-
aminoquinoline (8AQ) added to malaria treatment(s).
Control
Identical treatment for malaria not including PQ/8AQ (or substi-
tuting placebo for PQ/8AQ); or using a different 8AQ with same
malaria treatment, or using different dose of PQ/8AQ with same
malaria treatment(s).
Types of outcome measures
Primary outcomes
Figure 1 provides an outline of transmission of malaria that helps
clarify these terms.
a) Transmission
• Entomological inoculation rate
• Malaria incidence
• Malaria prevalence
b) Infectiousness
• People who infect mosquitoes
• Mosquitoes infected by direct feeding
c) Potential infectiousness
• AUC of gametocyte density (y-axis) over time (x-axis)
• Gametocyte prevalence (estimated by microscopy or PCR)
• Gametocyte density (estimated by microscopy or PCR)
• Gametocyte clearance time (duration of gametocyte
carriage)
Adverse events
• Serious adverse events leading to hospital admission or
death
• Haematologic effects
◦ Haemolysis (higher prevalence)
◦ Haemoglobin concentration (decline)
◦ Packed cell volume (decline)
Secondary outcomes
• Presence of asexual stage parasites (may be reported as
treatment failure rate)
• Asexual parasite clearance time (duration of asexual
carriage)
Search methods for identification of studies
We attempted to identify all relevant trials, regardless of language
or publication status (published, unpublished, in press, and in
progress).
The search strategy is in Appendix 1.
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Electronic searches
Databases
We searched the following databases up to 10 February 2014
using the search terms and strategy described in Appendix 1:
the Cochrane Infectious Diseases Group Specialized Register; the
Cochrane Central Register of Controlled Trials (CENTRAL),
published in The Cochrane Library (Issue 2 2014); MEDLINE
(1966 to 10 Feb 2014); EMBASE (1980 to 10 Feb 2014) ; and
LILACS (1982 to10Feb2014). Also, we checked themetaRegister
of Controlled Trials (mRCT) and the WHO trials search portal
(both accessed 10 Feb 2014) using ’malaria*’, ’falciparum’, and
’Primaquine’ as search terms.
Conference proceedings
We searched the following conference proceedings for relevant ab-
stracts: theMIM Pan-African Malaria Conferences and the Amer-
ican Society of Tropical Medicine and Hygiene (ASTMH) to De-
cember 2009.
Searching other resources
Researchers and organizations
We contacted researchers at the London School of Hygiene and
Tropical Medicine who were authors of some of the included and
in-progress trials, and other experts in the field of malaria chemo-
therapy, including those based at WHO.
Reference lists
We checked the reference lists of all studies identified by the above
methods.
Data collection and analysis
Selection of studies
Two authors (PMG and HG) independently screened all citations
and abstracts identified by the search strategy, including ongoing
studies, for potentially eligible studies. We independently assessed
full reports of potentially eligible studies for inclusion in the re-
view. Notably, we did not contact any trial authors for clarification
regarding inclusion (although we later contacted several about trial
details) because it was clear whether trials were or were not eligible
for inclusion. We used translations of eight papers published in
Chinese to assess eligibility. We resolved differences of opinion by
discussion with PG. There was one instance of duplicate reports
of the same trial in different languages.
Data extraction and management
Two authors (PMG and HG) independently extracted the follow-
ing information for each trial using a data extraction form.
Characteristics of trial
• Design (RCT or quasi-RCT, type of randomization)
• Dates and duration of trial
Characteristics of participants
• Number of participants
• Age and sex of participants
• Proportion with G6PD deficiency
• Proportion with gametocytes at onset of trial
• Inclusion criteria
• Exclusion criteria
Characteristics of interventions
• Type of drug, dose, and schedule
Presented outcomes
• Description of outcomes presented in the papers
Other
• Location of trial, setting, and source of funding
• Local endemicity of malaria
Outcomes data
For each trial, PMG and HG extracted data on the trial out-
comes eligible for inclusion in this review for the PQ and non-PQ
groups. We extracted the number of participants randomized and
the numbers analysed in each treatment group for each outcome.
For dichotomous data outcomes (proportion of participants with
gametocytes or asexual stages, proportion of participants infec-
tious to mosquitoes, and proportion of mosquitoes infected), we
extracted the number of participants experiencing the event of in-
terest and the total number of patients or mosquitoes in each treat-
ment arm of each trial. For continuous outcomes (AUC for game-
tocyte numbers over time), we extracted arithmetic or geometric
means and standard deviations for each treatment group by day of
assessment, together with the number of patients in each group.
We noted details on the method of determining parasite presence
and density, for example light microscopy (if so, the method of
staining and number of fields examined), PCR or other methods.
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For G6PD deficiency, we noted the sex of the carrier (if stated) and
the method used to determine G6PD deficiency, either phenotyp-
ically (by enzyme function) or PCR (by genotype). We adopted
the definition of ’deficient’ used in the trials that assessed this out-
come. We extracted adverse event data for each individual type
of event wherever possible. Where adverse events were reported
separately for more than one dose (for short-course regimens),
we attempted to record the average number of people reporting
each adverse event for each dose. If trials reported the occurrence
of adverse events at more than one time point following a single
dose, but did not record the total number of people reporting each
event, we attempted to record the events occurring in the first time
period.
In cases of disagreement, we double checked the data and we
reached consensus through discussion between all three authors.
Assessment of risk of bias in included studies
PMG and HG independently assessed the risk of bias of the in-
cluded trials as recommended in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). For each included
trial, we assigned a score of low, unclear or high risk of bias for the
following components: random sequence generation, allocation
concealment, blinding of participants and personnel, blinding of
outcome assessors, incomplete outcome data, selective outcome
reporting, and other biases.
For sequence generation and allocation concealment, we described
the methods used, if given. For blinding, we described who was
blinded and the blinding method. For incomplete outcome data,
we reported the percentage andproportionof loss to follow-up (the
number of patients for whom outcomes are not measured of the
number randomized), if given. For selective outcome reporting,
we stated any discrepancies between the methods and the results
in terms of the outcomes measured and the outcomes reported;
we also stated if we knew that an outcome was measured but was
not reported in the publication. For other biases we described any
other trial features that could have affected the trial’s results (for
example, whether a trial was stopped early or if no sample size
calculation was included).We resolved any disagreements through
discussion.
We reported the results of the risk of bias assessment in a ’Risk
of bias’ table and displayed them in a ’Risk of bias’ summary and
’Risk of bias’ graph (Figure 2; Figure 3).
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
trial
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included trials
Measures of treatment effect
We analysed the data using Review Manager (RevMan). For di-
chotomous data, we estimated the Risk Ratio (RR) and used the
Mantel-Haenszel method with fixed-effect, or with random-ef-
fects if there was heterogeneity. For continuous data, we estimated
the mean difference (MD). All results are presented with 95%
confidence intervals (CIs). We reported results only for days after
the first day of PQ treatment, which, in some trials, was later than
the beginning of primary treatment.
If trials reported gametocyte outcomes for days 1, 8, 15, 29, and
43, we estimated AUC using either the summary gametocyte mea-
sures reported by group in the paper, or by calculation from indi-
vidual patient data supplied by the authors. Since few patients had
gametocytes up to day 43, we also estimated AUC only up to day
15 and day 29 for the same trials. The AUC is a weighted sum of
gametocyte densities, with weights proportional to the difference
in time between adjacent sampling points as described by Dunyo
2006 and Mendez 2006 in trials assessing gametocytaemia af-
ter sulfadoxine-pyrimethamine (SP) treatment. However,Mendez
2006 used follow-up days 4 to 22 (reported as days 3 to 21 in trial),
which do not encompass the early days of highest gametocytaemia
nor the participants who still had gametocytes after day 21.
We used the following formulas:
AUC (days 1 to 15) = ((8-1)*(G1+G8)/2)+((15-8)*(G15+G8)/2)/
14 for days 1 through 15
AUC (days 1 to 29) = ((8-1)*(G1+G8)/2)+((15-8)*(G15+G8)/
2)+((29-15)*(G29+G15)/2)/28 for days 1 through 29
AUC (days 1 to 43) = ((8-1)*(G1+G8)/2)+((15-8)*(G15+G8)/
2)+((29-15)*(G29+G15)/2)+((43-29)*(G43+G29)/2)/42 for
days 1 through 43
where Gx = mean gametocyte density on day X (estimated using
data from all participants still enrolled on day X). We estimated
log(10)AUC values using geometric mean gametocyte density.
When one trial contained more than one comparison with the
same placebo group and there was an analysis total or subtotal, we
divided the placebo group participants between the comparisons
to avoid underestimating the CI.
Unit of analysis issues
All the included trials were individually randomized and analysed.
No cluster-RCTs met the inclusion criteria for the review.
Dealing with missing data
Where data weremissing from the trials or details were unclear, we
attempted to contact the authors. We used complete case analysis
for trials with missing data.
Assessment of heterogeneity
12Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
We assessed heterogeneity between the trials by examining the
forest plots to check for overlapping CIs, using the Chi2 test for
heterogeneity with a 10% level of significance, and the I2 statistic
using a value of 50% to represent moderate levels of heterogeneity.
Assessment of reporting biases
There were insufficient trials within each comparison to assess
the likelihood of small trial effects, such as publication bias, by
examining a funnel plot for asymmetry.
Data synthesis
We stratified trials by non-artemisinin or artemisinin basedmalaria
treatment regimens and described which antimalarial drug was
used for each comparison in the footnote. Also we stratified by
PQ dose category: low (< 0.4 mg/kg) medium (≥ 0.4 to < 0.6 mg/
kg); and high (≥ 0.6 mg/kg dose); by schedule (single dose day 1
or 2, single dose day 3 or 4, and multiple dose days 1 to 7) and
grouped the 8AQ drugs as PQ and other. Throughout this review,
we designated the first day of treatment as day 1 rather than day
0 as reported in some trials.
Where not stated as mg/kg, we reported the PQ dose as the adult
dose with the equivalent dose reported as mg/kg; most trials stated
that the dose was adjusted for children and we made this assump-
tion if not.
When there was no statistically significant heterogeneity between
trials, we applied the fixed-effect meta-analysis model. When we
observed statistically significant heterogeneity within groups that
could not be explained by subgroup or sensitivity analyses, we
used a random-effects meta-analysis model. When we determined
substantial heterogeneity from the assessments of heterogeneity
(such as high I2 value, low Chi2 statistic P value, or when a pooled
meta-analysis result was consideredmeaningless because of clinical
heterogeneity) we did not undertake meta-analysis but instead
presented a forest plot with the pooled effect suppressed.
Subgroup analysis and investigation of heterogeneity
In our protocol, we stated we would investigate heterogeneity in
relation to drug resistance pattern, the parasite density before treat-
ment and the local endemicity of malaria. However, we identified
too few trials for this analysis. We stratified outcomes under com-
parisons 1 and 2 (non-artemisinin-based and artemisinin-based
partner respectively) by time point after treatment, by dose and
by schedule of PQ where possible.
We stratified Comparison 3 by artemisinin-based and non-
artemisinin-based partners. In this case, we assessed the outcome
of percentage of people with gametocytes on day 8 only and com-
bined all trials in each subgroup that started PQ any time up to
day 7.
When we did not detect statistically significant heterogeneity
between trials, we applied the fixed-effect meta-analysis model.
When there was statistically significant heterogeneity within
groups that could not be explained by subgroup or sensitivity anal-
yses, we used a random-effects meta-analysis model.
When substantial heterogeneity was determined from the assess-
ments of heterogeneity (such as high I2 value, low Chi2 statis-
tic P value, or when we considered a pooled meta-analysis result
meaningless because of clinical heterogeneity), we did not perform
meta-analysis but instead presented a forest plot with the pooled
effect suppressed.
Sensitivity analysis
There were insufficient trials to conduct a sensitivity analysis to
investigate the robustness of the results to the quality (risk of bias)
components.
R E S U L T S
Description of studies
Results of the search
In the first version of this review (Graves 2012), we identified
45 potentially relevant publications from literature searches. Two
publications (in different languages) described the same trial (
Chen 1994), leaving 44 distinct trials. We excluded 13 at abstract
stage, excluded 20 after reading the full text article, and included
11 trials in the review.
For this update, we repeated the searches since we had expanded
the scope of the review to include other 8AQ and comparisons
of different doses of PQ and other 8AQ. We identified 65 more
potential studies in addition to the 45 previously identified, which
we rescreened due to revised inclusion criteria. We identified an
additional 41 papers from reference lists, personal knowledge of
new papers, or people consulted. Of the 151 abstracts we screened,
we selected 73 for full text review. Five papers were duplicates, we
could not locate three articles, and we included 18 trials (Figure
4). These 18 trials included a total of 30 distinct comparisons of
different malaria treatment drugs, doses or schedules.
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Figure 4. Study flow diagram
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Included studies
All 18 included trials were RCTs or quasi-RCTs. Two trials com-
pared PQ and bulaquine, while 16 trials compared PQ versus no
PQ. One trial of PQ (Khoo 1981) did not distinguish between
short or long course of PQ and therefore no outcomes are included
in this review. One trial did not include any gametocyte outcomes
(Wang 2006).
Sixteen trials examined the impact of PQ or 8AQ on various mea-
sures of potential infectiousness, such as gametocyte prevalence
over time or density in participants after treatment, gametocyte
clearance time or gametocyte circulation time.Most trials assessed
gametocyte prevalence by microscopy but two trials reported both
microscopy and PCR (Shekalaghe 2007; Eziefula 2013) and one
reported only PCR detection (El-Sayed 2007).
Two trials (Shekalaghe 2007; Eziefula 2013) reported log(10)AUC
as a summary combined measure of gametocyte prevalence and
density over time, using PCR estimates of density. For gameto-
cytes detected by microscopy, we calculated the outcomes of AUC
and log(10)AUC for four additional studies that provided appro-
priate information, either in the publications or from the authors
(Vasquez 2009; Smithuis 2010; Kolaczinski 2012; Sutanto 2013).
For direct measures of infectiousness, two small trials in China
(Chen 1993a; Chen 1994) evaluated the infectiousness to
mosquitoes of people treated with mefloquine (MQ) compared to
MQ+PQ.
Only five trials reported adverse effects quantitatively: three for
anaemia outcomes (El-Sayed 2007; Shekalaghe 2007; Eziefula
2013) and two for other outcomes (Wang 2006; Sutanto 2013).
No community trials examining malaria transmission intensity
(measuring incidence of malaria, prevalence or EIR) met the in-
clusion criteria.
Participants
Participants were people attending health clinics for treatment.
Four trials did not state the participants’ ages (Chen 1993a; Chen
1994; El-Sayed 2007; Khoo 1981), and three trials included chil-
dren only: Singhasivanon 1994 (5 to 12 years); Shekalaghe 2007
(3 to 15 years); and Eziefula 2013 (1 to 10 years). Six trials used a
wide age range of children and adults: Wang 2006 (6 to 60 years);
Vasquez 2009 (≥ 1 year); Smithuis 2010 (> six months); Arango
2012 (1 to 75 years); Kolaczinski 2012 (3 to 70 years); and Sutanto
2013 (≥ 5 years). The remaining five studies included teenagers
and adults only: Gogtay 2004 (> 18 years); Kamtekar 2004 (> 16
years); Pukrittayakamee 2004 (15 to 62 years); Gogtay 2006 (> 16
years); and Ledermann 2006 (≥ 15 years). See the Characteristics
of included studies section.
For G6PD deficiency, two studies did not screen participants
(Kamtekar 2004; Smithuis 2010), one trial screened and included
all participants (Shekalaghe 2007), one trial included only G6PD-
deficient participants (Khoo 1981), six studies included only
non-deficient participants (Gogtay 2004; Pukrittayakamee 2004;
Gogtay 2006; Ledermann 2006; Eziefula 2013; Sutanto 2013),
and the remaining eight studies made no comment (Chen 1993a;
Chen 1994; Singhasivanon 1994; Wang 2006; El-Sayed 2007;
Vasquez 2009; Arango 2012; Kolaczinski 2012); see Table 1.
Interventions
Non-artemisinin-based regimens
Twelve studies (15 treatment arms) evaluated PQ given alongside
non-artemisinin-based treatments: chloroquine alone (CQ) (two
trials), CQ+sulfadoxine-pyrimethamine (SP) (one trial), CQalone
orCQ+SP (one trial), SP (one trial),mefloquine (MQ) (two trials),
MQ+SP (two trials), quinine (QN) (two trials), and QN plus
doxycycline (two trials).
Artemisinin-based regimens
Eight studies (15 treatment arms) evaluated PQ given alongside
artemisinin-based treatments: artesunate (AS) (two trials), AS+SP
(two trials), AS+MQ (four trials), AS+amodiaquine (AQ) (one
trial), artemether-lumefantrine (AL) (four trials) and dihydrox-
yartemisinin-piperaquine (DHAP) (two trials).
Dose
Most trials used a target dose equivalent to 0.75 mg/kg PQ per
day (adult dose 45 mg/day), see Table 1. The exceptions were:
• Khoo 1981: adult dose of 25 mg or approximately 0.42
mg/kg/day;
• Kolaczinski 2012: (two comparisons) 0.5 mg/kg or adult
dose 30 mg/day;
• Pukrittayakamee 2004: the trial with QN had two arms,
one with 0.25 mg/kg and the other 0.5 mg/kg per day (adult
dose 15 mg or 30 mg per day respectively); the comparison with
AS used 0.5 mg/kg per day (adult dose 30 mg per day).
• Wang 2006: adult dose of 22.5 mg or approximately 0.38
mg/kg per day.
• Eziefula 2013: evaluated 0.1, 0.4 and 0.75 mg/kg and
placebo.
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Schedule
Most trials used a single dose of PQ given on the following days,
and we regarded the first day of any treatment as day 1:
• Day 1: Chen 1993a; Chen 1994; Singhasivanon 1994;
Ledermann 2006 (one of two comparisons); Smithuis 2010 (five
comparisons); and Kolaczinski 2012 (one of two comparisons);
• Day 2: Arango 2012 (two comparisons);
• Day 3: Ledermann 2006 (one of two comparisons);
Vasquez 2009; Kolaczinski 2012 (one of two comparisons);
Eziefula 2013; and Sutanto 2013;
• Day 4: Gogtay 2004; Kamtekar 2004 (one of two
comparisons); Gogtay 2006; El-Sayed 2007; and Shekalaghe
2007;
• Day 8: Kamtekar 2004 (one of two comparisons).
Three trials used a longer course of PQ:
• 3 days: Khoo 1981;
• 5 days: Wang 2006;
• 7 days: Pukrittayakamee 2004 (three comparisons).
Prevalence of gametocytes at start of trial
Five trials only included people with gametocytes at onset (as de-
tected by microscopy) (Chen 1993a; Chen 1994; Gogtay 2004;
Kamtekar 2004 (both comparisons); Gogtay 2006). However
Kamtekar 2004 reported this variable as “within 3 days” rather
than on day 1. Four trials did not report this statistic (Khoo 1981;
Singhasivanon 1994; Ledermann 2006 (both comparisons);Wang
2006).
In the remaining trials, one had low gametocyte prevalence at onset
(El-Sayed 2007, prevalence bymicroscopy 3.8%, by PCR 11.8%).
Trials with initial prevalence between 17.1% and 27.1% were:
Pukrittayakamee 2004 (all three comparisons); Vasquez 2009;
Arango 2012; Kolaczinski 2012 (both comparisons); Eziefula
2013; and Sutanto 2013. Shekalaghe 2007 reported gametocyte
prevalence bymicroscopy of 22.6%but byPCRof 87.7%.Eziefula
2013 observed a similar ratio betweenmicroscopy and PCR preva-
lence, with microscopy prevalence by arm of 20.4% to 24.3% and
PCRprevalence of 78.4% to 86.7%. Excluding trials that included
only gametocyte carriers, the five arms of the Smithuis 2010 trial
showed the highest prevalences, with gametocyte prevalence (mi-
croscopy) between 29% and 38%.
The details of the trial locations, malaria treatments, gametocyte
prevalence, PQ doses and schedules are in Table 1.
Excluded studies
We have listed the reasons for exclusion of 47 trials in the
Characteristics of excluded studies section. Some additional de-
tails are given here.
Six community-based trials did not meet criteria for inclusion.
Both Hii 1987 (MDA with SP+PQ (30 mg adult dose, 0.5 mg/
kg) + insecticide treated net (ITN) versus ITN only in Sabah,
Malaysia) and Shekalaghe 2011 (MDA with SP+AS+PQ (0.75
mg/kg) versus placebo) did not have appropriate comparison
groups. Doi 1989 was a community-based observational trial of
mass test and treat with SP+PQ (0.7 to 1 mg/kg) in one interven-
tion village, two schools in two other intervention villages, and
one control village (SP only) on the coast of north Sumatra, In-
donesia. There was no ’before’ data from these villages, and in the
control site it appears that some children received treatment with
PQ. Kaneko 1989, also in north Sumatra, Indonesia, tested mass
fever test and treat and/or mass test and treat in school children.
The drugs used were SP+PQ in one intervention village and SP
in one control village. Apart from there being only one cluster
(village) per arm and non-randomized, the main reason for exclu-
sion was the intensity of effort on case detection appeared much
greater in the intervention village, resulting in 75% of people in
the intervention village being treated over a 29-day period versus
18% in the control village over a 14-day period. The Barber 1932
trial in Liberia was a trial of MDA that administered the 8AQ
plasmoquine approximately twice weekly to ~133 people for peri-
ods ranging from nine to 28 days with follow up for several weeks.
Plasmoquine had a large (although short-lived) impact on trans-
mission in this trial. However the main reasons for its exclusion
were the lack of malaria treatment given together with plasmo-
quine, non-comparable control site and lack of parasite outcomes
in the control group. In the MDA trial of Clyde 1962 in Tanza-
nia, AQ+PQ was given every 1, 2 or 4 weeks to over 93% of the
populations residing in three sites near Morogoro, Tanzania for
periods ranging by site between 26 and 39 weeks. The dose of PQ
was 30 mg (~0.5 mg/kg for an adult) given to everyone over six
years of age, with half dose given to those aged between 0 and five
years. Transmission was greatly reduced, especially in the sites re-
ceiving MDA every one or two weeks (although transmission was
not interrupted). We excluded this trial because everyone received
malaria treatment as well as PQ, so the additional impact of PQ
cannot be assessed.
Several controlled or uncontrolled before-and-after studies, and
non-randomized comparative case series or trials, were excluded.
They were generally studies of small numbers of individuals on
whommosquitoeswere fed before and after they ingestedPQ,with
or without other malaria treatment. These studies, which include
Barber 1929, Barber 1932, Jerace 1933, Mackerras 1949, Jeffery
1956, Young 1959, Gunders 1961, Jeffery 1963, Rieckmann
1968, Rieckmann 1969, Clyde 1970, and Clyde 1971, have been
reviewed byWhite 2012 andWhite 2013 but did not meet our in-
clusion criteria. Abay 2013 also reviewed two of these before-and-
after studies which had four patients in total (Rieckmann 1968;
Clyde 1971). Two studies used varying doses of PQ (Jeffery 1956,
Rieckmann 1969), as did Burgess 1961 and Bunnag 1980. How-
ever, Burgess 1961 gave doses according to participants’ age rather
than testing different doses in comparable patients, and there was
no other malaria treatment drug given. In Bunnag 1980 all re-
ceived malaria treatment (SP) in addition to PQ.
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We sought publications for Chinese trials cited in White 2012,
White 2013 and by personal communication from Professor Li
Guo Qiao. We were unable to locate two (Chen 1993b; Li 2006);
the others were translated where required.We excluded the follow-
ing studies on the basis of no appropriate comparison (either all
groups got PQ or there was no comparator group with same dose
of malaria treatment drug but no PQ) (Yang 1989; Che 1990;
Che 1987; Huang 1996; Lin 2004; and Sun 2011) or lack of ran-
domization (Cai 1985 and Huang 1993). Three other trials of
artemether with and without PQ in Africa (Huang 2001, Li 2007,
and Li 2010) were stated to be randomized, but were excluded
due to the late administration of PQ (after five to seven days of
artemether) and lack of gametocyte outcomes.
Risk of bias in included studies
Of the 18 included studies, the risk of bias assessment for conceal-
ment of allocation was adequate in 4 studies; methods of random
allocation were adequate in 10; and blinding of outcome assess-
ment adequate in 7; see Figure 2 and Figure 3.
Pukrittayakamee 2004 excluded G6PD-deficient people from the
PQ group post-randomization. We had no reason to suppose it
biased the primary outcomes but it could have affected assessment
of adverse effects.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings table 1; Summary of findings 2 Summary of findings
table 2
For malaria transmission intensity (prevalence, incidence or EIR)
we found no community cluster-RCTs measuring these out-
comes. Regarding infectiousness, two trials (Chen 1993a; Chen
1994) measured this in 12 and 18 patients respectively for non-
artemisinin drugs, (in both cases MQ) with and without PQ.
All other trials reported potential infectiousness: the effects of PQ
on gametocyte prevalence, density or clearance time, or all three
outcomes. Only Shekalaghe 2007 and Eziefula 2013 reported a
summary measure of potential infectiousness using AUC of game-
tocyte density over time;we calculated this for four other trialswith
available data. We estimated the AUC for microscopy-determined
densities for trials of both non-artemisinin and artemisinin based
malaria treatments. In the former categorywe hadonlyKolaczinski
2012 (two comparisons). There were four trials with this informa-
tion for artemisinin-based partners: Shekalaghe 2007, Smithuis
2010 (five comparisons), Sutanto 2013, and Vasquez 2009. The
estimate used the mean (or geometric mean) gametocyte density
by group at a sequence of reported days of measurement. Since
trials were not consistent in the days on which they estimated ga-
metocyte density, we used the days on which measurements were
available for all trials (days 1, 8, 15, 29 and 43; see Methods sec-
tion). We estimated AUC up to day 15 (Table 2), day 29 (Table
3) and day 43 (Table 4). Results are presented separately by non-
artemisinin-based and artemisinin-based malaria treatments be-
low and given for log(10)AUC in the summary of findings tables
for days 1 to 43.
Primaquine plus non-artemisinin-based treatment
regimens (Comparison 1)
Eleven trials contributed comparisons to this analysis, of which
one trial tested a low dose PQ regimen (Pukrittayakamee 2004).
One trial (Khoo 1981) did not report results in a usable manner.
Gametocyte prevalence
There were fewer people with gametocytes (detected by mi-
croscopy) in the PQ group at days 8, 15, 22, 29 and 36 (Analysis
1.1). The largest number of trials and comparisons was included at
day 8 (RR 0.60, 95% CI 0.50 to 0.73, six trials, 498 participants,
nine comparisons) and the effect appeared larger at day 15 (RR
0.31, 95% CI 0.22 to 0.43, four trials, 366 participants, seven
comparisons).
The trials included three with CQ or CQ combination partner
treatment (Kamtekar 2004; Ledermann 2006 (two comparisons);
Kolaczinski 2012); one with SP (Kolaczinski 2012); one with
AQ+SP (Arango 2012 (one comparison)); one with MQ (Chen
1993a) and two with quinine (Kamtekar 2004 (one comparison);
Pukrittayakamee 2004 (two comparisons)).
Gametocyte clearance time or duration of gametocyte
carriage (the average number of days each person has
gametocytes)
Gametocyte clearance time (in days) was significantly reduced in
the PQgroup in Singhasivanon 1994 (which hadMQ+SPpartner)
with a mean difference of -14.90 days (95% CI -18.18 to -11.62).
(Analysis 1.2). The median gametocyte clearance time was also
reduced in Pukrittayakamee 2004 (two comparisons; partnerQN)
from 216 hours to 48 hours with 0.5 mg/kg PQ, or 87 hours with
0.25 mg/kg PQ, although results were not presented in a form
that could be shown graphically.
AUC of gametocyte density over time
Gametocyte density over time up to day 43 was assessed by mi-
croscopy in the trial of Kolaczinski 2012 (two comparisons). We
analysed the data further using the AUC and log(10)AUC mea-
sures for days 1 to 15, 1 to 29 and 1 to 43, estimated from data
provided by the authors (Table 2; Table 3; Table 4)
Reductions in AUC for non-artemisinin malaria treatment regi-
mens were 84.5% and 88.6% up to day 15, 83.6% and 91.7%
up to day 29, and 74.6% and 80.8% up to day 43 (one trial,
two comparisons). Using the log(10)AUC, for non-artemisinin
malaria treatment regimens the estimates were 21.4% and 26.0%
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to day 15, 19.1% and 27.3% to day 29, and 24.3% and 27.1%
to day 43 (one trial, two comparisons).
Infectiousness to mosquitoes
Two small trials in China (Chen 1993a; Chen 1994), with only
six and nine participants per group respectively, directly tested the
impact of PQ added to MQ on infectiousness to mosquitoes. On
day 1 all patients in the trial were infectious to Anopheles dirus
mosquitoes, but after a dose of PQ on day 1 the proportion of
people infectious was reduced to 0 when measured on days 2, 5
and 8 (Analysis 1.3). By day 15 and day 22 the difference was
attenuated as infectiousness in the control group declined.
Chen 1994 also reported the number of mosquitoes infected after
feeding on trial participants (Analysis 1.4; note the CIs are not
corrected for repeated observations in the same patients). None
of the mosquitoes feeding on people receiving PQ were infected,
with over 64% infected at day 5 after feeding on the group not
receiving PQ, with the effect still evident up to day 22, although
the proportion infected in the control group declined over time.
Asexual parasites at day 29 (recrudescence or reinfection)
In Kolaczinski 2012 there was no effect of PQ (added to either CQ
or SP) on prevalence of asexual parasites at day 29 (parasitological
treatment failure), whether or not the results were adjusted for
new infections detected by PCR (Analysis 1.5).
Asexual parasite clearance
There was no effect of PQ on asexual clearance time in
Singhasivanon 1994 (added toMQ+SP) or Pukrittayakamee 2004
(two comparisons, added to QN) (Analysis 1.6).
Adverse effects
Patients with G6PD deficiency were excluded (two trials), the only
patients included (one trial), not screened for (two trials), or not
reported or commented on (six trials).
The trials with non-artemisinin regimens did not report adverse ef-
fects well or consistently. None of these trials reported on haemol-
ysis, other haematological measures or severe adverse events.
Singhasivanon 1994 found no difference in frequency of reported
adverse effects (nausea, vomiting or dizziness) over 28 days follow-
up (Analysis 1.7).
We could not use data from one trial with non-artemisinin part-
ner, CQ, because it did not distinguish between patients with
P. falciparum and P. vivax and their respective treatments (Khoo
1981). There was a much higher risk of adverse haemolytic events
in those who received PQ in the Khoo 1981 trial (OR of 22.27
for both haemolysis and need for blood transfusion), but we could
not include the results because the groups combined participants
receiving a short course (three days) of PQ with those receiving a
14-day regimen. The most unusual aspect of the trial, however, is
that it only included individuals with G6PD deficiency.
Dose and schedule
Dose of PQ: We stratified trials into low, medium and high dose
category PQ. Only Pukrittayakamee 2004 used the low dose cat-
egory (0.25 mg/kg per day, given for seven days in conjunction
with QN). It used medium dose category (0.5 mg/kg) at the same
schedule also with QN, while Kolaczinski 2012 used the 0.5 mg/
kg medium dose in two comparisons (with CQ and SP). Three
trials used the high dose category 0.75 mg/kg of PQ: Arango 2012
in one comparison with AQ + SP); Ledermann 2006 in two com-
parisons, both with CQ+SP, and Kamtekar 2004 in one compar-
ison with CQ or (CQ+SP).
With the low dose, there was no difference detected between the
groups with and without PQ (Analysis 1.8, one trial), even though
this dose of PQ was given for seven days (RR 1.76, 95% CI 0.97
to 3.18, 59 participants, one trial).
Both the medium and high dose reduced the prevalence of game-
tocytes at day 8: RR = 0.62 (95% CI 0.50 to 0.76) for medium
dose, three comparisons; and RR 0.39 (95% CI 0.25 to 0.62 for
high dose, five comparisons) (Analysis 1.8).
Schedule of PQ: We stratified this comparison into three groups:
single dose on day 1 or 2, single dose day 3 or 4, andmultiple doses
day 1 to 7. The comparison is indirect, although the schedule on
day 3 or 4 seemed to have a greater effect. One arm of Ledermann
2006 received PQ on day 1 and the other on day 3. There was
no apparent difference in the outcome between these two arms
(Analysis 1.9).
Primaquine plus artemisinin-based treatment
regimens (Comparison 2)
Nine trials contributed comparisons to this analysis, including
ACTs (seven trials) and artemisinin monotherapy (two trials) for
malaria treatment. Only one trial tested a low dose PQ regimen,
0.1 mg/kg total dose.
Gametocyte prevalence
Microscopy analysis revealed that PQ clearly reduced the number
of people with gametocytes on day 8 (RR 0.24, 95% CI 0.10 to
0.55, six trials, 1121 participants, 10 comparisons), day 15 (RR
0.09, 95% CI 0.04 to 0.19, four trials, 995 participants, eight
comparisons), day 22 (RR 0.10, 95% CI 0.03 to 0.32, three trials,
858 participants, seven comparisons, four with estimable results,
507 participants) and day 29 (RR 0.17, 95%CI 0.04 to 0.72, four
trials, eight comparisons, four with estimable results) (Analysis
2.1). We used the random-effects model due to heterogeneity.
In Smithuis 2010, new gametocytaemia (by microscopy) on day
8 was also reduced by PQ (one of 272 versus 10 of 268; RR 0.1,
95% CI 0.01 to 0.76, P = 0.006).
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Three trials examined gametocytes by PCR rather than (or in ad-
dition to) microscopy. In Shekalaghe 2007 and Eziefula 2013, a
reduction in gametocyte prevalence was observed on day 8 and
day 15 (Analysis 2.2). However, in El-Sayed 2007, giving PQ did
not lead to a detectable difference between the two groups on these
two follow-up days, although therewere very few participants with
gametocytes in the control group. Given the clear statistical and
clinical heterogeneity between the two estimates (related to differ-
ent numbers of participants with gametocytes in the comparator
arm in these two studies) we used the random-effects model to
combine the trials in meta-analysis (Analysis 2.2). In Shekalaghe
2007 which had additional follow-up on day 29, reduction in ga-
metocyte prevalence was significant (RR 0.23, 95% CI 0.08 to
0.62, one trial, 90 participants), and on day 43, it was not (one
trial, 79 participants, Analysis 2.2).
Note that the trial of Eziefula 2013 was reported as a non-infe-
riority analysis comparing lower dose groups with the previously
recommended 0.75 mg/kg. In this review, in order to combine
trials for analysis, results in each arm have been compared with the
single placebo group, and where meta-analysis is done, numbers
in the placebo group have been divided into three to avoid biasing
the CIs.
Gametocyte clearance time or duration of gametocyte
carriage (the length of time each person has gametocytes)
Several authors presented gametocyte clearance time, sometimes
described as “duration of gametocyte carriage”. This was presented
in Shekalaghe 2007 and was significantly lower (by PCR) in the
PQ group (6.3 days, 95%CI 4.7 to 8.5) than in the non-PQ group
(28.6 days, 95% CI 17.0 to 48.0, P < 0.001). In Eziefula 2013,
also by PCR, the gametocyte clearance time was not significantly
longer in the 0.1mg/kg group (8.0 days, 95%CI 6.6 to 9.4) or the
0.4 mg/kg group (6.3 days, 95% CI 5.1 to 7.5) than the 0.75 mg/
kg group (6.6 days, 95% CI 5.3 to 7.8); however this group had
significantly shorter gametocyte clearance time than the placebo
group (12.4 days, 95% CI 9.9 to 15.0). Smithuis 2010, using mi-
croscopy, also reported significantly lower gametocyte clearance
time in the PQ groups, reported as person-gametocytaemia-weeks
standardized per 1000 person-weeks of follow-up. This was 5.5
weeks in the ACT+PQ groups versus 65.5 weeks in the non-PQ
groups (RR 11.9, 95% CI 7.4 to 20.5, P < 0.001) and the differ-
ence was very large for each individual malaria treatment regimen.
Although the duration of gametocyte carriage (without PQ) was
significantly longer for AS+AQ, AL and DHAP than for AS+MQ,
there was no significant difference in length of gametocyte carriage
between the ACT groups when PQ was added (Smithuis 2010).
Gametocyte circulation time
Another outcome related to gametocytes estimated by PCR in
Eziefula 2013 and Shekalaghe 2007 was the mean life (circulation
time) of gametocytes. In Eziefula 2013 the circulation time per
gametocyte was significantly longer in the 0.1 mg/kg group (1.47
days, 95% CI 1.22 to 1.73) than in the other two groups (0.95
and 0.98 days in the 0.4 and 0.75 mg/kg groups respectively),
and was similar to the placebo group (1.97 days, 95% CI 1.64 to
2.31). In Shekalaghe 2007, the mean gametocyte circulation time
was reduced from 4.6 days (95% CI 2.9 to 7.3) after AS+SP alone
to 0.5 days (95% CI 0.2 to 1.2) after AS+SP plus PQ (P < 0.001).
AUC of gametocyte density over time
Gametocyte density over time was assessed by microscopy in the
artemisinin-based regimen trials of Shekalaghe 2007, Smithuis
2010 (five comparisons), Sutanto 2013 and Vasquez 2009, and
we analysed this further using data provided by the authors (Table
2; Table 3; Table 4). All trials except Vasquez 2009 demonstrated
reduction in the AUC after PQ. The reduction ranged from -
63.7% to 67.3% up to day 15, -50.8% to 91.7% up to day 29,
and from -41.3% to 82.6% up to day 43. Using the log(10)AUC,
the reduction ranged from -8.6% to 18.4% up to day 15, from -
7.0% to 27.3% up to day 29 and -15.8% to 87.5% up to day 43.
Vasquez 2009 was an exception suggesting an increase in AUC
after PQ, possibly due to the small sample size and differing mean
gametocyte counts by group at baseline in this trial. Excluding
Vasquez 2009, reductions in AUC varied from 19.2% to 67.3%
for days 1 to 15, from 37.9% to 91.7% for days 1 to 29, and
42.1% to 82.6% for days 1 to 43, using the mean gametocyte
density. Using the log(10)AUC, the reduction ranged from 3.9%
to 18.4% for days 1 to 15, 8.3% to 27.3% for days 1 to 29 and
24.3% to 87.5% for days 1 to 43.
Eziefula 2013 used a duration of 14 days to estimate AUC using
PCR, but the results were not reported separately by group and
day so cannot be shown in Table 2. However the log(10)AUC
in the intervention groups were not significantly different from
placebo. It was 3.8 (95% CI 1.7 to 8.2) gametocytes per µL per
day in the placebo group, 3.8 (1.8 to 7.8) in the 0.1 mg/kg group,
2.1 (1.0 to 4.5) in the 0.4 mg/kg group, and 2.0 (0.9 to 4.3) in
the 0.75 mg/kg group.
Using PCR-detected gametocyte density estimates, Shekalaghe
2007 provided geometric mean and interquartile range (IQR) val-
ues on days 1, 4, 8, 15, 29 and 43. Mean density was consistently
lower in the PQ than the non-PQ group, for days when gameto-
cytes were detected (with PQ: 5.8, IQR 0.8 to 55.1; without PQ:
15.8, IQR 4.1 to 85.8).
Shekalaghe 2007 also presented a statistical comparison of AUC
of gametocyte density (by PCR) over a 43-day period, with a 95%
CI derived from generalized estimation equations. There was a
significant reduction in AUC in the PQ groups over 43 days after
treatment, reported as mean of 1.5 (IQR 0.3 to 8.8) in the PQ
group versus 11.1 (IQR 2.2 to 53.8) in the non-PQ group (P <
0.001).
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Asexual parasite prevalence
Analysis 2.3 shows the participants who had asexual parasites at
several time points after treatment. This analysis suggests a lower
proportion of asexual parasites at day 29 in the PQ group reflect-
ing possible recrudescence, late treatment failure or reinfection.
However, Wang 2006 did not adjust for reinfections by PCR. In
the other trials and time periods, there was no difference between
PQ and non-PQ groups in the low proportion of people with
asexual parasites.
Asexual parasite clearance
Pukrittayakamee 2004 noted no difference in parasite clearance
time (Analysis 2.4).
Adverse effects
For haematologic adverse events, Smithuis 2010 stated that there
were no cases of severe anaemia (< 5 g/dL) or blackwater fever
in any group. El-Sayed 2007 showed that there was no difference
in packed cell volume between groups at day 7 (34.2% (15%
to 44%) versus 36.2% (26% to 42%)) or day 14 (35.2% versus
35.4%). The difference was not significant at either day 7 (0.78,
(-0.75 to 0.23), P = 0.32) or day 14 (0.86, (-0.31 to 2.0), P =
0.15). Sutanto 2013 observed no significant difference in mean
haemoglobin between groups at days 1, 8 and 43.
In Shekalaghe 2007, although there was also no reduction inmean
haemoglobin by group (Analysis 2.5), there was a significantly
greater change (decrease) in haemoglobin status in the PQ group
on day 8; haemoglobin decreased by 5% in the PQ group com-
pared to 1% in the non-PQ group (Analysis 2.6). These findings
suggest that rather than looking at population mean of haemo-
globin, it would be more meaningful to examine the proportion
of individuals who had serious adverse events: Shekalaghe 2007
stated that 8 of 52 children in the PQ group had a 20% reduction
in haemoglobin by day 8, compared to 0 of 53 children in the
control group. However, Shekalaghe 2007 also stated that no child
developed clinical symptoms related to anaemia or a haemoglobin
below 5 g/dL. The effect on haemoglobin in the PQ group was
transient and was no longer significant by day 15.
Eziefula 2013 used the outcome ’mean max decrease in haemo-
globin’ from enrolment to day 29 and this was not significantly
different between the intervention groups or with placebo. Other
haematological outcomes were ’day of haemoglobin nadir’ - day 3
in all groups; maximum % decrease in haemoglobin (significantly
lower in the 0.75 mg/kg group than placebo, P = 0.023) and %
of patients with haemoglobin < 50 g/L (no differences between
groups). No children needed blood transfusion or had black urine
or any other severe adverse events.
El-Sayed 2007 assessed the minor adverse effects of vomiting,
insomnia and itching and found no difference between groups.
Smithuis 2010 found a higher percentage of patients in the PQ
groups had abdominal pain (16%;N=397 versus 11%;N=411, P
= 0.05); frequencies of dizziness, nausea, anorexia, diarrhoea, pal-
pitations, sleeplessness, headache and vomiting were not increased
in the PQ groups. Sutanto 2013 and Wang 2006 observed no dif-
ferences between groups regarding other adverse effects (Analysis
2.7).
Dose and schedule
Dose of PQ: We stratified trials into low, medium and high dose
PQ category and assessed the prevalence of gametocytes at day 8
by either microscopy or PCR (Analysis 2.8).
Only Eziefula 2013 used a low dose category - in this case 0.1 mg/
kg. There were fewer patients with gametocytes in the PQ group,
but the analysis was underpowered (Analysis 2.8). Two trials used
a medium dose category, with no detectable effect in one trial
with few patients with PQ in the control group (Pukrittayakamee
2004); but with clear effect in Eziefula 2013 with 0.4 mg/kg sin-
gle dose (Analysis 2.8), and an overall effect estimate in this dose
category of RR 0.34 (95% CI 0.19 to 0.59; two trials, 269 par-
ticipants). The high dose category of ≥ 0.6 mg/kg reduced the
prevalence of gametocytes at day 8: RR = 0.29 (0.22 to 0.37),
seven trials, 1380 participants, 11 comparisons; Analysis 2.8.
Schedule of PQ: We stratified this comparison into three groups:
single dose on day 1 or 2, single dose day 3 or 4, andmultiple doses
day 1 to 7 (Analysis 2.9). This indirect comparison suggested a
greater effect of single dose on days 1 to 2 than on days 3 to 4.
There was only one trial of multiple doses on days 1 to 7.
Summary analysis of gametocytes on day 8
(Comparison 3)
We have shown a single outcome, percent of participants with mi-
croscopy or PCR-detected gametocytes on day 8, for this compar-
ison as a representative outcome across the trials. We subgrouped
the data by whether or not the malaria treatment was artemisinin-
based.We included only PCRdata from the one trial that reported
both microscopy and PCR outcomes, to avoid duplicate reporting
of the same patients (Shekalaghe 2007).
We excluded the QN comparison of Kamtekar 2004 because PQ
was not given until day 8, but included all other trials with game-
tocyte outcomes (all trials except Khoo 1981 and Wang 2006).
The day on which PQ was given and the gametocyte detection
method varied and are presented for each trial in the footnotes
in Analysis 3.1. This comparison shows that, overall, PQ reduced
the prevalence of gametocytaemia on day 8 following treatment
(RR 0.43, 95% CI 0.32 to 0.58, 12 trials, 2141 participants). The
individual trials nearly all trended in the direction of a reduction,
but an indirect comparison suggested a smaller effect for non-
artemisinin-based (RR 0.63, 95% CI 0.44 to 0.88, six trials, 499
participants) than for artemisinin-based malaria treatments (RR
0.33, 95%CI 0.21 to 0.52, eight trials, 1642 participants, Analysis
3.1).
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Comparison of different 8AQ (Comparison 4)
Two small trials compared the effect of bulaquine and PQ on
gametocyte prevalence at day 8 (Gogtay 2004;Gogtay 2006). Both
trials suggested a greater reduction of gametocytes by bulaquine
(OR 0.41 95% CI 0.26 to 0.66, two trials, 112 participants,
Analysis 4.1). Neither trial concealed allocation.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
PQ for reducing P. falciparum transmission with non-artemisinin-based treatments
Patient or population: people with symptomatic malaria
Settings: malaria-endemic areas
Intervention: Single dose or short course PQ plus malaria treatment which does not include an artemisinin derivative
Control: Malaria treatment not including an artemisinin derivative, without PQ
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control PQ
Malaria incidence, preva-
lence or EIR
- - - 0 trials -
People infectious to
mosquitoes
(day 8)
93 per 100 7 per 100
(1 to 39)
RR 0.07 1
(0.01 to 0.45)
30
(2 trials)
⊕⊕©©
low 2,3
Participants with gameto-
cytes on microscopy
(day 8)
Dose <0.4 mg/kg RR 1.76
(0.97 to 3.18)
59
(1 trial)
⊕©©©
very low 4,5,6
33 per 100 58 per 100
(32 to 105)
Dose 0.4 to 0.6 mg/kg RR 0.62
(0.50 to 0.76)
283
(2 trials)
⊕⊕⊕⊕
high 7,8
70 per 100 43 per 100
(35 to 53)
Dose >0.6 mg/kg RR 0.44
(0.27 to 0.70)
206
(3 trials)
⊕⊕⊕⊕
high 9,10
35 per 100 15 per 100
(9 to 24)
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Evidence of haemolysis - - 0 trials9,10 -
*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk
in the comparison group and the relative effect of the intervention (and its 95% CI).
PQ: Primaquine; CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 High category dose PQ used in both studies >0.6 mg/kg.
2 Downgraded by 1 for serious risk of bias: allocation was not concealed; both experiments were performed by the same author team
and the methods were not clear.
3 Downgraded by 1 for serious imprecision: the sample size is small (N = 30; downgraded by 2) but the effect is large (upgraded by 1).
In the control group, infectivity wanes by day 15.
4 Downgraded by 1 for serious risk of bias: trial had methodological deficiencies.
5 Downgraded by 1 for serious imprecision: single trial, small sample size, wide CIs.
6 Downgraded by 1 for serious indirectness: 7 days of PQ given.
7No serious imprecision: although the sample size is limited, the effect is large .
8 Log(10)AUC day 1 to 43 % reduction relative decrease: 2 estimates from one trial of 24.3% to 27.1% (N = 219), assessed as moderate
quality evidence.
9 Data from Khoo 1981 could not be used because it did not distinguish between patients with P. falciparum and P. vivax and their
respective treatments. There was a much higher risk of adverse haemolytic events in those who received PQ (OR of 22.27 for both
haemolysis and need for blood transfusion), but the participants included those receiving a short course (three days) of PQ with those
receiving a 14-day regimen. Only individuals with G6PD deficiency were included.
10 For the ten included trials, the G6PD status of participants varied: two trials excluded patients with G6PD deficiency trials), one trial
included only those with G6PD deficiency, two trials did not screen for G6PD deficiency, and five trials did not report or comment on
screening for G6PD status. No trials systematically reported on adverse effects.
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D I S C U S S I O N
Summary of main results
PQ with artemisinin-based regimens.
See Summary of findings for the main comparison.
When added to artemisinin-based therapy, a single dose of PQ
above 0.4 mg/kg reduces the proportion of people with detectable
gametocytaemia on day eight by around two thirds (high quality
evidence), and can reduce the log(10) AUC estimates for gameto-
cytaemia by up to 87.5%. However, only a single trial evaluated
lower doses (0.1 mg/kg) and did not demonstrate an effect (low
quality evidence). No trials evaluated effects on infectiousness to
mosquitoes, or on malaria transmission directly (incidence, preva-
lence, or entomological inoculation rate).
PQ with non-artemisinin-based regimens.
See Summary of findings 2.
When added to non-artemisinin-based treatment regimens, a sin-
gle dose of PQ above 0.4 mg/kg reduces the proportion of people
with detectable gametocytaemia on day 8 by around a third (high
quality evidence), and may reduce infectiousness to mosquitoes
(low quality evidence).The single trial of lower doses (0.25 mg/
kg) did not demonstrate an effect on gametocytaemia (very low
quality evidence). No trials assessed effects on malaria transmission
directly.
Overall completeness and applicability of
evidence
What is known
Adding PQ to treatment doses of artemisinin-based combination
therapies appears to be an effective strategy to reduce the dura-
tion of potential infectiousness to mosquitoes (gametocytaemia).
Large effects have been seen across trials from different epidemio-
logical settings (Tanzania, Uganda, Myanmar, and Sumatra), and
with different artemisinin-based treatments (AS+SP, AL, AS+AQ,
AS+MQ,AS, andDHAP). Further studies evaluating this at single
doses above 0.4 mg/kg are therefore probably unnecessary.
What is unknown
While reducing the duration of gametocytaemia can be assumed
to reduce infectiousness at the level of the individual, it remains
unclear whether it will impact on community level transmission as
reliable trials have never evaluated this. The older trials, which are
often cited as proof of an effect on community transmission were
excluded from this review because either: i) they lacked an ade-
quate control group (Clyde 1962), ii) did not apply the interven-
tions equally in intervention and control groups or had no ’before’
data (Doi 1989; Kaneko 1989), iii) administered PQ alongside
vector control co-interventions which may equally be responsible
for any effect seen (Hii 1987; Kaneko 2000), or iv) administered
PQ alone and not alongside treatment regimens (which is the pol-
icy currently being considered) (Barber 1932).
In moderate and high transmission settings, a policy of adding
PQ to malaria treatment regimens is highly unlikely to impact
community transmission as most adults have a level of acquired
immunity that reduces the probability that parasitaemia will cause
clinical symptoms, and consequently they never seek care. These
asymptomatic people are thought to represent the major source of
gametocytes, and so will continue to facilitate transmission unless
they are also treated with gametocytocidal drugs. Low transmis-
sion settings, especially those approaching elimination, are there-
fore more suited to the current policy as most people will de-
velop symptoms following infection. However, Johnston and col-
leagues recently modelled the effect of PQ in low-transmission
areas, and concluded that the most important factor predicting
success is the percentage of infected individuals treated with an
ACT, and that adding PQ is of negligible benefit (Johnston 2014).
They estimated that “it would require switching 180 people from
ACTs to ACTs plus PQ to achieve the same transmission reduc-
tion as switching a single individual from untreated to treated with
ACTs”.
Mass treatment programmes (where everyone in the community
is treated at specified intervals until transmission is stopped) are a
potential strategy to overcome the problem of asymptomatic ga-
metocyte carriers (von Seidlein 2003; GMAP 2008;Mendis 2009;
Sturrock 2013). However, in theory, mass treatment consisting
only of primary treatment (an ACT alone), would interrupt trans-
mission, and the effects of additional PQ (interrupting transmis-
sion more quickly, or at a lower coverage levels) are unknown
(Poirot 2013).
Perhaps even more importantly, it also remains unknown whether
the current WHO-recommended dose of 0.25 mg/kg PQ has the
effects seen on gametocytes with higher doses.Whilst there is some
indirect evidence in narrative summaries and analyses that have
proposed widespread programmatic implementation of PQ (for
example, Bunnag 1980, with no difference in gametocyte out-
comes between 15 mg PQ for five days and single doses of 30 mg
or 45mgPQ in adults), the only two controlled studies which have
evaluated doses below 0.4 mg/kg failed to demonstrate reliable
effects. The WHO revised recommendation therefore appears to
be based more on concerns about safety than on proven efficacy.
In terms of safety, it is highly likely that adverse effects in people
with G6PD deficiency will be less common with lower doses of
PQ.However, the evidence to reliably demonstrate this with doses
0.25 mg/kg does not currently exist. Most of the trials included
in this review excluded individuals with G6PD deficiency, but in
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the few trials that included them no severe haematological effects
have been reported. However, there are hundreds of variants of
G6PD deficiency (albeit only a few that are common) and an ad-
equate picture of how PQ affects even the common ones is lack-
ing. Without this evidence, national malaria control programmes
may remain reluctant to introduce a drug for use in population-
based programmes which has the potential to harm individuals.
Health professionals and programme managers around the world
are aware of the association between haemolysis, G6PD deficiency
and PQ and will be wary of expanded use without evidence of
relative safety.
The trials included in this review do not mention PQ resistance as
a potential threat. PQ clearly should be used where it is of clinical
importance, especially for P. vivax and P. ovale. Its effectiveness
against those parasites could be compromised by resistance if used
at lowdoses in populationswhereP. falciparum,P. vivax andP. ovale
coexist. As for all antimalarial drugs, there is a global responsibility
to maintain the effectiveness of PQ for as long as possible without
withholding it when needed. In this case, that translates into using
it to reduce transmission only if there is reasonable evidence that
it actually has that effect. Otherwise, it will be used to little or
no effect but its value for radical cure may be diminished by the
development of resistant Plasmodium parasites.
Potential biases in the review process
None known.
Agreements and disagreements with other
studies or reviews
In aCochrane Review ofmass drug administration (MDA) (Poirot
2013), the authors found no studies directly comparing MDA
regimens that included 8AQs with regimens that did not. In a
secondary analysis, the authors then subgrouped included non-
randomized controlled trials by regimens with and without 8AQs.
In high endemicity areas, two studies included PQ, and one study
did not. During multiple MDA rounds, there were substantial
drops in parasitaemia regardless of whether PQ was included. At
1 to 3 months, the studies without PQ showed larger impact than
the one study that did, but this single observation from a non-
randomized comparison cannot be relied upon. In a second similar
subgroup analysis of four before and after studies, the stratified
analysis was uninformative.
In an opinion piece in the Lancet, the possibility that doses lower
than 0.5 to 0.75 mg/kg might still be very effective in blocking
transmission is raised (White 2013). Based on the current review,
however, there is insufficient information to know whether the
effect is preserved with doses of less than 0.4 mg/kg.
A review in the Malaria Journal provides an analysis of published
and unpublished data on 158 subjects with different drug expo-
sures spanning 80 years (White 2012). The methods and sources
of data are not clearly specified, but the authors argue this provides
evidence that PQ decreases infectivity much faster than the effect
on gametocytes would suggest. Our review identified very limited
data from controlled studies testing the effect of PQ on infectious-
ness to mosquitoes (2 trials, with 30 participants, in people given
non-artemisinin treatments), so was not able to confirm or refute
this early effect on gametocyte viability.
A paper whose title implies it was a systematic review of the impact
of artemisinin derivatives and PQ on infectiousness (Abay 2013)
included only two before-and-after trials using PQ with small
numbers of patients. Neither of these studies met our inclusion
criteria (Rieckmann 1968; Clyde 1971). A historical review of
patients treated at clinics in India with either AS+SP+PQ (single
dose 0.75 mg/kg on the third treatment day, nine sites) or AS+SP
alone (12 sites) observed that PQ reduced the gametocyte clearance
time by 45% and the AUC of gametocyte density over time (up
to 28 days) by about the same proportion (Shah 2013). They
expressed the reduction as a hazard ratio with PQ increasing the
rate of gametocyte clearance by 1.9 (95% CI 1.1 to 1.3). These
results are consistent with our findings.
In relation to current WHO guidelines, no direct evidence was
available to include in this systematic review to support the cur-
rently recommended 0.25 mg/kg dose as effective in reducing
transmission either from individuals or in communities (WHO
2012b). Ongoing studies may help inform this current gap in our
knowledge (Eziefula 2012).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current policy recommendations that 0.25 mg/kg PQ should
be added as a single dose to primary treatment for P. falci-
parum malaria in areas that are targeting elimination or are fac-
ing artemisinin resistance are based on judgements and inferences
rather than reliable evidence of an effect at this dose.
Decisions must be specific to the country or area where the in-
troduction is being considered. In a high endemicity area, the di-
lutional effects are likely to be important. If PQ is given as part
of clinical treatment in a low endemicity area, what might be im-
portant is whether most people with parasitaemia are likely to be
seen at clinic. Thus the evidence presented in this review is likely
to be used to lead to different decisions depending on a variety of
epidemiological, malarial and logistic factors.
Whilst harm at the currently recommended dose of 0.25 mg/
kg is likely to be much less than at higher doses, these trials are
insufficient to evaluate whether the drug is safe (for widespread
use) at any dose.
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Implications for research
Future RCTs of low dose PQ should include measures of infec-
tiousness to mosquitoes over an extended period including the
days immediately following treatment, and stratify the analysis by
participants with and without gametocytes at baseline.
The impact on individuals with G6PD deficiency (an agreed upon
set of the most widespread genotypes and those with the greatest
likelihood for harm) should be assessed.
Given the high frequency of asymptomatic infections, information
on individual patients should be combined with modelling or
community-based trials of treatment regimens with and without
PQ to determine the malaria and population characteristics under
which PQ is likely to be an important additional contributor to
malaria elimination programmes (including mass treatment and
’test and treat’) .
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arango 2012
Methods Quasi-RCT: alternate allocation to AQ+SP and AQ+SP+PQ, then MQ+AS and
MQ+AS+PQ
Participants Inclusion criteria:
1. Uncomplicated malaria
2. Pf only
3. Not pregnant
4. Voluntary consent
Colombia
82 patients, aged one to 75 years (mean age ranged from 24 to 35 years in four groups)
Gametocytes in 23/82 (28%)
Interventions All loose combinations
1. AQ+SP
2. AQ+SP+PQ
3. MQ+AS
4. MQ+AS+PQ
AQ: 25 mg/kg total dose divided into 10 mg/kg on day 1 and 7.5 mg/kg on days 2 and
3
SP: 25 mg/kg/1.25 mg/kg single dose on day 1
MQ: 25 mg/kg total dose, divided into 8.3 mg/kg per day for 3 days
AS: 4 mg/kg per day for 3 days
PQ: 0.75 mg/kg, total single dose on day 2
Outcomes Day 1 (pretreatment with schizonticide), 4, and 8
Asexual and gametocyte counts in thick smears
Gametocyte prevalence
Gametocyte density
Notes No mention of G6PD status
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Alternate allocation.
Allocation concealment (selection bias) Unclear risk Not discussed.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of incomplete data.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
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Arango 2012 (Continued)
Other bias Unclear risk Nothing obvious.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not discussed.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not discussed.
Chen 1993a
Methods RCT
Participants 18 participants with P. falciparum
Interventions A: MQ 750 mg
B: MQ 750 mg + SP (1500 mg/75 mg)
C: MQ 750 mg + PQ 45 mg
All single doses
Follow-up: 28 days for gametocytes and 21 days for infectiousness
Outcomes Gametocyte prevalence at days 3, 8, 14, and 21
Infectiousness to An. dirus
Sporozoite infections in mosquitoes
Infectivity of sporozoite-infected mosquitoes to subsequent patients
Notes Only abstract available.
Mosquitoes fed on the patients were allowed to develop sporozoites which were then fed
on uninfected people. One of the MQ + PQ group passed the infection to a new person
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Trial authors stated it was randomized in abstract.
Allocation concealment (selection bias) Unclear risk No information in abstract.
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients were followed up.
Selective reporting (reporting bias) Unclear risk No information in abstract.
Other bias Unclear risk None known.
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Chen 1993a (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Stated to be double blind in title.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information in abstract.
Chen 1994
Methods Possibly individually RCT (stated to be randomized but no information given)
Dates of trial not reported.
Participants 27 patients with slide positive P. falciparum including both asexual stages and gameto-
cytes. No information given on age or sex. All dosages appear to be adult dosages
Site: malaria-endemic Hainan Island, China.
Exclusion criteria: history of antimalarial treatment for present attack
Interventions 1. Artemisinin: 1200 mg per day for 5 days (not included in review)
2. MQ 750 mg single dose day 1 (reported as day 0).
3. MQ 750 mg single dose + PQ 45 mg single dose day 1 (reported as day 0)
Outcomes 1. Gametocyte density: days 5, 8, 15, 22, and 29 (reported in paper as days 4, 7, 14, 21,
and 28 since first day was day 0). Given as % of initial density on chart only
2. Percentage of participants infectious to An. dirus: days 5, 8, 15, and 22 (reported as
days 4, 7, 14, and 21).
3. Percentage of mosquitoes infected: days 5, 8, 15, and 22 (reported as days 4, 7, 14,
and 21)
Notes For gametocyte density, graph only of percentages; no raw numbers given except range
of asexuals and gametocyte numbers reported for each group on day 1 (reported as day
0)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information on sequence generation.
Trial authors described process as partici-
pants “divided into groups A, B, and C”.
Equal number in each group and lack of
detail suggests randomization not done ad-
equately
Allocation concealment (selection bias) High risk No data to suggest any measures to conceal
allocation.
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Chen 1994 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing participants in intervention
groups 2 and 3.
Selective reporting (reporting bias) Low risk No obvious selective reporting.
Other bias Low risk No indication of other bias.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
El-Sayed 2007
Methods Individually RCT
Dates of trial: Randomization June 2004; trial done 17 August 2004 to 3 September
2004
Participants 104peoplewith asymptomaticP. falciparumpositive by slide andpositive for gametocytes
by PCR. No information given on age and sex
Site: Two villages in East Sudan where there is seasonal malaria, mainly P. falciparum,
during October to December.
Exclusion criteria: pregnancy, history of sulfa allergy, fever or other symptoms, Plasmod-
ium spp other than P. falciparum present.
Interventions 1. AS: Children < 50 kg: 4 mg/kg; All > 50 kg: 200 mg (two 100 mg tabs) days 1, 2,
and 3 (reported as days 0, 1, and 2)
SP: Children < 50 kg: 25 mg/kg S + 1.25 mg/kg P; All > 50 kg: 3 tablets of 500 mg S +
25 mg P
2. As for 1. above plus PQ 0.75 mg/kg day 4 (reported as day 3)
Outcomes 1. Proportion of people with P. falciparum parasites by PCR days 4, 8 and 15 (reported
as days 3, 7 and 14)
2. Proportion of people with gametocytes by RT-PCR days 8 and 15 (reported as days
7 and 14)
3. Adverse events days 2, 3, 4, 8 and 15 (reported as days 1, 2, 3, 7 and 14)
4. Packed cell volume days 1, 8 and 15 (reported as days 0, 7 and 14)
Notes The trial was conducted about twomonths after the initial screening for positives (asymp-
tomatic carriers)
Risk of bias
Bias Authors’ judgement Support for judgement
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El-Sayed 2007 (Continued)
Random sequence generation (selection
bias)
Low risk “The list of carriers was sorted according
to village and age to ensure that the treat-
ment groups were balanced with respect to
these two variables. The random allocation
of this ordered list into the treatment arms
was then created using restricted random-
ization with a block size of 12 in STATA
v7”
Allocation concealment (selection bias) Unclear risk No information given.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only three of 104 participants did not
complete follow-up.
Selective reporting (reporting bias) Low risk No obvious selective reporting.
Other bias Low risk No indication of other bias.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Patients and health staff were not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Lab staff doing PCR were blinded.
Eziefula 2013
Methods Individually randomized placebo-controlled, double blind trial conducted December,
2011 to March, 2013
Participants 468 randomized, aged one to 10 years old, male and female
Inclusion criteria:
1. P. falciparum mono infection with parasite density lower than 500000 parasites/µL
2. Normal G6PD enzyme function
3. Fever or history of fever in past 24 hours
Exclusion criteria:
1. Signs of severity
2. Haemoglobin concentration < 80 g/L
3. Known allergy to the trial drugs
4. Antimalarials taken within the past two days
5. PQ taken within the past four weeks
6. Blood transfusion within the past 90 days
Interventions 1. AL standard three day (twice per day) course + placebo (given with 5th AL dose, ie,
with 1st dose on 3rd day of treatment)
2. AL + 0.1 mg/kg PQ
3. AL + 0.4 mg/kg PQ
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Eziefula 2013 (Continued)
4. AL + 0.75 mg/kg PQ (reference)
Outcomes Primary efficacy: Mean duration of gametocyte carriage
Secondary efficacy: Point prevalence of gametocytes on days 7, 10, and 14; gametocyte
circulation time (days), AUC of gametocyte density
Primary safety: Arithmeticmeanmaximum decrease in haemoglobin concentration from
enrolment to day 28
Secondary safety: Day of haemoglobin nadir, maximum percentage decrease in haemo-
globin, percentage of participants with haemoglobin concentration lower than 50 g/
L, requirement for blood transfusion, evidence of black urine, and frequency of severe
adverse events
Notes G6PD enzyme function based on a fluorescence spot test (R&D Diagnostics, Aghia
Paraskevi, Greece)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated four-digit treatment
assignment codes and allocated these to
random dose groups in block sizes of 16
Allocation concealment (selection bias) Low risk Only the pharmacist was aware of alloca-
tion.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 8% of patients were lost to follow-
up. No group significantly different from
others
Selective reporting (reporting bias) Low risk None detected or suspected.
Other bias Low risk None detected or suspected.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Masking syrup” added to all treatments to
mask taste of drug
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded.
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Gogtay 2004
Methods Allocated by “simple, computer-generated randomization code”
Participants Twenty-two patients in Mumbai, India
Inclusion criteria:
1. > 18 years
2. normal G6PD
3. > 55 P. falciparum gametocytes/µL on admission
Exclusion criteria:
1. Complicated malaria
Interventions 1. Quinine days 1 to 7: 30 mg/kg/day + PQ (45 mg)
2. Quinine days 1 to 7: 30 mg/kg/day + bulaquine (approximately 75 mg base)
Outcomes Asexual and gametocyte counts on days 1, 4, 8, 15, 22 and 29
Adverse events
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomization.
Allocation concealment (selection bias) Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of incomplete data.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias High risk Unbalanced allocation (9 versus 13) and
small number of participants
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Laboratory technician reading blood
smears was blinded.
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Gogtay 2006
Methods Randomized (computer-generated) to PQ or bulaquine (1:2 ratio) after primary treat-
ment with quinine + doxycycline
Participants 93 participants in India
Inclusion criteria:
1. > 16 years
2. Male
3. Uncomplicated Pf only
4. > 55 P. falciparum gametocytes/µL on admission
Exclusion criteria:
1. Antimalarial treatment in previous two weeks
2. Allergy to trial drug
3. G6PD deficient
Interventions All patients:
Quinine days 1 to 7: 30 mg/kg/day (10 mg/kg/day three times per day) + 100 mg
doxycycline
Randomization and treatment on day 4
1. PQ
2. Bulaquine
Outcomes Gametocyte prevalence, density and viability on days 1, 4, 15, 22 and 29
Adverse events
Notes Gametocyte viability assessed by Shute’s technique (exflagellation)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomization.
Allocation concealment (selection bias) Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of incomplete data. Three par-
ticipants (two bulaquine, one PQ) did not
return for follow-up
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk None noted.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
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Gogtay 2006 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Slide readers were blinded.
Kamtekar 2004
Methods Individually RCT, comprising two distinct comparisons a: (CQ or [CQ+SP]) with and
without PQ and b: QN with and without PQ
Dates of trial: not given.
Participants 57 people aged≥ 16 years with symptomatic uncomplicated and 46 with severe (WHO
criteria) P. falciparummalaria, diagnosed by thick and thin blood slides. Gametocytaemic
within first 72 hrs with > 55 P. falciparum gametocytes/µL
Site: urban areas of Mumbai, India.
Exclusion criteria: Pregnant or lactating, treatment for malaria within last two weeks,
co-infection with P.vivax, history of PQ allergy.
Interventions Comparison a: for uncomplicated malaria
All received CQ (some also got SP)
Day 4: randomized to PQ or placebo (45 mg)
Comparison b: for severe malaria
All received quinine
Day 8: randomized to PQ or placebo (dose 45 mg)
Doses background drugs: CQ 10 mg/kg on days 1 and 2; 5 mg/kg on day 3; SP 1500
mg; quinine dose 10 mg/kg every 8 hrs for 24 to 48 hrs and orally for total of 7 days
Outcomes 1. Proportion of people with gametocytes, days 1, 4, 8, 15, 22, 29
2. Proportion of people with viable gametocytes (exflagellation), days 1, 4, 8, 15, 22, 29
3. Gametocyte density (given as range) days 1, 4, 8, 15, 22, 29
Notes No screening for G6PD deficiency. It is not stated how many got SP in addition to CQ
or why
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “simple computer generated randomiza-
tion code”.
Not all patients had gametocytes on day 1.
Inclusion criteria were that the person had
to have gametocytes in the first 72 hours
(from day 1?). This suggests some post ran-
domization inclusions or exclusions
Allocation concealment (selection bias) Unclear risk No information.
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Kamtekar 2004 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Originally there were 57 people included
inuncomplicated comparison (a), ofwhom
2 were lost to follow-up and 9 were not
evaluated as they showed CQ resistance
There were 46 in severe comparison (b), of
whom 3 were lost to follow-up
The final numbers evaluated in each group
were (a) 22 and 24 (b) 22 and 21
Selective reporting (reporting bias) Unclear risk No obvious selective reporting.
Other bias High risk It was not clear why some patients got SP
and others did not, and the numbers in
each group are not given
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Trial used a placebo for PQ. Patients and
health workers were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Slide readers were blinded.
Khoo 1981
Methods Individually RCT
Dates of trial: between June 1976 and March 1978.
Participants 69 people (adults and children of both sexes, no ages specified) with G6PD deficiency
(full or partial by Brewer’s methaemoglobin reduction test) who were slide positive for
malaria (P. falciparum, P. vivax or mixed).
Site: Sabah, Malaysia.
Exclusion criteria: other associated clinical conditions.
Interventions 1. CQ: 1.5 g CQ over 3 days for P. falciparum, P. vivax or mixed, less for children
2. CQ + PQ: CQ as above plus 75 mg PQ over 3 days for P. falciparum; 210 mg PQ
over 14 days for P. vivax and mixed infections; less for children
3. SP (not included in this review): 1.5 g S and 75 mg P, single dose
Outcomes 1. Haemolysis
2. Proportion cleared parasites by 72 hours
3. Need for blood transfusion
4. Renal failure
Notes The participants are not divided by P. falciparum, P. vivax or mixed, so it is not possible
to use the data.
Risk of bias
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Khoo 1981 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “those found G6PD deficient were ran-
domly assigned”.
Allocation concealment (selection bias) Unclear risk No information given.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information given.
Selective reporting (reporting bias) Low risk No apparent selective reporting.
Other bias Low risk No indication of other bias.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Kolaczinski 2012
Methods Individually RCT
Dates of trial: between July and January, from 2000 to 2003.
Participants 237 individuals aged from 3 to 70 years, in 5 villages for Afghan refugees in Pakistan
Inclusion: > 2 years of age, P. falciparum mono-infection, confirmed by slide, will be
resident during entire follow-up period
Exclusions: pregnancy, signs of severe malaria, report of antimalarial drug in past 21
days, other serious disease
Interventions 1. CQ: 3 days 25 mg/kg.
2. CQ+PQ: CQ as in 1; PQ on day 3 (0.5 mg/kg).
3. SP: 25(S)/1.25(P) mg/kg in single dose.
4. SP+PQ: SP as in 3; PQ on same day (0.5 mg/kg).
Outcomes 1. Clinical treatment failure (PCR non-adjusted and adjusted)
2. Gametocytes on day 8.
3. Gametocyte density on days 1 to 8 of follow-up.
4. Genotyping of resistant strains for CQ and SP-specific mutations
Notes Also included CQ + AS and SP + AS arms, compared with CQ +/- PQ and SP +/- PQ
arms, respectively
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients numbered sequentially at enrol-
ment. Randomnumberswith treatment as-
signment from Excel-generated lists, then
paired with patient numbers
Allocation concealment (selection bias) Low risk Patient number concealed until after enrol-
ment.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 209 of 237 randomized completed treat-
ment and at least one follow-up test. 47
(13%) of those randomized did not con-
tribute data. Variable numbers tested dur-
ing follow-up (see analyses)
Selective reporting (reporting bias) Low risk None detected.
Other bias Low risk None noted.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Identified in report as ’single-blind’. Man-
ager (gave Rx) not blinded; patients, mi-
croscopists and health workers ’partially
blinded’ due to different drug appearance
and times of follow-up. No placebos used,
but vitamin given to those in non-PQ arms
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Implied only.
Ledermann 2006
Methods Individually RCT
Date of trial: July to Oct 2001.
Participants 117 malaria cases with P. falciparum ≥ 400 asexual stages/µL (thick film) recruited by
mass blood survey and passive case detection. Symptoms not required
Age: ≥ 15 years
Site: Central Java, Indonesia, an area with high CQ resistance and resurgent malaria
approximately equal P. falciparum and P. vivax.
Exclusion criteria: Pregnancy, breast feeding, body weight < 40kg, G6PD deficiency,
history of antimalarial or antibiotic in last seven days, severe or complicated malaria,
history or allergy or adverse reaction to trial medications, Pv or mixed infection
Interventions 1. CQ only (not included in this review).
2. CQ+SP: CQ 150 mg base, 10, 10 and 5 mg/kg on days 1, 2, 3 (reported as days 0,
1, 2)
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SP 500 mg S 25 mg P on day 1 (reported as day 0).
3. CQ+SP as for group 2 above plus PQ 45 mg on day 1 (reported as day 0)
4. CQ+SP as for group 2 above plus PQ 45 mg on day 3 (reported as day 2)
Outcomes 1. Parasite clearance time assessed at days 1, 3, 8, 15, 22, 29 or day of recurrent para-
sitaemia (reported as days 0, 2, 7, 14, 21, 28)
2. Fever clearance time at days 2, 3, 4, 5, 8, 12, 15, 19, 22, 29
3. Proportion of people with gametocytes (from chart) days 1 to 29
4. Adverse events.
Notes Some comparisons in the results reported include the CQ only group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Trial subject codes were assigned to treat-
ment arms by a random process (not spec-
ified)
Allocation concealment (selection bias) High risk Eligibles were assigned a sequential par-
ticipant number by the screening physi-
cian. Pre-packaged treatment but not stated
whether allocation was concealed
Incomplete outcome data (attrition bias)
All outcomes
Low risk 7%of participants withdrew before day 28.
Selective reporting (reporting bias) Unclear risk Abstract states that drugs were well toler-
ated and safe but no evidence is given in
report
Other bias Low risk No indication of other bias.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding was implied only.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding was implied only.
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Methods Individually RCT
Dates of trial not stated.
Participants 176 patients with acute uncomplicated P. falciparum. After exclusion of QN+tetracycline
group: 146.
Age 14 to 62.
All male.
Site: Hospital for Tropical Diseases, Bangkok, Thailand.
Exclusion criteria: Severe malaria, mixed malaria infection, history of drug hypersensi-
tivity, any antimalarial within last 48 hrs, urine positive for sulfonamide or 4AQ
People with G6PD deficient phenotype were excluded from receiving PQ
Interventions 1. QN: QN sulfate (300 mg salt/tab) at 10 mg salt/kg, three times per day for 7 days
2. QN+tetracycline (excluded from this review).
3. QN+PQ low dose: QN as above in 1 plus PQ 15 mg base/tab, 0.25 mg/kg base (adult
dose 15 mg base) daily for 7 days
4. QN+PQ high dose: QN as above in 1 plus PQ 0.50 mg/kg base (adult dose 30 mg
base) daily for 7 days
5. AS: AS 50 mg salt/tab 3.3 mg/kg (adult dose 200 mg) on day 1 and 1.65 mg/kg (adult
dose 100 mg) daily on days 2 to 7
6. AS+PQ (high dose): AS as above plus PQ 0.5 mg/kg base daily on days 1 to 7
Outcomes 1. Parasite clearance time: measured at 12 hrs until clearance
2. Gametocyte clearance time: median, 12 hrs until clearance
3. Fever clearance time (measured every 4 hr at first and then every 6 to 12 hrs until
resolution of fever)
4. Parasite reduction ratio at 48 hrs.
5. Reappearance of infection P. falciparum/P. vivax up to 28 days.
6. Prevalence of gametocytes on admission/after treatment/total
7. Gametocyte carriage: total number of hours for which gametocytes were detectable
Notes Patients with recrudescence of P. falciparum or relapse of P. vivax were re-treated with 7
day QN+tetracycline or ’standard doses’ of CQ+PQ respectively; not clear if they were
excluded from further trial
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Method not stated. Patients with G6PD
deficiency were excluded from getting PQ
which suggests randomization was biased
Allocation concealment (selection bias) Unclear risk No information given.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 122/142 of the original participants in the
5 groups studied here completed follow-
up. Patients with recrudescences of P. falci-
parum or relapse of P. vivax were re-treated
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Pukrittayakamee 2004 (Continued)
with QN+tetracycline or CQ+PQ respec-
tively; not clear if they were excluded from
further trial
Selective reporting (reporting bias) Unclear risk Not detected.
Other bias Unclear risk Those who were unable to stay in hospital
until clearance of both fever and parasites
were excluded from trial of fever clearance
time
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not reported.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Shekalaghe 2007
Methods Individually RCT
Dates of trial: June to Sept 2006.
Participants 108 children with fever > 37.5 °C or history of fever in last 48 hours and P. falciparum
mono-infection 500 to 100,000/µL.
Age three to 15 years.
Both sexes.
Site: Mynuzi health center, NE Tanzania, a hyperendemic area with rainy seasons in
Mar-June and Oct-Dec
Exclusion criteria: Hb < 8, inability to take drugs orally, known hypersensitivity to meds,
reported anti-malarial treatment in last two weeks, evidence of chronic disease or acute
infection other than malaria, domicile outside trial area, signs of severe malaria, eligible
for other malaria studies
Interventions 1. AS+SP: AS: 4 mg/kg once daily for 3 days; SP: S 25 mg/kg and P: 1.125 mg/kg
2. AS+SP+PQ: As above for AS and SP plus PQ base 0.75 mg/kg on the third day
Outcomes 1. Proportion of people with gametocytes (by microscopy) days 1, 4, 8, 15, 29, and 43
(reported as 0, 3, 7, 14, 28, and 42)
2. Proportion with gametocytes (by PCR), same time points.
3. Gametocyte density by PCR.
4. AUC for gametocyte presence.
5. Adverse events.
6. Adequate clinical and parasitological response.
7. Haemoglobin.
Notes Hb outcome assessed with respect to G6PD variant.
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generated in STATA 8.0 using restricted
randomization with block size of 20
Allocation concealment (selection bias) Unclear risk Pre-prepared envelopes (but person who
opened envelope administered treatment)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 2 out of 108 failed to complete fol-
low-up.
Selective reporting (reporting bias) Low risk No information given.
Other bias Low risk No indication of other bias.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Trial physician evaluated patients, opened
envelopes, and administered treatment.
Other staff were blinded. Not clear if par-
ticipants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Singhasivanon 1994
Methods Individually RCT
Dates of trial: not stated.
Participants 23 people with uncomplicated P. falciparum malaria, parasitaemia between 1-5 per 1000
rbc.
Age five to 12 years, sex not stated.
Exclusion criteria: antimalarial drugs, urine with quinoline and sulfonamide drugs, other
diseases, hematocrit ≤ 20%, inability to take oral medication
Interventions 1. MSP: MQ 20 mg/kg; S 40 mg base/kg; P 2 mg/kg; single dose
2. MSP + PQ: As above plus PQ 0.75 mg/kg single dose. MSP+PQ crushed and mixed
with 30 ml syrup (83% dextrose)
Outcomes 1. Gametocyte clearance time (days) (assessed twice daily until negative, then once daily,
by blood slide)
2. Adverse drug reactions, assessed once daily in first week then once a week
3. Parasite clearance time (hrs).
4. Fever clearance time (hrs).
5. Cure rate.
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Notes Those who vomited within three hours of Rx were excluded - this is a post randomization
exclusion
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information given.
Allocation concealment (selection bias) Unclear risk No information given.
Incomplete outcome data (attrition bias)
All outcomes
High risk Outcomes only reported for 18 of the 23
participants.
Selective reporting (reporting bias) Unclear risk No information given.
Other bias High risk Those who vomited within three hours of
Rx were excluded- this is a post randomiza-
tion exclusion
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Smithuis 2010
Methods Individually RCT (5 comparisons - 10 arms).
Follow-up: Patients were asked to return weekly for 9 weeks for assessment and at any
other time they were unwell
Dates: Dec 2008 to March 2009.
Participants Number: 808 people attending clinics in Myanmar.
Inclusion criteria: Age > 6 months, weight > 5 kg, P. falciparum mono-infection 500 to
200,000 parasites/µL or co-infection with P. vivax, informed consent.
Exclusion criteria: Pregnancy, signs of severe malaria, severe malnutrition, history of
hypersensitivity to any of the trial drugs, severe malnutrition, concomitant febrile illness,
history of psychiatric disorder, a full course of MQ in the previous nine weeks or any
other antimalarial in the previous 48 hrs
Interventions Each of the five trial arms was divided into two where one half also received a one-off
dose of 0.75 mg/kg PQ on day 1
Groups:
1+2. AS plus amodiaquine, fixed-dose combination: 25 mg/67.5 mg or 50 mg/135 mg
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or 100 mg/270 mg tablets
• AS 4 mg/kg once daily for 3 days
• AQ 10.8 mg base/kg once daily for 3 days
3+4. AL, fixed-dose combination: 20 mg/120 mg tablets.
• A 3.3 mg/kg in two divided doses each day for 3 days
• L 19.8 mg/kg in two divided doses each day for 3 days
• Advised to consume fatty food or breast feed before each dose
5+6. AS plus MQ, fixed-dose combination: 25 mg/55 mg or 100 mg/220 mg tablets
(artesunate: Guilin, Lariam: Hoffman-La Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 8.8 mg/kg once daily for 3 days
7+8. Artesunate plus MQ, loose combination (artesunate: Guilin, Lariam: Hoffman-La
Roche)
• AS 4 mg/kg once daily for 3 days
• MQ 25 mg base/kg as a single dose on day 1 (reported as day 0)
9+10.DHAP, fixed-dose combination: 40mg/320mg or 20mg/160mg tablets (Artekin:
Holleykin)
• DHA 2.5 mg/kg once daily for 3 days
• P 20 mg/kg once daily for 3 days
First dose supervised, all others unsupervised.
Outcomes 1. Recurrent parasitaemia at day 15, 29, 43 and 64 (reported as days 14, 28, 42 and
63).
2. Treatment failure due to P. falciparum.
3. Gametocytaemia prevalence.
4. Person-gametocyte weeks.
5. Haemoglobin on days 1 and 64.
6. Adverse events (monitoring not described).
Notes Funding: Médecins sans Frontières (Holland).
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “After patients were screened and enrolled
in the study, they were stratified prospec-
tively into three age groups (1 to 4 years,
5 to 14 years and older than 14 years).
Patients were randomly assigned in equal
numbers to receive one of the five different
treatments. They were then randomly as-
signed either a single dose of PQ ... or not”
Allocation concealment (selection bias) Low risk “Treatment allocations were put in sealed
envelopes in blocks of 50 for each
age group, and random assignment was
achieved by patients drawing an envelope
from a box after enrollment. When the
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box was empty, another 50 envelopes were
added”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition is low in absolute numbers and
unlikely to have introduced significant bias
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk No indication of other bias.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open label trial for patients and medical
staff.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Microscopists were blinded.
Sutanto 2013
Methods 2-arm open-label RCT
Follow-up: days 1, 2, 3, 7, 14, 21, 28, 35 and 42, and any other day in between if they
felt ill. Thin and thick blood smears and dried blood spot for genotyping
Dates of randomization: December 2008 to March 2010
Participants 188 (178 left on day 3) + 186 (171 day 3). Analysis based on those still present on day 3
Setting: Hanura Primary Health Center, Padang Cermin district, Lampung province
located at the southern end of Sumatra
Endemicity: low malaria endemicity with a malaria prevalence of 1.8% across all age
groups. Seasonal transmission
Inclusion criteria:
(1) parasite density ≥ 1000 parasites/µL;
(2) age ≥ 5 years;
(3) normal glucose-6-phosphate dehydrogenase (G6PD) enzyme levels based on a qual-
itative test;
(4) haemoglobin level ≥ 8 g/dL;
(5) negative pregnancy test (assessed by human chorionic gonadotropin urine test) or
not breastfeeding;
(6) no signs of severe malnutrition;
(7) no other chronic diseases;
(8) no history of allergy
to the trial drugs;
(9) ability to return for 42 days of follow-up.
Interventions 1. Standard 3-day DHAP (fixed-dose tablets of 40 mg dihydroartemisinin and 320 mg
piperaquine; D-ARTEPP, Guilin Pharmaceutical Co, Ltd)
2. DHAP as in intervention 1; PQ: Day 3, single dose of 0.75 mg/kg, rounded to the
nearest half tablet. Mean dose was 0.74 mg/kg (range, 0.5 to 0.94 mg/kg)
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Outcomes 1. Gametocyte prevalence-days 7, 14, 21, 28, 35, and 42
2. Gametocyte clearance rates by day 42 in patients with gametocytes on day 3,
3. Recurrence of asexual stages ofP. falciparum, polymerase chain reaction (PCR) adjusted
and unadjusted for reinfections
4. Gametocyte development by day 42 in patients who were gametocyte free on day 3
5. Gametocyte densities between days 3 and 42 inclusive.
6. Asexual infection recurrence by PCR.
7. Hemoglobin on days 7, 42.
8. Adverse events.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated sequences in blocks
of four.
Allocation concealment (selection bias) Low risk Opaque envelopes used in order at the
health centre.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No evidence of differential attrition.
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk None detected.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding, no PQ placebo.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information.
Vasquez 2009
Methods Individually RCT
Dates of trial: April 2007 to Feb 2008.
Participants 50 people with uncomplicated P. falciparum diagnosis by thick blood slide, 150 to 50,
000 parasites/µL
Age one year and over, both sexes.
Exclusion criteria: pregnant, mixed infection, danger signs and complications, allergy
to antimalarials, serious illness at time or presentation, antimalarial treatment in last 72
hrs, MQ in last four weeks
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Interventions 1. AS+MQ
Age 1 to 6: AS 50 mg on days 1, 2, 3 (reported as 0, 1, 2); MQ 250 mg on day 2
Age 7 to 13: AS 100 mg on days 1, 2, 3, MQ 250 mg on days 1, 2, 3
Age > 13: AS 200 mg on days 1, 2, 3, MQ 500 mg on days 1, 2, 3
2. AS+MQ+PQ
As above plus PQ:
Age 1 to 6: 0.3-0.6 mg/kg day 3 (reported as day 2).
Age 7 to 13: 22.5 mg/kg day 3.
Age > 13: 45 mg day 3.
Outcomes Assessed on days 2, 3, 4, 8, 15, 22, 29, 36, and 43.
1. Clinical recurrence.
2. Parasitemia prevalence.
3. Parasite density.
4. Fever resolution.
5. Prevalence of gametocytes.
6. Density of gametocytes.
7. Adverse effects.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Seems to be alternate allocation following
order of arrival (“segun el ordende llegada”)
Allocation concealment (selection bias) Unclear risk Not clear.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts noted.
Selective reporting (reporting bias) Low risk No evidence of bias.
Other bias Low risk No suggestion of other bias.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Does not seem to be blinded (“con de-
termination no ciega del efecto en grupos
iguales”)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk
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Wang 2006
Methods Individually RCT
Participants Number of participants: 214 (no dropouts mentioned)
Gabon International Tropical Medicine Institute
Age range: 6-60,
All have P. falciparum malaria clinical symptoms and blood smear positive.
1. Trial group: 108, male 50, female 58, age 16.4 +/-10.5
2. Control group: 106, male 52, female 54, age 18.2 +/- 9.4
Exclusion criteria:
N/A
Interventions 1. Artesunate IM injection, daily for 5 days, 1.2 mg/kg each dose, first dose double.
PQ 3 tablets (base 7.5 mg/tablet, children use half ) once a day, for 5 days.
2. Only artesunate IM injection daily for 5 days, 1.2 mg/kg each dose, the first dose
double total 5 days.
Outcomes 1. Fever clearance time: (hrs) below 37°C continuously measured four times
2. Clinical cure rate at day 7
3. Adverse events (not specified)
4. Recrudescence rate: symptoms appeared again after clinical cure; parasite
appeared in blood smear by 28 days
Follow-up: 28 days
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stated to be randomized, and the fact that numbers per group
are not equal supports this contention
Allocation concealment (selection bias) Unclear risk No information given.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not stated.
Selective reporting (reporting bias) Unclear risk Not stated.
Other bias Unclear risk Unknown.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not stated to be blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated to be blinded.
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AL = artemether-lumefantrine
AQ = amodiaquine
AS = artesunate
CQ = chloroquine
DHAP = dihydroartemisinin-piperaquine
G6PD = glucose-6-phosphate dehydrogenase
IM = Intramuscular
MQ = mefloquine
PCR = polymerase chain reaction
Pf = Plasmodium falciparum
PQ = primaquine
QN = quinine
RCT = randomized controlled trial
SP = sulfadoxine-pyrimethamine
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baird 2002 Outcome is cure of asexual infection. No gametocyte outcomes
Barber 1929 Not a RCT or quasi-RCT. No controls.
Barber 1932 MDA with PQ; no other drug.
Brueckner 1998 Participants were not infected. Safety only trial.
Bunnag 1980 Comparison of SP plus either five day PQ 15mg, single dose PQ 30mg or single dose PQ 45 mg in patients
with and without gametocytes at presentation. No regimen without PQ. Not a RCT or quasi-RCT. Authors
state they will do further studies, including transmission. No difference in gametocyte outcomes between
regimens, and gametocytes persisted for up to 21 days
Burgess 1961 Comparison of 15 mg, 30 mg and 45 mg dose of PQ. Outcomes were gametocyte prevalence, density,
percent of mosquitoes infected and mean oocysts per mosquito up to eight days. Not a RCT or quasi-RCT.
No other drug. Although this trial used different doses by group (12 participants total), they were assigned
to participants based on age or body size, and therefore it was not a valid comparison of different doses
Cai 1985 Not a RCT.
Carter 2011 No 8AQ in trial.
Che 1987 No mention of randomization. No valid comparison group (pyronaridine phosphate plus sulfadoxine plus
PQ versus pyronaridine phosphate only)
Che 1990 No appropriate control group.
Chevalley 2010 In vitro studies only. Not a RCT.
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Clyde 1962 All patients got PQ.
Clyde 1970 Individual before-and-after but small number of patients and not controlled
Clyde 1971 Individual before-and-after but small number of patients and not controlled
da Silva 1984 Trial of treatment regimens, some including PQ, for P. vivax and P. falciparum.
Degowin 1966 No 8AQ in trial.
Doi 1989 Community observational study. Except for a small pilot study, everyone in the intervention villages got
PQ. There no ’before’ data from these villages. In the control site, some children received treatment
Giao 2004 No appropriate control group (trial of CV8 (contains PQ) versus atovaquone-proguanil)
Gogtay 1999 Compares QN+PQ against QN+bulaquine. Not a relevant comparison
Gunders 1961 Before-and-after studies of gametocytes and mosquito feeds on people with gametocytes given
pyrimethamine and PQ in doses ranging from 10 mg to 40 mg base. No group without other drug
Hii 1987 Controlled before-and-after study comparing SP+PQ+ITN versus SP+PQ only. Only one cluster per arm
and no group without PQ
Huang 1993 Not a RCT. Unbalanced groups.
Huang 1996 PQ given to both intervention groups in same regimen. Malaria treatment regimen was varied (low and
higher dose pyronardine/SP)
Huang 2001 No gametocyte outcomes.
Jeffery 1956 Non-randomized comparison of gametocytes and infectivity of artificially infected patients treated with CQ
or CQ+PQ
Jeffery 1963 Observational study of gametocytes and infectivity of two patients given PQ
Jerace 1933 Case series studying gametocytes and infectivity of patients given PQ
Kaneko 1989 Non-randomized community trial comparing SP+PQ in one village with SP only in another. Only one
cluster per arm. The trial was predominantly mass fever test and treat but 75% of people in the intervention
village were treated versus 18% in the control village
Karbwang 1991 Not randomized, no gametocyte outcomes.
Karbwang 1992 Pharmacokinetic study; no gametocyte outcomes or control group
Kyaw 1994 No control group. All patients got PQ.
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Li 2007 No gametocyte outcomes.
Li 2010 No gametocyte outcomes.
Lin 2004 All patients got PQ.
Mackerras 1949 No other malaria treatment ; one patient fed on before and after PQ
Rieckmann 1968 Two patients given 45 mg PQ only and fed on by mosquitoes before and after. No other malaria treatment
or control group
Rieckmann 1969 18 patients given CQ alone (N = 2), CQ plus 45 mg PQ (N = 3), or PQ alone in doses ranging from 15
to 45 mg, at either single dose or at one to two week intervals, and fed on before and after one of the doses
of PQ. Non-randomized or quasi-randomized
Santana 2007 Study of 14 day regimen of 15 mg PQ. Some P. falciparum cases were included but study did not distinguish
between the patients with P. falciparum and P. vivax . Study was a comparison of association between
methaemoglobinaemia after 14 day PQ in people with and without G6PD deficiency
Shah 2013 Review of 21 trials from national drug resistance monitoring system of India. Compares 9 sites where
AS+SP+PQ was used with 12 sites where it was not
Shekalaghe 2010 Randomized comparison of anaemia after SP+AS+PQ versus placebo. Children with haemoglobin < 8 g
were excluded from receiving PQ
Shekalaghe 2011 Trial was a comparison of SP+AS+PQ versus placebo. No comparison of groups with and without PQ
Sun 2011 Artesunate + PQ versus Quinimax only. No appropriate control group
Suputtamongkol 2003 Comparison of MQ+AS versus MQ + PQ. No appropriate control group
Tangpukdee 2008 Comparison of Artequick (contains PQ) with MQ+AS. No appropriate control group and no gametocyte
outcomes
Yang 1989 All patients got PQ, though different doses of PQ and other malaria treatments
Yeramian 2005 PQ given only to P. vivax patients for 14 days.
Young 1959 No other malaria treatment; case series of PQ given daily, bi weekly or weekly to Pf patients
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Characteristics of studies awaiting assessment [ordered by study ID]
Chen 1993b
Methods
Participants
Interventions
Outcomes
Notes Study not yet located
Ishii 2009
Methods Unclear
Participants Residents of trial villages in Solomon Islands (number not given)
Interventions Testing of clinical malaria patients for G6PD and addition of single dose PQ to other malaria treatment if appropriate
Outcomes Village prevalence of malaria
Notes
Li 2006
Methods
Participants
Interventions
Outcomes
Notes Study not yet located
Characteristics of ongoing studies [ordered by study ID]
D’Alessandro ongoing
Trial name or title Primaquine’s Gametocytocidal Efficacy inMalaria Asymptomatic Carriers TreatedWith Dihydroartemisinin-
piperaquine in The Gambia
Methods Randomized, open label
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D’Alessandro ongoing (Continued)
Participants 1200 participants will be recruited
Inclusion criteria:
• Age ≥ 1 year
• Weight > 10 kg
• P. falciparum mono-infection, density of at least 20 parasites/µL
• Axillary temperature < 37.5ºC
• Resident in the trial area and willingness to reside for the duration of the trial
• Written informed consent (plus an assent in children > 12 years of age)
Exclusion criteria:
• G6PD deficiency haemoglobin < 8 g/dL
• Known allergy to any of the trial medications
• Known pregnancy or breastfeeding
• Clear/documented history of anti-malarial treatment two weeks before contact with trial team
• History of blood transfusion in the previous three months
• Any chronic or acute conditions that might interfere with the trial as judged by the research clinician
• History of sickle cell anaemia
Interventions 1. Control: complete course of DHA-PPQ (Eurartesim)
2. Experimental: DHA-PPQ plus single dose PQ at 0.75 mg/kg body weight
3. Experimental: DHA-PPQ plus single dose PQ at 0.4 mg base/kg body weight
4. Experimental: DHA-PPQ plus single dose PQ at 0.2 mg base/kg body weight
Outcomes Primary: Prevalence of P. falciparum gametocyte carriers (QT-NASBA) (time frame: Day 7)
Secondary:
1. Prevalence of P. falciparum gametocytes carriers on days 3, 10, 14, 28 and 42 as determined by QT-
NASBA
2. Proportion of individuals infectious to mosquitoes (DMFA) on day 7, with direct membrane feeding
assay
3. Haemoglobin change from day 0 on days 3, 7, 10, 14, 21, 28, 35 and 42, as mean (±SD) difference in
haemoglobin measured between baseline (day 0) and each follow-up visit day by trial arm
4. Prevalence of infection (asexual stages) on day 3
5. Proportion of participants with recurrent infection (PCR adjusted and unadjusted) from day 7 to day
42
6. Occurrence of adverse events and serious adverse events
Starting date August 2013; December 2014 (final data collection date for primary outcome measure)
Contact information udalessandro@mrc.gm +220-4495442-6 ext 4001
jokebe@mrc.gm +220-4495442-6 ext 4009 (Joseph Okebe)
Notes
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Gosling ongoing
Trial name or title Phase 2a Dose Escalation Study of the Efficacy, Safety, and Pharmacokinetics of Low Dose Primaquine for
Gametocytocidal Activity Against P. Falciparum in Sub-Saharan Africa and South East Asia
Methods Randomized, single blind (outcomes assessor blinded)
Participants 50 participants being recruited
Inclusion criteria:
• Male
• Age ≥ 18 years and < 50 years
• Malaria blood thick film positive
• Presence of gametocytes on thick blood film
• Agrees to admission to trial ward for 26 hours post diagnosis and available for follow-up visits
• No allergies to trial drugs
• Hemoglobin ≥ 8 g/dL
• No evidence of severe or chronic disease
• Written, informed consent
Interventions Group 1: Active comparator: dihydroartemisinin-piperaquine (DP) only
Group 2: Experimental: DP and 0.125 mg/kg PQ
Group 3: Experimental: DP and 0.5 mg/kg PQ
Outcomes Primary: mosquito infectivity assessed through membrane feeding (time frame: 7 days)
Secondary:
1. Gametocyte prevalence and density, hours 2, 6, 12, and 24, days 2, 3, 7, 14, and 28
2. PQ pharmacokinetics - AUC of parent drug and metabolite, hours 1, 2, 3, 4, 6, 8, 12, and 24
3. Asexual parasite prevalence and density baseline, hours 2, 6, 12, and 24, days 2, 3, 7, 14, and 28
4. Safety measurements including haemoglobin and signs of haemolysis baseline, days 1, 2, 3, 7, and 14
Starting date September 2014 (final data collection date for primary outcome measure)
Contact information goslingr@globalhealth.ucsf.edu 415 597 8114
Notes Sites in Mali and Thailand
Indonesia ongoing
Trial name or title Surveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine (MTC Belu)
Sub-title: Impact of Mass Screening and Selective Treatment With Dihydroartemisinin-piperaquine Plus
Primaquine on Malaria Transmission in High Endemic Area, Belu Regency, Nusa Tenggara Timur Province,
Indonesia: a Randomized Cluster Trial
Methods Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment,
Masking: Open Label, Primary Purpose: Treatment
Cluster randomized.
Participants Target sample size: 1488 participants
Inclusion criteria:
• All villagers of the all selected clusters
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Indonesia ongoing (Continued)
Exclusion criteria:
• Pregnant women during their first trimester
• Single dose PQ should not be given for infants under one year-old, pregnant women in all trimesters of
pregnancy, breast-feeding mother and patients with G6PD deficiency
Age minimum: N/A
Age maximum: N/A
Gender: Both
Interventions Drug: dihydroartemisinin-piperaquine
Drug: PQ
(1) intervention arm of mass screening and treatment with interval of 6 weeks; (2) intervention arm of mass
screening and treatment with interval of three months; and (3) control arm without mass screening and
treatment. The intervention arm with six weeks interval represents a new proposed method to detection
malaria infections, while the intervention arm with three month interval represents the Ministry of Health
current policy of active case detection in Indonesia, and the third arm will serve as the control for Ministry
of Health’s policy
No arm without PQ
Outcomes Malaria incidence (time frame: six months)
Anemia (time frame: six months)
Starting date June 2013
Contact information Indonesia University/ Walter and Eliza Hall Institute of Medical Research
Notes http://clinicaltrials.gov/show/NCT01878357 Stated to be completed
Saunders ongoing
Trial name or title Active Surveillance for P. falciparum Drug Resistance With Assessment of Transmission Blocking Activity of
Single Dose Primaquine in Cambodia
Methods Randomized, open label
Participants 150 male and female participants
Inclusion criteria:
1. Volunteer with uncomplicated P. falciparum malaria (volunteers with mixed P. falciparum and P. vivax
infections may be enrolled), 18 to 65 years of age
2. Baseline asexual parasite density between 1000 to 200,000 parasites/µL
3. Able to provide informed consent
4. Available and agree to follow-up for anticipated trial duration including three day treatment course at
the MTF and weekly follow-up for the 42-day period
5. Authorized by local commander to participate if active duty military
Exclusion criteria:
1. Allergic reaction or contraindication to DHA, piperaquine or PQ
2. Significant acute comorbidity requiring urgent medical intervention
3. Signs or symptoms and parasitological confirmation of severe malaria
4. Use of any antimalarial within the past 14 days.
61Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Saunders ongoing (Continued)
5. Class I or II G6PD deficiency (defined as severe) as determined at screening
6. Pregnant or lactating female, or female of childbearing age, up to 50 years of age, who does not agree
to use an acceptable form of contraception during the trial
7. Clinically significant abnormal EKG, including a QTcF interval > 500 ms at enrolment.
8. Known or suspected concomitant use of QTc prolonging medications.
9. Judged by the investigator to be otherwise unsuitable for trial participation
Interventions Group 1: DHA-piperaquine 3-day course plus 45 mg single dose PQ
Group 2: DHA-piperaquine 3-day course of DHA-piperaquine
Outcomes Primary: Efficacy rates at 42 days for DP with and without single dose PQ for uncomplicated P. falciparum
diagnosed by positive PCR-corrected malaria microscopy
Secondary: Efficacy of PQ to treat sexual stage gametocyte infection and prevent transmission of P. falciparum
gametocytes to mosquitoes.
Starting date December 2012; December 2014 (final data collection date for primary outcome measure)
Contact information David Saunders, MD, MPH 66-2-696-2798 david.saunders@afrims.org
Chanthap Lon, MD, MCTM 855 23 881 845 chanthapl@afrims.org
Notes
Shekalaghe ongoing
Trial name or title The Optimal Timing of Primaquine to Prevent Malaria Transmission After Artemisinin-Combination Ther-
apy
Methods Randomized, open label
Participants 250 male and female participants
Inclusion criteria:
• Age three years to 17 years
• Residents of research area
• Willingness to come for complete scheduled follow-up
• Uncomplicated malaria with P. falciparum mono-infection
• Axillary temperature > 37.5°C and < 39.5°C, or history of fever in previous 48 hours
• No history of adverse reactions to trial medication
• Understanding of the trial procedures by parent or guardian and willing to participate by signing
written informed consent forms
Exclusion criteria:
• Haemoglobin below 9 g/dL
• Inability to take drugs orally
• Known hypersensitivity to any of the drugs given
• Reported treatment with antimalarial chemotherapy in the past two weeks
• Evidence of chronic disease or acute infection other than malaria
• Domicile outside the trial area
• Signs of severe malaria (such as respiratory distress, altered consciousness deep breathing, anaemia)
• Participating in other malaria studies conducted in the region
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Shekalaghe ongoing (Continued)
• Mixed malaria parasite species infection
• Positive pregnant test by urine (UPT) if participant is female aged above 12 years
• G6PD deficient using the fluorescence spot test
Interventions Group 1: Artemether lumefantrine (AL) 6 dose regime orally
Group 2: AL 6 dose regime plus single dose PQ (0.75/kg) on day 0
Group 3: AL 6 dose regimen plus single dose PQ (0.75/kg) on day 2
Outcomes Primary: Gametocyte prevalence and density by microscopy and QT-NASBA on day 14
Secondary:
• Haemoglobin level on days 3, 7, 10 and 14
• Proportion of infected mosquitoes on day 7 after initiation of treatment and the intensity of infection
(oocyst burden) by membrane feeding assay
Starting date May 2013; October 2013 (final data collection date for primary outcome measure)
Contact information Seif Shekalaghe, MD, PhD sshekalaghe@ihi.or.tz +255 755 470472
Notes ClinicalTrials.gov NCT019067889. Tanzania KCMC and Ifakara
Thailand Pharmacokinetic
Trial name or title Pharmacokinetic Study of Primaquine and Dihydroartemisinin-Piperaquine in Healthy Subjects
Methods Phase 1
Randomized, crossover, open label safety/efficacy study. Primary purpose: treatment
Participants Inclusion criteria:
1. Healthy as judged by a responsible physician with no abnormality identified on a medical evaluation
including medical history and physical examination.
2. Male and female non-smokers aged between 18 years to 60 years.
3. Males and females weight between 36 to 75 kilograms.
4. A female is eligible to enter and participate in this study if she is: of non-childbearing potential
including pre-menopausal females with documented (medical report verification) hysterectomy or double
oophorectomy; or postmenopausal defined as 12 months of spontaneous amenorrhoea or 6 months of
spontaneous amenorrhoea with serum follicle stimulating hormone levels > 40 mIU/mL or 6 weeks
postsurgical bilateral oophorectomy with or without hysterectomy; or of childbearing potential, has a
negative serum pregnancy test at screening and prior to start the study drug in each period, and abstain from
sexual intercourse or agrees to using effective contraceptive methods (for example, intrauterine device,
hormonal contraceptive drug, tubal ligation or female barrier method with spermicide) during the study
until completion of the follow-up procedures.
5. A male is eligible to enter and participate in this study if he: agrees to abstain from (or use a condom
during) sexual intercourse with females of childbearing potential or lactating females; or is willing to use a
condom/spermicide, during the study until completion of the follow-up procedures.
6. Provide a signed and dated written informed consent prior to study participation.
7. Normal electrocardiogram (ECG) with QTc < 450 msec.
8. Willingness and ability to comply with the study protocol for the duration of the trial.
Exclusion criteria:
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Thailand Pharmacokinetic (Continued)
1. Females who are pregnant, trying to get pregnant, or are lactating.
2. The subject has evidence of active substance abuse that may compromise safety, pharmacokinetics, or
ability to adhere with protocol instructions.
3. A positive pre-study hepatitis B surface antigen, positive hepatitis C antibody, or positive human
immunodeficiency virus-1 (HIV-1) antibody result at screening.
4. Subjects with a personal history of cardiac disease, symptomatic or asymptomatic arrhythmias,
syncopal episodes, or additional risk factors for torsades de points (heart failure, hypokalaemia) or with a
family history of sudden cardiac death.
5. A creatinine clearance < 70 mL/min as determined by Cockcroft-Gault equation: CLcr (mL/min) =
(140 - age) * Wt / (72 * Scr) (multiply answer by 0.85 for females) where age is in years, weight (wt) is in kg,
and serum creatinine (Scr) is in units of mg/dL (Cockroft 1976).
6. History of alcohol or substance abuse or dependence within six months of the study.
7. Use of prescription or non-prescription drugs except paracetamol at doses of up to 2 g/day, including
vitamins, herbal and dietary supplements (including St. John’s Wort) within seven days (or 14 days if the
drug is a potential enzyme inducer) or five times the drug half-life (whichever is longer) prior to the first
dose of study medication until the completion of the follow-up procedure, unless in the opinion of
investigator, the medication will not interfere with the study procedures or compromise subject safety; the
investigator will take advice from the manufacturer representative as necessary.
8. The subject has participated in a clinical trial and has received a drug or a new chemical entity within
30 days, or five half-lives, or twice the duration of the biological effect of any drug (whichever is longer)
prior to the first dose of study medication.
9. The subject is unwilling to abstain from ingesting alcohol within 48 hours prior to the first dose of
study medication until collection of the final pharmacokinetic sample during each regimen.
10. Subjects who have donated blood to the extent that participation in the study would result in more
than 300 mL blood donated within a 30-day period. Note: This does not include plasma donation.
11. Subjects who have a history of allergy to the study drug or drugs of this class, or a history of drug or
other allergy that, in the opinion of the investigator, contraindicates participation in the trial. In addition, if
heparin is used during pharmacokinetic sampling, subjects with a history of sensitivity to heparin or
heparin-induced thrombocytopenia should not be enrolled.
12. Lack of suitability for participation in this study, including but not limited to, unstable medical
conditions, systemic disease manifested by tendency to granulocytopenia for example rheumatoid arthritis
and lupus erythematosus that in the opinion of the investigator would compromise their participation in
the trial.
13. AST or ALT > 1.5 upper limit of normal (ULN).
14. Subjects with history of renal disease, hepatic disease or cholecystectomy or both.
15. G6PD deficient detected by Beutler’s dye test.
16. Abnormal methaemoglobin level.
17. History of antimalarial drugs use including but not limited to MQ, chloroquine, PQ, artesunate,
piperaquine and pyronaridine treatment within 12months.
18. Subject who received quinacrine in last 30 days.
Interventions This study is planned to evaluate potential pharmacokinetic interaction of orally administered PQ and
dihydroartemisinin-piperaquine (DHA-PQP) in healthy adult subjects. The results of these interaction studies
are important in order to provide clinical guidance for the optimum combination of PQ and DHA-PQP
treatment regimens in malaria infections
Outcomes Primary
* AUC for PQ (Time frame: 36 days; designated as safety issue: no)
Area under the concentration-time curve [(AUC(0-) and AUC(0-last)] and maximal concentration (Cmax )
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Thailand Pharmacokinetic (Continued)
for PQ and metabolites when given alone or together with DHA-PQP
* AUC for dihydroartemisinin (DHA) and piperaquine (PQP) (Time frame: 36 days; designated as safety
issue: no)
Area under the concentration-time curve [(AUC(0-) and AUC(0-last)] and maximal concentration (Cmax )
for piperaquine and dihydroartemisinin when given alone as DHA-PQP or together with PQ
Secondary
Clearance rate and half life of PQ and its metabolites (Time frame: 36 days; designated as safety issue: no)
PQ, carboxyprimaquine (and other detectable major metabolites) elimination clearance rate (CL/F), terminal
elimination half-life (t1/2) and apparent volume of distribution (Vd)
Dihydroartemisinin and piperaquine elimination clearance rate (CL/F), terminal elimination half-life (t1/2)
and apparent volume of distribution (Vd).
Safety of dihydroartemisinin-piperaquine (DHA-PQP) (Time frame: 36 days; designated as safety issue: yes)
Safety and tolerability parameters, including adverse events, clinical laboratory, and vital signs assessments,
in particular QTc prolongation for DHA-PQP
Pharmacogenetic polymorphisms (Time frame: 36 days; designated as safety issue: yes) in the case of unusually
high or low drug levels
Starting date February 2012
Contact information Sasithon Pukrittayakamee, MD, Principal Investigator, Mahidol University
Salwaluk Panapipat, MBA salwaluk@tropmedres.ac
Notes NCT01525511
University of Oxford
Tiono ongoing
Trial name or title Low Dose Primaquine for Clearance of Gametocytes: LOPRIM-1
Methods Randomized, parallel assignment, double blind (subject, caregiver, investigator, outcomes assessor); safety/
efficacy study
Participants Target sample size 360 participants
Inclusion criteria
• Age > 2 and <15 years
• P. falciparum parasitaemia > 1000 and < 200,000 parasites/µL
• P. falciparum gametocytes
• Normal G6PD
• Informed consent by legally acceptable representative
Exclusion criteria
• Enrolled in another study
• Fever or history of fever in last 24 hours
• Evidence of severe illness/danger signs
• Known allergy to study medications
• Hb < 8 g/dL
• Started menstruation
• Pregnancy or breastfeeding
• Antimalarials taken within last 2 days
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Tiono ongoing (Continued)
• PQ taken within last 4 weeks
• Blood transfusion within the last 90 days
• Non-falciparum malaria co-infection
Interventions Group 1: Artemether lumefantrine
Group 2: Artemether lumefantrine with a single dose of 0.25 mg/kg PQ
Group 3: Artemether lumefantrine with a single dose of 0.4 mg/kg PQ
Outcomes Primary: gametocyte carriage (time frame: 14 days during follow-up)
Secondary:
• haematological recovery (time frame: 14 days during follow-up)
• transmission to An. gambiae mosquitoes (time frame: day 3, 7, 10 and 14)
Starting date September 2013
Contact information t.alfred@fasonet.bf; teun.bousema@lshtm.ac.uk
Notes Burkina Faso, Centre international de recherche et de formation sur le paludisme. Ougadougou
clinicaltrials.gov NCT01935882
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D A T A A N D A N A L Y S E S
Comparison 1. Non-artemisinin treatment regimen: PQ versus no PQ
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants with gametocytes 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Day 2 2 96 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.46, 1.12]
1.2 Day 3 1 83 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.45, 1.27]
1.3 Day 4 or 5 3 273 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.64, 1.09]
1.4 Day 8 6 498 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.50, 0.73]
1.5 Day 15 4 366 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.22, 0.43]
1.6 Day 22 4 323 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.20, 0.46]
1.7 Day 29 4 290 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.19, 0.60]
1.8 Day 36 1 81 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.15, 0.94]
1.9 Day 43 1 73 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.04, 1.71]
2 Gametocyte clearance time
(days)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Participants infectious 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Day 5 2 30 Risk Ratio (M-H, Fixed, 95% CI) 0.06 [0.01, 0.42]
3.2 Day 8 2 30 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.01, 0.45]
3.3 Day 15 2 30 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.02, 1.04]
3.4 Day 22 2 30 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.02, 7.24]
4 Mosquitoes infected 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Day 5 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Day 8 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Day 15 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Day 22 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Participants with asexual
parasites at day 29
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Not PCR adjusted 1 209 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.78, 1.15]
5.2 PCR adjusted 1 209 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.69, 1.23]
6 Asexual parasite clearance time
(hrs)
2 144 Mean Difference (IV, Fixed, 95% CI) -1.68 [-9.60, 6.25]
7 Adverse effects 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 Nausea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Dizziness 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.4 Any adverse effect 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 By dose: Participants with
gametocytes at day 8
(microscopy)
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 <0.4 mg/kg PQ per day 1 59 Risk Ratio (M-H, Fixed, 95% CI) 1.76 [0.97, 3.18]
8.2 ≥ 0.4 to < 0.6 mg/kg PQ
per day
2 283 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.50, 0.76]
8.3 ≥ 0.6 mg/kg PQ per day 4 186 Risk Ratio (M-H, Fixed, 95% CI) 0.39 [0.25, 0.62]
9 By schedule: Participants with
gametocytes at day 8
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 Single dose day 1 or 2 4 191 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.49, 0.84]
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9.2 Single dose day 3 or 4 3 243 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.33, 0.60]
9.3 Multiple dose days 1 to 7 1 96 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.69, 2.18]
Comparison 2. Artemisinin treatment regimen: PQ versus no PQ
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants with gametocytes
(microscopy)
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Day 4 4 971 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.95, 1.05]
1.2 Day 8 6 1121 Risk Ratio (M-H, Random, 95% CI) 0.24 [0.10, 0.55]
1.3 Day 15 4 995 Risk Ratio (M-H, Random, 95% CI) 0.09 [0.04, 0.19]
1.4 Day 22 3 858 Risk Ratio (M-H, Random, 95% CI) 0.10 [0.03, 0.32]
1.5 Day 29 4 945 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.04, 0.72]
1.6 Day 36 3 838 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.01, 4.32]
1.7 Day 43 4 917 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.04, 3.89]
2 Participants with gametocytes
(PCR)
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Day 8 3 627 Risk Ratio (M-H, Random, 95% CI) 0.42 [0.26, 0.69]
2.2 Day 15 3 609 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.11, 0.70]
2.3 Day 29 1 90 Risk Ratio (M-H, Random, 95% CI) 0.23 [0.08, 0.62]
2.4 Day 43 1 79 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.17, 1.16]
3 Participants with asexual
parasites
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Day 8 1 94 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.30, 5.40]
3.2 Day 15 2 198 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.23, 4.15]
3.3 Day 29 3 747 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.33, 0.88]
3.4 Day 43 2 178 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.59, 1.81]
4 Asexual parasite clearance time
(hrs)
1 50 Mean Difference (IV, Fixed, 95% CI) -6.0 [-16.31, 4.31]
5 Haemoglobin concentration 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Day 8 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Day 15 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.3 Day 29 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.4 Day 43 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 % change in haemoglobin
concentration
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Day 8 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 Day 15 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 Day 29 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.4 Day 43 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Other adverse effects 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 Headache 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 Fatigue 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 Nausea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.4 Vomiting 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.5 Abdominal pain 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.6 Diarrhea 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.7 Pruritis 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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7.8 Paresthesia 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.9 Unspecified 1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 By dose: Participants with
gametocytes at day 8
(microscopy or PCR)
8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 < 0.4 mg/kg PQ per day 1 223 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.44, 1.02]
8.2 ≥ 0.4 to < 0.6 mg/kg PQ
per day
2 269 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.19, 0.59]
8.3 ≥ 0.6 mg/kg PQ per day 7 1380 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.22, 0.37]
9 By schedule: Participants
with gametocytes at day 8
(microscopy or PCR)
8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 Single dose day 1 or 2 2 843 Risk Ratio (M-H, Fixed, 95% CI) 0.13 [0.07, 0.22]
9.2 Single dose day 3 or 4 5 748 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.37, 0.59]
9.3 Multiple dose days 1 to 7 1 50 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.16, 2.56]
Comparison 3. PQ versus no PQ; gametocytes at day 8 (microscopy or PCR); stratified by non-artemisinin versus
artemisinin regimen
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants with gametocytes at
day 8 (microscopy or PCR)
12 2141 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.32, 0.58]
1.1 Non-artemisinin-based
partner drug
6 499 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.44, 0.88]
1.2 Artemisinin-based partner
drug
8 1642 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.21, 0.52]
Comparison 4. PQ versus other 8AQ
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Participants with gametocytes on
day 8
2 112 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.26, 0.66]
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Analysis 1.1. Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 1
Participants with gametocytes.
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 1 Non-artemisinin treatment regimen: PQ versus no PQ
Outcome: 1 Participants with gametocytes
Study or subgroup With primaquine Without primaquine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 2
Chen 1993a (1) 6/6 6/6 27.5 % 1.00 [ 0.75, 1.34 ]
Kolaczinski 2012 (2) 10/40 18/44 72.5 % 0.61 [ 0.32, 1.16 ]
Subtotal (95% CI) 46 50 100.0 % 0.72 [ 0.46, 1.12 ]
Total events: 16 (With primaquine), 24 (Without primaquine)
Heterogeneity: Chi2 = 5.23, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 1.47 (P = 0.14)
2 Day 3
Kolaczinski 2012 (3) 14/39 21/44 100.0 % 0.75 [ 0.45, 1.27 ]
Subtotal (95% CI) 39 44 100.0 % 0.75 [ 0.45, 1.27 ]
Total events: 14 (With primaquine), 21 (Without primaquine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
3 Day 4 or 5
Arango 2012 (4) 8/20 7/20 10.5 % 1.14 [ 0.51, 2.55 ]
Chen 1993a (5) 3/6 6/6 9.8 % 0.54 [ 0.25, 1.16 ]
Kolaczinski 2012 (6) 12/38 23/44 32.1 % 0.60 [ 0.35, 1.04 ]
Kolaczinski 2012 (7) 32/71 31/68 47.6 % 0.99 [ 0.69, 1.42 ]
Subtotal (95% CI) 135 138 100.0 % 0.84 [ 0.64, 1.09 ]
Total events: 55 (With primaquine), 67 (Without primaquine)
Heterogeneity: Chi2 = 4.01, df = 3 (P = 0.26); I2 =25%
Test for overall effect: Z = 1.30 (P = 0.19)
4 Day 8
Arango 2012 (8) 7/20 11/20 7.8 % 0.64 [ 0.31, 1.30 ]
Chen 1993a (9) 0/6 6/6 4.6 % 0.08 [ 0.01, 1.12 ]
Kamtekar 2004 (10) 7/24 16/22 11.8 % 0.40 [ 0.20, 0.79 ]
Kolaczinski 2012 (11) 24/36 37/43 23.8 % 0.77 [ 0.60, 1.01 ]
Kolaczinski 2012 (12) 27/70 52/67 37.5 % 0.50 [ 0.36, 0.69 ]
Ledermann 2006 (13) 2/28 2/16 1.8 % 0.57 [ 0.09, 3.68 ]
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(. . . Continued)
Study or subgroup With primaquine Without primaquine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ledermann 2006 (14) 0/28 3/16 3.1 % 0.08 [ 0.00, 1.53 ]
Pukrittayakamee 2004 (15) 17/29 5/15 4.7 % 1.76 [ 0.81, 3.83 ]
Pukrittayakamee 2004 (16) 9/37 5/15 5.0 % 0.73 [ 0.29, 1.82 ]
Subtotal (95% CI) 278 220 100.0 % 0.60 [ 0.50, 0.73 ]
Total events: 93 (With primaquine), 137 (Without primaquine)
Heterogeneity: Chi2 = 17.88, df = 8 (P = 0.02); I2 =55%
Test for overall effect: Z = 5.32 (P < 0.00001)
5 Day 15
Chen 1993a 0/6 6/6 7.0 % 0.08 [ 0.01, 1.12 ]
Kamtekar 2004 (17) 1/24 8/22 9.0 % 0.11 [ 0.02, 0.84 ]
Kamtekar 2004 (18) 2/21 7/22 7.4 % 0.30 [ 0.07, 1.28 ]
Kolaczinski 2012 18/32 34/41 32.1 % 0.68 [ 0.48, 0.95 ]
Kolaczinski 2012 4/53 37/51 40.6 % 0.10 [ 0.04, 0.27 ]
Ledermann 2006 0/28 1/16 2.0 % 0.20 [ 0.01, 4.53 ]
Ledermann 2006 0/28 1/16 2.0 % 0.20 [ 0.01, 4.53 ]
Subtotal (95% CI) 192 174 100.0 % 0.31 [ 0.22, 0.43 ]
Total events: 25 (With primaquine), 94 (Without primaquine)
Heterogeneity: Chi2 = 28.69, df = 6 (P = 0.00007); I2 =79%
Test for overall effect: Z = 6.88 (P < 0.00001)
6 Day 22
Chen 1993a 0/6 3/6 5.8 % 0.14 [ 0.01, 2.28 ]
Kamtekar 2004 0/24 6/22 11.3 % 0.07 [ 0.00, 1.19 ]
Kamtekar 2004 0/21 0/22 Not estimable
Kolaczinski 2012 14/33 33/40 49.6 % 0.51 [ 0.34, 0.78 ]
Kolaczinski 2012 1/33 15/28 27.0 % 0.06 [ 0.01, 0.40 ]
Ledermann 2006 0/28 1/16 3.1 % 0.20 [ 0.01, 4.53 ]
Ledermann 2006 0/28 1/16 3.1 % 0.20 [ 0.01, 4.53 ]
Subtotal (95% CI) 173 150 100.0 % 0.30 [ 0.20, 0.46 ]
Total events: 15 (With primaquine), 59 (Without primaquine)
Heterogeneity: Chi2 = 10.52, df = 5 (P = 0.06); I2 =52%
Test for overall effect: Z = 5.61 (P < 0.00001)
7 Day 29
Chen 1993a 0/6 0/6 Not estimable
Kamtekar 2004 1/24 6/22 18.4 % 0.15 [ 0.02, 1.17 ]
Kamtekar 2004 0/21 0/22 Not estimable
Kolaczinski 2012 7/28 26/38 64.8 % 0.37 [ 0.19, 0.72 ]
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Study or subgroup With primaquine Without primaquine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kolaczinski 2012 3/20 5/15 16.8 % 0.45 [ 0.13, 1.59 ]
Ledermann 2006 0/28 0/16 Not estimable
Ledermann 2006 0/28 0/16 Not estimable
Subtotal (95% CI) 155 135 100.0 % 0.34 [ 0.19, 0.60 ]
Total events: 11 (With primaquine), 37 (Without primaquine)
Heterogeneity: Chi2 = 0.82, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 3.68 (P = 0.00023)
8 Day 36
Kolaczinski 2012 3/28 12/34 77.4 % 0.30 [ 0.09, 0.97 ]
Kolaczinski 2012 2/10 3/9 22.6 % 0.60 [ 0.13, 2.82 ]
Subtotal (95% CI) 38 43 100.0 % 0.37 [ 0.15, 0.94 ]
Total events: 5 (With primaquine), 15 (Without primaquine)
Heterogeneity: Chi2 = 0.49, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.10 (P = 0.036)
9 Day 43
Kolaczinski 2012 0/27 4/34 77.4 % 0.14 [ 0.01, 2.47 ]
Kolaczinski 2012 1/7 1/5 22.6 % 0.71 [ 0.06, 8.90 ]
Subtotal (95% CI) 34 39 100.0 % 0.27 [ 0.04, 1.71 ]
Total events: 1 (With primaquine), 5 (Without primaquine)
Heterogeneity: Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
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(1) Partner MQ: 0.75 mg/kg PQ day 1
(2) Partner SP: 0.5 mg/kg PQ day 1
(3) Partner SP: 0.5 mg/kg PQ day 1
(4) Partner AQ+SP: 0.75 mg/kg PQ day 2; outcome day 4
(5) Partner MQ: 0.75 mg/kg PQ day 1; outcome day 5
(6) Partner SP: 0.5 mg/kg PQ day 1; outcome day 4
(7) Partner CQ: 0.5 mg/kg PQ day 3; outcome day 4
(8) Partner AQ+SP: 0.75 mg/kg PQ day 2
(9) Partner MQ: 0.75 mg/kg PQ day 1
(10) Partner (CQ or (CQ+SP)): 0.75 mg/kg PQ day 4
(11) Partner SP: 0.5 mg/kg PQ day 1
(12) Partner CQ: PQ 0.5 mg/kg day 3
(13) Partner CQ+SP: 0.75 mg/kg PQ day 1
(14) Partner CQ+SP: 0.75 mg/kg PQ day 3
(15) Partner QN: 0.25 mg/kg PQ days 1-7
(16) Partner QN: 0.5 mg/kg PQ days 1-7
(17) Partner (CQ or (CQ+SP)): 0.75 mg/kg PQ day 4
(18) Partner QN: 0.75 mg/kg PQ day 8
Analysis 1.2. Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 2
Gametocyte clearance time (days).
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 1 Non-artemisinin treatment regimen: PQ versus no PQ
Outcome: 2 Gametocyte clearance time (days)
Study or subgroup WIth primaquine Without primaquine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Singhasivanon 1994 (1) 7 7 (2.7) 11 21.9 (4.4) -14.90 [ -18.18, -11.62 ]
-100 -50 0 50 100
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(1) Partner MQ+SP: 0.75 mg/kg PQ day 1
Analysis 1.3. Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 3
Participants infectious.
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 1 Non-artemisinin treatment regimen: PQ versus no PQ
Outcome: 3 Participants infectious
Study or subgroup Favours primaquine Without primaquine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 5
Chen 1993a (1) 0/6 6/6 40.6 % 0.08 [ 0.01, 1.12 ]
Chen 1994 (2) 0/9 9/9 59.4 % 0.05 [ 0.00, 0.79 ]
Subtotal (95% CI) 15 15 100.0 % 0.06 [ 0.01, 0.42 ]
Total events: 0 (Favours primaquine), 15 (Without primaquine)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 2.85 (P = 0.0043)
2 Day 8
Chen 1993a 0/6 6/6 43.3 % 0.08 [ 0.01, 1.12 ]
Chen 1994 0/9 8/9 56.7 % 0.06 [ 0.00, 0.89 ]
Subtotal (95% CI) 15 15 100.0 % 0.07 [ 0.01, 0.45 ]
Total events: 0 (Favours primaquine), 14 (Without primaquine)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.78 (P = 0.0054)
3 Day 15
Chen 1993a 0/6 2/6 35.7 % 0.20 [ 0.01, 3.46 ]
Chen 1994 0/9 4/9 64.3 % 0.11 [ 0.01, 1.80 ]
Subtotal (95% CI) 15 15 100.0 % 0.14 [ 0.02, 1.04 ]
Total events: 0 (Favours primaquine), 6 (Without primaquine)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.055)
4 Day 22
Chen 1993a 0/6 0/6 Not estimable
Chen 1994 0/9 1/9 100.0 % 0.33 [ 0.02, 7.24 ]
Subtotal (95% CI) 15 15 100.0 % 0.33 [ 0.02, 7.24 ]
Total events: 0 (Favours primaquine), 1 (Without primaquine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
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(1) Partner MQ: 0.75 mg/kg PQ day 1
(2) Partner MQ: 0.75 mg/kg PQ day 1
Analysis 1.4. Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 4 Mosquitoes
infected.
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 1 Non-artemisinin treatment regimen: PQ versus no PQ
Outcome: 4 Mosquitoes infected
Study or subgroup WIth primaquine Without primaquine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 5
Chen 1994 (1) 0/88 47/73 0.01 [ 0.00, 0.14 ]
2 Day 8
Chen 1994 0/62 49/90 0.01 [ 0.00, 0.23 ]
3 Day 15
Chen 1994 0/81 12/87 0.04 [ 0.00, 0.71 ]
4 Day 22
Chen 1994 0/88 5/64 0.07 [ 0.00, 1.18 ]
0.001 0.01 0.1 1 10 100 1000
Favours primaquine Favours control
(1) Partner MQ: 0.75 mg/kg PQ day 1; CI not corrected for unit of analysis throughout
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Analysis 1.5. Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 5
Participants with asexual parasites at day 29.
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 1 Non-artemisinin treatment regimen: PQ versus no PQ
Outcome: 5 Participants with asexual parasites at day 29
Study or subgroup Favours primaquine Without primaquine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Not PCR adjusted
Kolaczinski 2012 (1) 5/33 4/41 6.1 % 1.55 [ 0.45, 5.33 ]
Kolaczinski 2012 (2) 49/67 55/68 93.9 % 0.90 [ 0.75, 1.09 ]
Subtotal (95% CI) 100 109 100.0 % 0.94 [ 0.78, 1.15 ]
Total events: 54 (Favours primaquine), 59 (Without primaquine)
Heterogeneity: Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
2 PCR adjusted
Kolaczinski 2012 5/33 4/41 7.9 % 1.55 [ 0.45, 5.33 ]
Kolaczinski 2012 36/67 42/68 92.1 % 0.87 [ 0.65, 1.16 ]
Subtotal (95% CI) 100 109 100.0 % 0.92 [ 0.69, 1.23 ]
Total events: 41 (Favours primaquine), 46 (Without primaquine)
Heterogeneity: Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.90), I2 =0.0%
0.01 0.1 1 10 100
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(1) Partner SP: 0.5 mg/kg PQ day 1
(2) Partner CQ: 0.5 mg/kg PQ day 3
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Analysis 1.6. Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 6 Asexual
parasite clearance time (hrs).
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 1 Non-artemisinin treatment regimen: PQ versus no PQ
Outcome: 6 Asexual parasite clearance time (hrs)
Study or subgroup WIth primaquine Without primaquine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pukrittayakamee 2004 (1) 29 78 (23) 30 80 (26) 40.1 % -2.00 [ -14.52, 10.52 ]
Pukrittayakamee 2004 (2) 37 79 (19) 30 80 (26) 50.6 % -1.00 [ -12.14, 10.14 ]
Singhasivanon 1994 (3) 7 93 (15) 11 97 (39.9) 9.2 % -4.00 [ -30.07, 22.07 ]
Total (95% CI) 73 71 100.0 % -1.68 [ -9.60, 6.25 ]
Heterogeneity: Chi2 = 0.05, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
Test for subgroup differences: Not applicable
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(2) Partner QN: 0.5 mg/kg PQ days 1-7
(3) Partner MQ+SP: 0.75 mg/kg PQ day 1
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Analysis 1.7. Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 7 Adverse
effects.
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 1 Non-artemisinin treatment regimen: PQ versus no PQ
Outcome: 7 Adverse effects
Study or subgroup With primaquine Without primaquine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nausea
Singhasivanon 1994 (1) 1/7 3/11 0.52 [ 0.07, 4.09 ]
2 Vomiting
Singhasivanon 1994 2/7 2/11 1.57 [ 0.28, 8.74 ]
3 Dizziness
Singhasivanon 1994 1/7 1/11 1.57 [ 0.12, 21.26 ]
4 Any adverse effect
Singhasivanon 1994 2/7 3/11 1.05 [ 0.23, 4.78 ]
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better with primaquine worse with primaquine
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Analysis 1.8. Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 8 By dose:
Participants with gametocytes at day 8 (microscopy).
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 1 Non-artemisinin treatment regimen: PQ versus no PQ
Outcome: 8 By dose: Participants with gametocytes at day 8 (microscopy)
Study or subgroup With Primaquine Without Primaquine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 <0.4 mg/kg PQ per day
Pukrittayakamee 2004 (1) 17/29 10/30 100.0 % 1.76 [ 0.97, 3.18 ]
Subtotal (95% CI) 29 30 100.0 % 1.76 [ 0.97, 3.18 ]
Total events: 17 (With Primaquine), 10 (Without Primaquine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.061)
2≥ 0.4 to < 0.6 mg/kg PQ per day
Kolaczinski 2012 (2) 27/70 52/67 54.3 % 0.50 [ 0.36, 0.69 ]
Kolaczinski 2012 (3) 24/36 37/43 34.4 % 0.77 [ 0.60, 1.01 ]
Pukrittayakamee 2004 (4) 9/37 10/30 11.3 % 0.73 [ 0.34, 1.56 ]
Subtotal (95% CI) 143 140 100.0 % 0.62 [ 0.50, 0.76 ]
Total events: 60 (With Primaquine), 99 (Without Primaquine)
Heterogeneity: Chi2 = 4.82, df = 2 (P = 0.09); I2 =58%
Test for overall effect: Z = 4.52 (P < 0.00001)
3≥ 0.6 mg/kg PQ per day
Arango 2012 (5) 7/20 11/20 26.7 % 0.64 [ 0.31, 1.30 ]
Chen 1993a (6) 0/6 6/6 15.8 % 0.08 [ 0.01, 1.12 ]
Kamtekar 2004 (7) 7/24 16/22 40.6 % 0.40 [ 0.20, 0.79 ]
Ledermann 2006 (8) 2/28 2/16 6.2 % 0.57 [ 0.09, 3.68 ]
Ledermann 2006 (9) 0/28 3/16 10.7 % 0.08 [ 0.00, 1.53 ]
Subtotal (95% CI) 106 80 100.0 % 0.39 [ 0.25, 0.62 ]
Total events: 16 (With Primaquine), 38 (Without Primaquine)
Heterogeneity: Chi2 = 4.46, df = 4 (P = 0.35); I2 =10%
Test for overall effect: Z = 4.01 (P = 0.000061)
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(1) Partner QN: 0.25 mg/kg PQ days 1-7
(2) Partner SP: 0.5 mg/kg PQ day 1
(3) Partner CQ: 0.5 mg/kg PQ day 3
(4) Partner QN: 0.5 mg/kg PQ days 1-7
(5) Partner AQ+SP: 0.75 mg/kg PQ day 2
(6) Partner MQ: 0.75 mg/kg PQ day 1
(7) Partner (CQ or (CQ+SP)): 0.75 mg/kg PQ day 4
(8) Partner CQ+SP: 0.75 mg/kg PQ day 1
(9) Partner CQ+SP: 0.75 mg/kg PQ day 3
Analysis 1.9. Comparison 1 Non-artemisinin treatment regimen: PQ versus no PQ, Outcome 9 By
schedule: Participants with gametocytes at day 8.
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 1 Non-artemisinin treatment regimen: PQ versus no PQ
Outcome: 9 By schedule: Participants with gametocytes at day 8
Study or subgroup With primaquine Without primaquine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Single dose day 1 or 2
Arango 2012 (1) 7/20 11/20 19.7 % 0.64 [ 0.31, 1.30 ]
Chen 1993a (2) 0/6 6/6 11.6 % 0.08 [ 0.01, 1.12 ]
Kolaczinski 2012 (3) 24/36 37/43 60.3 % 0.77 [ 0.60, 1.01 ]
Ledermann 2006 (4) 2/28 5/32 8.4 % 0.46 [ 0.10, 2.17 ]
Subtotal (95% CI) 90 101 100.0 % 0.64 [ 0.49, 0.84 ]
Total events: 33 (With primaquine), 59 (Without primaquine)
Heterogeneity: Chi2 = 4.65, df = 3 (P = 0.20); I2 =36%
Test for overall effect: Z = 3.23 (P = 0.0012)
2 Single dose day 3 or 4
Kamtekar 2004 (5) 7/24 16/22 22.3 % 0.40 [ 0.20, 0.79 ]
Kolaczinski 2012 (6) 27/70 52/67 70.9 % 0.50 [ 0.36, 0.69 ]
Ledermann 2006 (7) 0/28 5/32 6.9 % 0.10 [ 0.01, 1.79 ]
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Study or subgroup With primaquine Without primaquine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Subtotal (95% CI) 122 121 100.0 % 0.45 [ 0.33, 0.60 ]
Total events: 34 (With primaquine), 73 (Without primaquine)
Heterogeneity: Chi2 = 1.51, df = 2 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 5.33 (P < 0.00001)
3 Multiple dose days 1 to 7
Pukrittayakamee 2004 (8) 17/29 5/15 48.1 % 1.76 [ 0.81, 3.83 ]
Pukrittayakamee 2004 (9) 9/37 5/15 51.9 % 0.73 [ 0.29, 1.82 ]
Subtotal (95% CI) 66 30 100.0 % 1.22 [ 0.69, 2.18 ]
Total events: 26 (With primaquine), 10 (Without primaquine)
Heterogeneity: Chi2 = 2.06, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Chi2 = 9.77, df = 2 (P = 0.01), I2 =80%
0.005 0.1 1 10 200
Favours experimental Favours control
(1) Partner AQ+SP: 0.75 mg/kg PQ day 2
(2) Partner MQ: 0.75 mg/kg PQ day 1
(3) Partner SP: 0.5 mg/kg PQ day 1
(4) Partner CQ+SP: 0.75 mg/kg PQ day 1
(5) Partner (CQ or (CQ+SP)): 0.75 mg/kg PQ day 4
(6) Partner CQ: 0.5 mg/kg PQ day 3
(7) Partner CQ+SP; 0.75 mg/kg PQ day 3
(8) Partner QN: 0.25 mg/kg PQ days 1-7
(9) Partner QN: 0.5 mg/kg PQ days 1-7
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Analysis 2.1. Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 1 Participants
with gametocytes (microscopy).
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 2 Artemisinin treatment regimen: PQ versus no PQ
Outcome: 1 Participants with gametocytes (microscopy)
Study or subgroup Favours primaquine Without primaquine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Day 4
Arango 2012 (1) 3/19 7/23 0.2 % 0.52 [ 0.15, 1.74 ]
Smithuis 2010 (2) 26/71 27/84 1.5 % 1.14 [ 0.74, 1.76 ]
Smithuis 2010 (3) 25/78 29/84 1.5 % 0.93 [ 0.60, 1.44 ]
Smithuis 2010 (4) 24/86 26/83 1.3 % 0.89 [ 0.56, 1.42 ]
Smithuis 2010 (5) 21/79 25/82 1.2 % 0.87 [ 0.53, 1.42 ]
Smithuis 2010 (6) 27/83 24/78 1.4 % 1.06 [ 0.67, 1.67 ]
Sutanto 2013 (7) 41/41 31/31 93.0 % 1.00 [ 0.95, 1.06 ]
Vasquez 2009 (8) 2/25 4/24 0.1 % 0.48 [ 0.10, 2.38 ]
Subtotal (95% CI) 482 489 100.0 % 1.00 [ 0.95, 1.05 ]
Total events: 169 (Favours primaquine), 173 (Without primaquine)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.80, df = 7 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
2 Day 8
Arango 2012 1/19 3/23 7.4 % 0.40 [ 0.05, 3.57 ]
Pukrittayakamee 2004 (9) 3/27 4/23 10.5 % 0.64 [ 0.16, 2.56 ]
Shekalaghe 2007 (10) 0/53 6/53 5.5 % 0.08 [ 0.00, 1.33 ]
Smithuis 2010 3/71 24/84 11.5 % 0.15 [ 0.05, 0.47 ]
Smithuis 2010 1/78 28/84 8.2 % 0.04 [ 0.01, 0.28 ]
Smithuis 2010 3/84 17/83 11.3 % 0.17 [ 0.05, 0.57 ]
Smithuis 2010 3/77 18/80 11.4 % 0.17 [ 0.05, 0.56 ]
Smithuis 2010 3/83 24/78 11.5 % 0.12 [ 0.04, 0.37 ]
Sutanto 2013 22/41 25/31 14.2 % 0.67 [ 0.48, 0.93 ]
Vasquez 2009 2/25 2/24 8.5 % 0.96 [ 0.15, 6.28 ]
Subtotal (95% CI) 558 563 100.0 % 0.24 [ 0.10, 0.55 ]
Total events: 41 (Favours primaquine), 151 (Without primaquine)
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Study or subgroup Favours primaquine Without primaquine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Heterogeneity: Tau2 = 1.29; Chi2 = 43.87, df = 9 (P<0.00001); I2 =79%
Test for overall effect: Z = 3.33 (P = 0.00086)
3 Day 15
Shekalaghe 2007 0/52 2/52 6.4 % 0.20 [ 0.01, 4.07 ]
Smithuis 2010 1/67 18/83 14.8 % 0.07 [ 0.01, 0.50 ]
Smithuis 2010 1/73 8/81 13.8 % 0.14 [ 0.02, 1.08 ]
Smithuis 2010 0/81 4/80 6.9 % 0.11 [ 0.01, 2.01 ]
Smithuis 2010 0/73 4/77 6.9 % 0.12 [ 0.01, 2.14 ]
Smithuis 2010 2/80 24/76 29.4 % 0.08 [ 0.02, 0.32 ]
Sutanto 2013 1/41 17/31 15.2 % 0.04 [ 0.01, 0.32 ]
Vasquez 2009 0/25 2/23 6.5 % 0.18 [ 0.01, 3.65 ]
Subtotal (95% CI) 492 503 100.0 % 0.09 [ 0.04, 0.19 ]
Total events: 5 (Favours primaquine), 79 (Without primaquine)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.33, df = 7 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 6.16 (P < 0.00001)
4 Day 22
Smithuis 2010 0/58 15/74 18.0 % 0.04 [ 0.00, 0.67 ]
Smithuis 2010 1/69 5/79 31.2 % 0.23 [ 0.03, 1.91 ]
Smithuis 2010 0/84 0/79 Not estimable
Smithuis 2010 0/70 0/72 Not estimable
Smithuis 2010 0/78 15/76 17.9 % 0.03 [ 0.00, 0.52 ]
Sutanto 2013 1/41 6/31 32.9 % 0.13 [ 0.02, 0.99 ]
Vasquez 2009 0/25 0/22 Not estimable
Subtotal (95% CI) 425 433 100.0 % 0.10 [ 0.03, 0.32 ]
Total events: 2 (Favours primaquine), 41 (Without primaquine)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.89, df = 3 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 3.86 (P = 0.00011)
5 Day 29
Shekalaghe 2007 2/51 3/52 40.0 % 0.68 [ 0.12, 3.90 ]
Smithuis 2010 0/54 8/75 20.2 % 0.08 [ 0.00, 1.38 ]
Smithuis 2010 0/69 0/78 Not estimable
Smithuis 2010 0/82 0/76 Not estimable
Smithuis 2010 0/67 0/70 Not estimable
Smithuis 2010 0/75 10/77 20.3 % 0.05 [ 0.00, 0.82 ]
Sutanto 2013 0/41 4/31 19.6 % 0.08 [ 0.00, 1.52 ]
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Study or subgroup Favours primaquine Without primaquine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Vasquez 2009 0/25 0/22 Not estimable
Subtotal (95% CI) 464 481 100.0 % 0.17 [ 0.04, 0.72 ]
Total events: 2 (Favours primaquine), 25 (Without primaquine)
Heterogeneity: Tau2 = 0.52; Chi2 = 3.96, df = 3 (P = 0.27); I2 =24%
Test for overall effect: Z = 2.42 (P = 0.015)
6 Day 36
Smithuis 2010 0/55 0/76 Not estimable
Smithuis 2010 0/70 0/74 Not estimable
Smithuis 2010 0/80 0/79 Not estimable
Smithuis 2010 0/69 0/70 Not estimable
Smithuis 2010 0/71 2/75 100.0 % 0.21 [ 0.01, 4.32 ]
Sutanto 2013 0/41 0/31 Not estimable
Vasquez 2009 0/25 0/22 Not estimable
Subtotal (95% CI) 411 427 100.0 % 0.21 [ 0.01, 4.32 ]
Total events: 0 (Favours primaquine), 2 (Without primaquine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
7 Day 43
Shekalaghe 2007 0/50 0/52 Not estimable
Smithuis 2010 0/50 1/74 50.0 % 0.49 [ 0.02, 11.80 ]
Smithuis 2010 0/62 0/75 Not estimable
Smithuis 2010 0/79 0/76 Not estimable
Smithuis 2010 0/69 1/71 50.0 % 0.34 [ 0.01, 8.27 ]
Smithuis 2010 0/71 0/69 Not estimable
Sutanto 2013 0/41 0/31 Not estimable
Vasquez 2009 0/25 0/22 Not estimable
Subtotal (95% CI) 447 470 100.0 % 0.41 [ 0.04, 3.89 ]
Total events: 0 (Favours primaquine), 2 (Without primaquine)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
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(1) Partner MQ+AS: 0.75 mg/kg PQ day 2
(2) Partner AS+AQ: 0.75 mg/kg PQ day 1
(3) Partner AL: 0.75 mg/kg PQ day 1
(4) Partner AS+MQ (fixed): 0.75 mg/kg PQ day 1
(5) Partner AS+MQ (loose): 0.75 mg/kg PQ day 1
(6) Partner DHAP: 0.75 mg/kg PQ day 1
(7) Partner DHAP: 0.75 mg/kg PQ on day 4
(8) Partner AS+MQ; 0.75 mg/kg PQ day 3
(9) Partner AS: 0.5 mg/kg PQ days 1-7
(10) Partner AS+SP: 0.75 mg/kg PQ day 4
Analysis 2.2. Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 2 Participants
with gametocytes (PCR).
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 2 Artemisinin treatment regimen: PQ versus no PQ
Outcome: 2 Participants with gametocytes (PCR)
Study or subgroup Favours primaquine Without primaquine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Day 8
El-Sayed 2007 (1) 4/48 3/46 9.0 % 1.28 [ 0.30, 5.40 ]
Eziefula 2013 (2) 25/108 13/38 24.9 % 0.68 [ 0.39, 1.18 ]
Eziefula 2013 (3) 11/104 13/38 20.9 % 0.31 [ 0.15, 0.63 ]
Eziefula 2013 (4) 15/104 14/39 23.0 % 0.40 [ 0.21, 0.75 ]
Shekalaghe 2007 (5) 8/51 36/51 22.2 % 0.22 [ 0.11, 0.43 ]
Subtotal (95% CI) 415 212 100.0 % 0.42 [ 0.26, 0.69 ]
Total events: 63 (Favours primaquine), 79 (Without primaquine)
Heterogeneity: Tau2 = 0.18; Chi2 = 9.44, df = 4 (P = 0.05); I2 =58%
Test for overall effect: Z = 3.40 (P = 0.00067)
2 Day 15
0.02 0.1 1 10 50
Favours primaquine Favours control
(Continued . . . )
85Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(. . . Continued)
Study or subgroup Favours primaquine Without primaquine Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
El-Sayed 2007 3/47 2/45 15.8 % 1.44 [ 0.25, 8.20 ]
Eziefula 2013 6/103 5/35 23.1 % 0.41 [ 0.13, 1.25 ]
Eziefula 2013 2/103 5/35 17.3 % 0.14 [ 0.03, 0.67 ]
Eziefula 2013 6/106 6/35 23.9 % 0.33 [ 0.11, 0.96 ]
Shekalaghe 2007 2/51 30/49 19.8 % 0.06 [ 0.02, 0.25 ]
Subtotal (95% CI) 410 199 100.0 % 0.27 [ 0.11, 0.70 ]
Total events: 19 (Favours primaquine), 48 (Without primaquine)
Heterogeneity: Tau2 = 0.67; Chi2 = 9.84, df = 4 (P = 0.04); I2 =59%
Test for overall effect: Z = 2.72 (P = 0.0066)
3 Day 29
Shekalaghe 2007 4/46 17/44 100.0 % 0.23 [ 0.08, 0.62 ]
Subtotal (95% CI) 46 44 100.0 % 0.23 [ 0.08, 0.62 ]
Total events: 4 (Favours primaquine), 17 (Without primaquine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.90 (P = 0.0037)
4 Day 43
Shekalaghe 2007 5/40 11/39 100.0 % 0.44 [ 0.17, 1.16 ]
Subtotal (95% CI) 40 39 100.0 % 0.44 [ 0.17, 1.16 ]
Total events: 5 (Favours primaquine), 11 (Without primaquine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.66 (P = 0.097)
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(1) Partner AS+SP: 0.75 mg/kg PQ day 4
(2) Partner AL: 0.1 mg/kg PQ day 3
(3) Partner AL: 0.4 mg/kg PQ day 3
(4) Partner AL: 0.75 mg/kg PQ day 3
(5) Partner AS+SP: 0.75 mg/kg PQ day 4
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Analysis 2.3. Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 3 Participants
with asexual parasites.
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 2 Artemisinin treatment regimen: PQ versus no PQ
Outcome: 3 Participants with asexual parasites
Study or subgroup WIth primaquine Without primaquine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Day 8
El-Sayed 2007 (1) 4/48 3/46 100.0 % 1.28 [ 0.30, 5.40 ]
Subtotal (95% CI) 48 46 100.0 % 1.28 [ 0.30, 5.40 ]
Total events: 4 (WIth primaquine), 3 (Without primaquine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
2 Day 15
El-Sayed 2007 3/47 2/45 57.7 % 1.44 [ 0.25, 8.20 ]
Shekalaghe 2007 (2) 0/53 1/53 42.3 % 0.33 [ 0.01, 8.00 ]
Subtotal (95% CI) 100 98 100.0 % 0.97 [ 0.23, 4.15 ]
Total events: 3 (WIth primaquine), 3 (Without primaquine)
Heterogeneity: Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
3 Day 29
Eziefula 2013 (3) 7/108 1/34 3.9 % 2.20 [ 0.28, 17.28 ]
Eziefula 2013 (4) 0/106 1/34 5.8 % 0.11 [ 0.00, 2.62 ]
Eziefula 2013 (5) 5/111 2/34 7.8 % 0.77 [ 0.16, 3.77 ]
Shekalaghe 2007 9/53 12/53 30.7 % 0.75 [ 0.35, 1.63 ]
Wang 2006 (6) 6/108 20/106 51.7 % 0.29 [ 0.12, 0.70 ]
Subtotal (95% CI) 486 261 100.0 % 0.54 [ 0.33, 0.88 ]
Total events: 27 (WIth primaquine), 36 (Without primaquine)
Heterogeneity: Chi2 = 5.50, df = 4 (P = 0.24); I2 =27%
Test for overall effect: Z = 2.46 (P = 0.014)
4 Day 43
Shekalaghe 2007 17/53 15/53 86.8 % 1.13 [ 0.63, 2.03 ]
Sutanto 2013 (7) 1/41 2/31 13.2 % 0.38 [ 0.04, 3.98 ]
Subtotal (95% CI) 94 84 100.0 % 1.03 [ 0.59, 1.81 ]
Total events: 18 (WIth primaquine), 17 (Without primaquine)
Heterogeneity: Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
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(1) Partner AS+SP: 0.75 mg/kg PQ day 4
(2) Partner AS+SP: 0.75 mg/kg day 4
(3) Partner AL: 0.1 mg/kg PQ day 3
(4) Partner AL: 0.4 mg/kg PQ day 3
(5) Partner AL: 0.75 mg/kg PQ day 3
(6) Partner AS: 0.38 mg/kg PQ days 1-5
(7) Partner DHAP: 0.75 mg/kg PQ day 4
Analysis 2.4. Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 4 Asexual
parasite clearance time (hrs).
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 2 Artemisinin treatment regimen: PQ versus no PQ
Outcome: 4 Asexual parasite clearance time (hrs)
Study or subgroup WIth primaquine Without primaquine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Pukrittayakamee 2004 (1) 27 63 (18) 23 69 (19) 100.0 % -6.00 [ -16.31, 4.31 ]
Total (95% CI) 27 23 100.0 % -6.00 [ -16.31, 4.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Test for subgroup differences: Not applicable
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(1) Partner AS: 0.5 mg/kg PQ days 1-7
88Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 2.5. Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 5 Haemoglobin
concentration.
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 2 Artemisinin treatment regimen: PQ versus no PQ
Outcome: 5 Haemoglobin concentration
Study or subgroup WIth primaquine Without primaquine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Day 8
Shekalaghe 2007 (1) 10.0965 (1.643201) 52 53 10.48 (1.544036) -0.39 [ -1.00, 0.22 ]
2 Day 15
Shekalaghe 2007 53 10.686 (1.16135) 53 10.73 (1.379669) -0.04 [ -0.53, 0.44 ]
3 Day 29
Shekalaghe 2007 53 11.448 (1.30371) 52 11.19 (1.3591) 0.26 [ -0.25, 0.77 ]
4 Day 43
Shekalaghe 2007 11.79718 (1.625543) 51 52 11.85 (1.273753) -0.05 [ -0.61, 0.52 ]
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Analysis 2.6. Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 6 % change in
haemoglobin concentration.
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 2 Artemisinin treatment regimen: PQ versus no PQ
Outcome: 6 % change in haemoglobin concentration
Study or subgroup WIth primaquine Without primaquine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Day 8
Shekalaghe 2007 (1) -0.0513034 (0.1411953) 51 50 0.01 (0.0922952) -0.06 [ -0.11, -0.02 ]
2 Day 15
Shekalaghe 2007 0.0148362 (0.134191) 52 50 0.04 (0.1272108) -0.03 [ -0.08, 0.02 ]
3 Day 29
Shekalaghe 2007 0.0930569 (0.1671262) 52 49 0.09 (0.1698335) 0.00 [ -0.06, 0.07 ]
4 Day 43
Shekalaghe 2007 0.1164377 (0.1546697) 50 49 0.15 (0.1973936) -0.03 [ -0.10, 0.04 ]
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Analysis 2.7. Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 7 Other adverse
effects.
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 2 Artemisinin treatment regimen: PQ versus no PQ
Outcome: 7 Other adverse effects
Study or subgroup With primaquine Without primaquine Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Headache
Sutanto 2013 (1) 13/97 18/96 0.71 [ 0.37, 1.38 ]
2 Fatigue
Sutanto 2013 13/93 11/96 1.22 [ 0.58, 2.58 ]
3 Nausea
Sutanto 2013 1/139 4/150 0.27 [ 0.03, 2.38 ]
4 Vomiting
Sutanto 2013 1/163 1/168 1.03 [ 0.07, 16.34 ]
5 Abdominal pain
Sutanto 2013 4/156 4/170 1.09 [ 0.28, 4.28 ]
6 Diarrhea
Sutanto 2013 1/163 3/172 0.35 [ 0.04, 3.35 ]
7 Pruritis
Sutanto 2013 0/170 0/177 Not estimable
8 Paresthesia
Sutanto 2013 2/170 2/161 0.95 [ 0.14, 6.64 ]
9 Unspecified
Wang 2006 (2) 7/108 6/106 1.15 [ 0.40, 3.30 ]
0.01 0.1 1 10 100
Favours control Favours primaquine
(1) Partner DHAP: 0.75 mg/kg PQ on day 4
(2) Partner AS: 0.38 mg/kg PQ days 1-5
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Analysis 2.8. Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 8 By dose:
Participants with gametocytes at day 8 (microscopy or PCR).
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 2 Artemisinin treatment regimen: PQ versus no PQ
Outcome: 8 By dose: Participants with gametocytes at day 8 (microscopy or PCR)
Study or subgroup With Primaquine Without Primaquine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 < 0.4 mg/kg PQ per day
Eziefula 2013 (1) 25/108 40/115 100.0 % 0.67 [ 0.44, 1.02 ]
Subtotal (95% CI) 108 115 100.0 % 0.67 [ 0.44, 1.02 ]
Total events: 25 (With Primaquine), 40 (Without Primaquine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.060)
2≥ 0.4 to < 0.6 mg/kg PQ per day
Eziefula 2013 (2) 11/104 40/115 89.8 % 0.30 [ 0.16, 0.56 ]
Pukrittayakamee 2004 (3) 3/27 4/23 10.2 % 0.64 [ 0.16, 2.56 ]
Subtotal (95% CI) 131 138 100.0 % 0.34 [ 0.19, 0.59 ]
Total events: 14 (With Primaquine), 44 (Without Primaquine)
Heterogeneity: Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 3.82 (P = 0.00014)
3≥ 0.6 mg/kg PQ per day
Arango 2012 (4) 1/19 3/23 1.2 % 0.40 [ 0.05, 3.57 ]
El-Sayed 2007 (5) 4/48 3/46 1.4 % 1.28 [ 0.30, 5.40 ]
Eziefula 2013 (6) 15/104 40/115 17.4 % 0.41 [ 0.24, 0.71 ]
Shekalaghe 2007 (7) 8/51 36/51 16.5 % 0.22 [ 0.11, 0.43 ]
Smithuis 2010 (8) 3/71 24/84 10.1 % 0.15 [ 0.05, 0.47 ]
Smithuis 2010 (9) 1/78 28/84 12.3 % 0.04 [ 0.01, 0.28 ]
Smithuis 2010 (10) 3/84 17/83 7.8 % 0.17 [ 0.05, 0.57 ]
Smithuis 2010 (11) 3/77 18/80 8.1 % 0.17 [ 0.05, 0.56 ]
Smithuis 2010 (12) 3/83 24/78 11.3 % 0.12 [ 0.04, 0.37 ]
Sutanto 2013 (13) 22/41 25/31 13.0 % 0.67 [ 0.48, 0.93 ]
Vasquez 2009 (14) 2/25 2/24 0.9 % 0.96 [ 0.15, 6.28 ]
Subtotal (95% CI) 681 699 100.0 % 0.29 [ 0.22, 0.37 ]
Total events: 65 (With Primaquine), 220 (Without Primaquine)
Heterogeneity: Chi2 = 41.58, df = 10 (P<0.00001); I2 =76%
Test for overall effect: Z = 9.79 (P < 0.00001)
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(1) Partner AL: 0.1 mg/kg PQ day 3; PCR
(2) Partner AL: 0.4 mg/kg PQ day 3; PCR
(3) Partner AS: 0.5 mg/kg PQ days 1-7; Microscopy
(4) Partner MQ+AS: 0.75 mg/kg PQ day 2; Microscopy
(5) Partner AS+SP: 0.75 mg/kg PQ day 4; PCR
(6) Partner AL: 0.75 mg/kg PQ day 3; PCR
(7) Partner AS+SP: 0.75 mg/kg PQ day 4; PCR
(8) Partner AS+AQ: 0.75 mg/kg PQ day 1; Microscopy
(9) Partner AL: 0.75 mg/kg PQ day 1; Microscopy
(10) Partner AS+MQ (fixed): 0.75 mg/kg PQ day 1; Microscopy
(11) Partner AS+MQ (loose): 0.75 mg/kg PQ day 1; Microscopy
(12) Partner DHAP: 0.75 mg/kg PQ day 1; Microscopy
(13) Partner DHAP: 0.75 mg/kg PQ day 4; Microscopy
(14) Partner AS+MQ: 0.75 mg/kg PQ day 3; Microscopy
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Analysis 2.9. Comparison 2 Artemisinin treatment regimen: PQ versus no PQ, Outcome 9 By schedule:
Participants with gametocytes at day 8 (microscopy or PCR).
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 2 Artemisinin treatment regimen: PQ versus no PQ
Outcome: 9 By schedule: Participants with gametocytes at day 8 (microscopy or PCR)
Study or subgroup With primaquine Without primaquine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Single dose day 1 or 2
Arango 2012 (1) 1/19 3/23 2.4 % 0.40 [ 0.05, 3.57 ]
Smithuis 2010 (2) 3/71 24/84 19.8 % 0.15 [ 0.05, 0.47 ]
Smithuis 2010 (3) 3/84 17/83 15.4 % 0.17 [ 0.05, 0.57 ]
Smithuis 2010 (4) 3/77 18/80 15.9 % 0.17 [ 0.05, 0.56 ]
Smithuis 2010 (5) 1/78 28/84 24.2 % 0.04 [ 0.01, 0.28 ]
Smithuis 2010 (6) 3/83 24/77 22.4 % 0.12 [ 0.04, 0.37 ]
Subtotal (95% CI) 412 431 100.0 % 0.13 [ 0.07, 0.22 ]
Total events: 14 (With primaquine), 114 (Without primaquine)
Heterogeneity: Chi2 = 3.08, df = 5 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 7.46 (P < 0.00001)
2 Single dose day 3 or 4
El-Sayed 2007 (7) 4/48 3/46 2.4 % 1.28 [ 0.30, 5.40 ]
Eziefula 2013 (8) 25/108 14/39 16.0 % 0.64 [ 0.37, 1.11 ]
Eziefula 2013 (9) 15/104 13/38 14.8 % 0.42 [ 0.22, 0.80 ]
Eziefula 2013 (10) 11/104 13/38 14.8 % 0.31 [ 0.15, 0.63 ]
Shekalaghe 2007 (11) 8/51 36/51 28.1 % 0.22 [ 0.11, 0.43 ]
Sutanto 2013 (12) 22/41 25/31 22.2 % 0.67 [ 0.48, 0.93 ]
Vasquez 2009 (13) 2/25 2/24 1.6 % 0.96 [ 0.15, 6.28 ]
Subtotal (95% CI) 481 267 100.0 % 0.47 [ 0.37, 0.59 ]
Total events: 87 (With primaquine), 106 (Without primaquine)
Heterogeneity: Chi2 = 14.36, df = 6 (P = 0.03); I2 =58%
Test for overall effect: Z = 6.34 (P < 0.00001)
3 Multiple dose days 1 to 7
Pukrittayakamee 2004 (14) 3/27 4/23 100.0 % 0.64 [ 0.16, 2.56 ]
Subtotal (95% CI) 27 23 100.0 % 0.64 [ 0.16, 2.56 ]
Total events: 3 (With primaquine), 4 (Without primaquine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Chi2 = 19.07, df = 2 (P = 0.00), I2 =90%
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(1) Partner MQ+AS: 0.75 mg/kg PQ day 2; Microscopy
(2) Partner ASAQ: 0.75 mg/kg PQ; Microscopy
(3) Partner AS+MQ (fixed dose): 0.75 mg/kg; Microscopy
(4) Partner AS+MQ (loose): 0.75 mg/kg PQ; Microscopy
(5) Partner AL: 0.75 mg/kg PQ; Microscopy
(6) Partner DHAP: 0.75 mg/kg PQ; Microscopy
(7) Partner AS+SP: 0.75 mg/kg PQ day 4; PCR
(8) Partner AL: 0.1 mg/kg PQ day 3: PCR
(9) Partner AL: 0.75 mg/kg PQ day 3: PCR
(10) Partner AL: 0.4 mg/kg PQ day 3: PCR
(11) Partner AS+SP: PQ 0.75 mg/kg day 4; PCR
(12) Partner DHAP: 0.75 mg/kg PQ day 3; Microscopy
(13) Partner AS+MQ: 0.75 mg/kg day 3; Microscopy
(14) Partner AS: 0.5 mg/kg PQ days 1-7; Microscopy
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Analysis 3.1. Comparison 3 PQ versus no PQ; gametocytes at day 8 (microscopy or PCR); stratified by non-
artemisinin versus artemisinin regimen, Outcome 1 Participants with gametocytes at day 8 (microscopy or
PCR).
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 3 PQ versus no PQ; gametocytes at day 8 (microscopy or PCR); stratified by non-artemisinin versus artemisinin regimen
Outcome: 1 Participants with gametocytes at day 8 (microscopy or PCR)
Study or subgroup with PQ without PQ Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Non-artemisinin-based partner drug
Arango 2012 (1) 7/20 11/20 5.7 % 0.64 [ 0.31, 1.30 ]
Chen 1993a (2) 0/6 6/6 1.1 % 0.08 [ 0.01, 1.12 ]
Kamtekar 2004 (3) 7/24 16/22 5.9 % 0.40 [ 0.20, 0.79 ]
Kolaczinski 2012 (4) 24/36 37/43 7.9 % 0.77 [ 0.60, 1.01 ]
Kolaczinski 2012 (5) 27/70 52/67 7.6 % 0.50 [ 0.36, 0.69 ]
Ledermann 2006 (6) 2/28 3/16 2.4 % 0.38 [ 0.07, 2.04 ]
Ledermann 2006 (7) 0/28 2/16 0.9 % 0.12 [ 0.01, 2.30 ]
Pukrittayakamee 2004 (8) 17/30 5/15 5.4 % 1.70 [ 0.78, 3.71 ]
Pukrittayakamee 2004 (9) 9/37 5/15 4.8 % 0.73 [ 0.29, 1.82 ]
Subtotal (95% CI) 279 220 41.7 % 0.63 [ 0.44, 0.88 ]
Total events: 93 (with PQ), 137 (without PQ)
Heterogeneity: Tau2 = 0.11; Chi2 = 17.11, df = 8 (P = 0.03); I2 =53%
Test for overall effect: Z = 2.69 (P = 0.0072)
2 Artemisinin-based partner drug
Arango 2012 (10) 1/19 3/23 1.6 % 0.40 [ 0.05, 3.57 ]
El-Sayed 2007 (11) 4/48 3/46 2.9 % 1.28 [ 0.30, 5.40 ]
Eziefula 2013 (12) 25/108 13/38 6.5 % 0.68 [ 0.39, 1.18 ]
Eziefula 2013 (13) 11/104 13/38 5.7 % 0.31 [ 0.15, 0.63 ]
Eziefula 2013 (14) 15/104 14/39 6.2 % 0.40 [ 0.21, 0.75 ]
Pukrittayakamee 2004 (15) 3/27 4/23 3.0 % 0.64 [ 0.16, 2.56 ]
Shekalaghe 2007 (16) 8/51 36/51 6.0 % 0.22 [ 0.11, 0.43 ]
Smithuis 2010 (17) 3/71 24/84 3.8 % 0.15 [ 0.05, 0.47 ]
Smithuis 2010 (18) 3/77 18/80 3.7 % 0.17 [ 0.05, 0.56 ]
Smithuis 2010 (19) 3/84 17/83 3.7 % 0.17 [ 0.05, 0.57 ]
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(. . . Continued)
Study or subgroup with PQ without PQ Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Smithuis 2010 (20) 1/78 28/84 1.9 % 0.04 [ 0.01, 0.28 ]
Smithuis 2010 (21) 3/83 24/78 3.8 % 0.12 [ 0.04, 0.37 ]
Sutanto 2013 (22) 22/41 25/31 7.6 % 0.67 [ 0.48, 0.93 ]
Vasquez 2009 (23) 2/25 2/24 2.0 % 0.96 [ 0.15, 6.28 ]
Subtotal (95% CI) 920 722 58.3 % 0.33 [ 0.21, 0.52 ]
Total events: 104 (with PQ), 224 (without PQ)
Heterogeneity: Tau2 = 0.44; Chi2 = 44.82, df = 13 (P = 0.00002); I2 =71%
Test for overall effect: Z = 4.79 (P < 0.00001)
Total (95% CI) 1199 942 100.0 % 0.43 [ 0.32, 0.58 ]
Total events: 197 (with PQ), 361 (without PQ)
Heterogeneity: Tau2 = 0.29; Chi2 = 74.95, df = 22 (P<0.00001); I2 =71%
Test for overall effect: Z = 5.45 (P < 0.00001)
Test for subgroup differences: Chi2 = 4.85, df = 1 (P = 0.03), I2 =79%
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(1) Partner AQ+SP: 0.75 mg/kg PQ day 2; microscopy
(2) Partner MQ: 0.75 mg/kg PQ day 1; microscopy
(3) Partner CQ or (CQ+SP): 0.75 mg/kg PQ day 4; microscopy
(4) Partner SP: 0.5 mg/kg PQ day 1; microscopy
(5) Partner CQ: 0.5 mg/kg PQ day 3; microscopy
(6) Partner CQ+SP: 0.75 mg/kg PQ day 1; microscopy
(7) Partner CQ+SP: 0.75 mg/kg PQ day 3; microscopy
(8) Partner QN: 0.25 mg/kg PQ days 1-7; microscopy
(9) Partner QN: 0.5 mg/kg PQ days 1-7; microscopy
(10) Partner MQ+AS: 0.75 mg/kg PQ day 2; microscopy
(11) Partner AS+SP: 0.75 mg/kg PQ day 4; PCR
(12) Partner AL: 0.1 mg/kg PQ day 3; PCR
(13) Partner AL: 0.4 mg/kg PQ day 3: PCR
(14) Partner AL: 0.75 mg/kg PQ day 3: PCR
(15) Partner AS: 0.5 mg/kg PQ days 1-7; microscopy
(16) Partner AS+SP: PQ 0.75 mg/kg day 4; PCR
(17) Partner AS+AQ; 0.75 mg/kg PQ day 1; microscopy
(18) Partner AS+MQ (loose); 0.75 mg/kg PQ day 1; microscopy
(19) Partner AS+MQ (fixed); 0.75 mg/kg PQ day 1; microscopy
(20) Partner AL; 0.75 mg/kg PQ day 1; microscopy
(21) Partner DHAP; 0.75 mg/kg PQ day 1; microscopy
(22) Partner DHAP; 0.75 mg/kg PQ day 4; microscopy
(23) Partner AS+MQ; 0.75 mg/kg PQ day 3; microscopy
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Analysis 4.1. Comparison 4 PQ versus other 8AQ, Outcome 1 Participants with gametocytes on day 8.
Review: Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission
Comparison: 4 PQ versus other 8AQ
Outcome: 1 Participants with gametocytes on day 8
Study or subgroup Bulaquine Primaquine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gogtay 2004 (1) 1/9 10/13 23.8 % 0.14 [ 0.02, 0.94 ]
Gogtay 2006 (2) 19/59 20/31 76.2 % 0.50 [ 0.32, 0.79 ]
Total (95% CI) 68 44 100.0 % 0.41 [ 0.26, 0.66 ]
Total events: 20 (Bulaquine), 30 (Primaquine)
Heterogeneity: Chi2 = 1.86, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 3.74 (P = 0.00018)
Test for subgroup differences: Not applicable
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(1) Partner QN+Doxycycline: 0.75 mg/kg PQ or 75mg BQ day 4
(2) Partner QN+docycycline: 0.75mg/kg PQ or 75mg BQ day 4
A D D I T I O N A L T A B L E S
Table 1. G6PD status, partner drugs, gametocyte status at onset, and PQ dose and treatment schedule
Compara-
tor
Trial Compari-
son
Place G6PD sta-
tus
Parasite
species
Partner or
alternative
drug
Propor-
tion with
game-
tocytes at
on-
set (by mi-
croscopy
unless
noted)
PQ day(s)
*
Target PQ
dose per
day
Non-artemisinin partner
CQ or
(CQ+SP)
Kamtekar
2004
a India
(Mumbai)
Not
screened
Pf only CQ days 1
to 3 or
CQ days 1
to 3 + SP
day 1
100%
(within 3
days)
(N = 46)
day 4 45 mg
(~0.75
mg/kg)
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Table 1. G6PD status, partner drugs, gametocyte status at onset, and PQ dose and treatment schedule (Continued)
Khoo
1981
Malaysia
(Sabah)
Only defi-
cient
(method:
Brewer’s
methaemoglobin
reduction
test)
Pf, Pv or
mixed
CQ days 1
to 3
Not
reported
days 1 to 3 25 mg
(~0.42
mg/kg)
Kolaczin-
ski
2012
a Pakistan (3
Afghan
refugee
camps)
Not
reported
Pf only CQ days 1
to 3
17.8%
(N = 152)
day 3 0.5
mg/kg
Leder-
mann
2006
a Indonesia
(Central
Java)
Only non-
deficient
(method:
semiquan-
titative
glucose-6-
phosphate
dehydro-
genase
(G6PD)
assay)
Pf only CQ days 1
to 3 + SP
day 1
Not
reported
(N = 60)
day 1 45 mg
(~0.75
mg/kg)
Leder-
mann
2006
b Indonesia
(Central
Java)
Only non-
deficient
(method:
semiquan-
titative
glucose-6-
phosphate
dehydro-
genase
(G6PD)
assay)
Pf only CQ days 1
to 3 + SP
day 1
Not
reported
(N = 60)
day 3 45 mg
(~0.75
mg/kg)
SP Kolaczin-
ski
2012
b Pakistan (2
Afghan
refugee
camps)
Not
reported
Pf only SP day 1 27.1%
(N = 85)
day 1 0.5 mg/kg
AQ+SP Arango
2012
a Colombia Not
reported
Pf only AQ days 1
to 3 + SP
day 1
22.5%
(N = 40)
day 2 0.75 mg/
kg
MQ or
(MQ+SP)
Chen
1993a
China Not
reported
Pf only MQ day 1 100%
(N = 12)
day 1 45 mg (~0.
75 mg/kg)
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Table 1. G6PD status, partner drugs, gametocyte status at onset, and PQ dose and treatment schedule (Continued)
Chen
1994
China
(Hainan
province)
Not
reported
Pf only MQ day 1 100%
(N = 18)
day 1 45 mg
(~0.75
mg/kg)
Singhasi-
vanon
1994
Thailand
(Bangkok)
Not
reported
Pf only MQ+SP
fixed day 1
Not
reported
(N = 18)
day 1 0.75 mg/
kg
QN Kamtekar
2004
b India
(Mumbai)
Not
screened
Pf only QN i.v.
days 1 to 2
and orally
days 1 to 7
100%
(within 3
days)
(N = 43)
day 8 45 mg
(~0.75
mg/kg)
Pukrit-
tayakamee
2004
a Thailand Pa-
tients with
G6PD de-
ficiency
were
excluded
from get-
ting PQ
(method
not
reported)
Pf only QN days 1
to 7
18.6% (N
= 59)
days 1 to 7 0.25 mg
base/kg
Pukrit-
tayakamee
2004
b Thailand Pa-
tients with
G6PD de-
ficiency
were
excluded
from get-
ting PQ
(method
not
reported)
Pf only QN days 1
to 7
22.4%
(N = 67)
days 1 to 7 0.5 mg
base/kg
Artemisinin-based partner
AS or ACT Arango
2012
b Colombia Not
reported
Pf only AS+MQ
days 1 to 3
17.1%
(N = 42)
day 2 0.75 mg/
kg
El-Sayed
2007
Sudan
(east)
Not
reported
Pf only AS+SP
days 1 to 3
3.8%
(N = 104)
11.6%
PCR
(N = 95)
day 4 0.75 mg/
kg
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Table 1. G6PD status, partner drugs, gametocyte status at onset, and PQ dose and treatment schedule (Continued)
Eziefula
2013
a Uganda Patients
without
nor-
mal G6PD
were
excluded
(method
fluores-
ence spot
test)
Pf only AL days 1
to 3
24.3% (N
= 115)
86.7%
PCR (N =
113)
day 3 0.1 mg/kg
Eziefula
2013
b Uganda Patients
without
nor-
mal G6PD
were
excluded
(method
fluores-
ence spot
test)
Pf only AL days 1
to 3
20.4% (N
= 113)
78.7%
PCR (N =
108)
day 3 0.4 mg/kg
Eziefula
2013
c Uganda Patients
without
nor-
mal G6PD
were
excluded
(method
fluores-
ence spot
test)
Pf only AL days 1
to 3
22.4% (N
= 116)
82.0%
PCR (N =
111)
day 3 0.75 mg/
kg
Pukrit-
tayakamee
2004
c Thailand Pa-
tients with
G6PD de-
ficiency
were
excluded
from get-
ting PQ
(method
not
reported)
Pf only AS days 1
to 7
26.0% (N
= 50)
days 1 to 7 0.5 mg
base/kg
Shekalaghe
2007
Tanzania
(North
east)
Screened
and all in-
cluded
(method:
Pf only AS+SP
days 1 to 3
22.6% (N
= 106)
87.7%
day 4 0.75 mg/
kg
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Table 1. G6PD status, partner drugs, gametocyte status at onset, and PQ dose and treatment schedule (Continued)
de-
tection of
single nu-
cleotide
polymor-
phisms
in
the human
G6PD
gene
(G202A,
A376G)
by a simple
high
through-
put
PCR using
sequence
specific
oligo-
nucleotide
probes
(SSOPs)
and ELISA
testing)
PCR
(N = 106)
Smithuis
2010
a Myanmar
(3 states)
Not
screened
Pf or
mixed
AS+AQ
days 1 to 3
34%
(N = 155)
day 1 0.75 mg/
kg
Smithuis
2010
b Myanmar
(3 states)
Not
screened
Pf or
mixed
AL days 1
to 3
33%
(N = 152)
day 1 0.75 mg/
kg
Smithuis
2010
c Myanmar
(3 states)
Not
screened
Pf or
mixed
AS+MQ
fixed dose
days 1 to 3
30%
(N = 169)
day 1 0.75 mg/
kg
Smithuis
2010
d Myanmar
(3 states)
Not
screened
Pf or
mixed
AS days 1
to 3 + MQ
day 1 loose
29%
(N = 161)
day 1 0.75 mg/
kg
Smithuis
2010
e Myanmar
(3 states)
Not
screened
Pf or
mixed
DHAP
days 1 to 3
38%
(N = 161)
day 1 0.75 mg/
kg
Sutanto
2013
Indonesia
(south
Sumatra)
Screened
and only
normals
included
(method:
qualitative
Pf only DHAP
days 1 to 3
20.6% (on
day 3)
(N = 349)
day 3 0.75 mg/
kg
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Table 1. G6PD status, partner drugs, gametocyte status at onset, and PQ dose and treatment schedule (Continued)
test)
Vasquez
2009
Colom-
bia (Antio-
quia)
Not
reported
Pf only AS+MQ
days 1 to 3
(MQ only
on day
2 for chil-
dren < 6)
20.0%
(N = 50)
day 3 45 mg
(~0.75
mg/kg)
Wang
2006
Gabon Not
reported
Pf AS i.m.
days 1 to 5
Not
reported
(N = 204)
days 1 to 5 22.5 mg
(~0.38
mg/kg)
Comparison of different 8AQ
PQ versus
Bulaquine
Gogtay
2004
India
(Mumbai)
Only non-
deficient
(method:
not stated)
Pf QN
+ doxycy-
cline days
1 to 7
+ BQ day 4
100%
(N = 22)
day 4 45 mg
(~0.75
mg/kg)
Gogtay
2006
India Only non-
deficient
(method:
not stated)
Pf QN
+ doxycy-
cline days
1 to 7
+ BQ day 4
100%
(N = 93)
day 4 45 mg
(~0.75
mg/kg)
* first day of any treatment = day 1
i.v. = intravenous injection; i.m. = intramuscular injection; Pf = P. falciparum; Pv = P. vivax
Table 2. AUC of gametocyte density over time, days 1 to 15 after treatment
Other
malaria
treatment
type
Trial Malaria
treatment
Dose PQ
mg/kg
AUC with
PQ days 1
to 15
AUC
without
PQ days 1
to 15
% reduc-
tion AUC
days 1 to
15
log(10)
AUC with
PQ days 1
to 15
log(10)
AUC
without
PQ days1
to 15
% reduc-
tion log
(10)
AUC days
1 to 15
Non-
artemisinin-
based
Kolaczin-
ski
2012
a: CQ 0.5 485.26 4266.61 88.6 2.69 3.63 26.0
Kolaczin-
ski
2012
b: SP 0.5 924.87 5964.77 84.5 2.97 3.78 21.4
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Table 2. AUC of gametocyte density over time, days 1 to 15 after treatment (Continued)
Artemisinin-
based
Shekalaghe
2007
AS+SP 0.75 40.15 65.06 38.3 1.60 1.81 11.6
Smithuis
2010
a: AS+AQ 0.75 140.35 428.51 67.3 2.15 2.63 18.4
Smithuis
2010
b: AL 0.75 196.24 242.86 19.2 2.29 2.39 3.9
Smithuis
2010
c: AS+MQ
fixed
0.75 237.78 510.03 53.4 2.38 2.71 12.2
Smithuis
2010
d: AS+MQ
loose
0.75 183.51 293.28 37.4 2.26 2.47 8.3
Smithuis
2010
e: DHAP 0.75 295.24 709.60 58.4 2.47 2.85 13.4
Sutanto
2013
DHAP 0.75 1252.48 2355.84 46.8 3.10 3.37 8.1
Vasquez
2009
AS+MQ 0.75 500.40 305.67 -63.7 2.70 2.49 -8.6
Table 3. AUC of gametocyte density over time, days 1 to 29 after treatment
Other
malaria
treatment
type
Trial Malaria
treatment
Dose PQ
mg/kg
AUC with
PQ days 1
to 29
AUC
without
PQ days 1
to 29
% reduc-
tion AUC
days 1 to
29
log(10)
AUC with
PQ days 1
to 29
log(10)
AUC
without
PQ days 1
to 29
% reduc-
tion log
(10)
AUC days
1 to 29
Non-
artemisinin-
based
Kolaczin-
ski
2012
a: CQ 0.5 732.98 8777.24 91.7 2.87 3.94 27.3
Kolaczin-
ski
2012
b: SP 0.5 2111.55 12847.37 83.6 3.32 4.11 19.1
Artemisinin-
based
Shekalaghe
2007
AS+SP 0.75 40.30 87.69 54.0 1.61 1.94 17.4
Smithuis
2010
a: AS+AQ 0.75 141.08 649.46 78.3 2.15 2.81 23.6
Smithuis
2010
b: AL 0.75 197.57 318.23 37.9 2.3 2.5 8.3
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Table 3. AUC of gametocyte density over time, days 1 to 29 after treatment (Continued)
Smithuis
2010
c: AS+MQ
fixed
0.75 240.79 535.40 55.0 2.38 2.73 12.7
Smithuis
2010
d: AS+MQ
loose
0.75 183.51 321.96 43.0 2.26 2.51 9.7
Smithuis
2010
e: DHAP 0.75 307.14 952.93 67.8 2.49 2.98 16.5
Sutanto
2013
DHAP 0.75 1363.10 3108.05 56.1 3.13 3.49 10.3
Vasquez
2009
AS+MQ 0.75 526.40 349.04 -50.8 2.72 2.54 -7.0
Table 4. AUC of gametocyte density over time, days 1 to 43 after treatment
Other
malaria
treatment
type
Trial Malaria
treatment
Dose PQ AUC with
PQ days 1
to 43
AUC
without
PQ days 1
to 43
% reduc-
tion AUC
days 1 to
43
log(10)
AUC with
PQ days 1
to 43
log(10)
AUC
without
PQ days 1
to 43
% reduc-
tion log
(10)
AUC days
1 to 43
Non-
artemisinin-
based
Kolaczin-
ski
2012
CQ 0.5 71.02 279.13 74.6 1.85 2.45 24.3
SP 0.5 85.47 445.65 80.8 1.93 2.65 27.1
Artemisinin-
based
Shekalaghe
2007
AS+SP 0.75 1.16 3.22 64.1 0.06 0.51 87.5
Smithuis
2010
AS+AQ 0.75 3.36 19.29 82.6 0.53 1.29 59.1
AL 0.75 4.70 8.12 42.1 0.67 0.91 26.1
AS+MQ
fixed
0.75 5.73 12.75 55.0 0.76 1.11 31.4
AS+MQ
loose
0.75 4.37 7.74 43.5 0.64 0.89 27.9
DHAP 0.75 7.38 25.49 71.1 0.87 1.41 38.3
Sutanto
2013
DHAP 0.75 32.73 83.15 60.6 1.51 1.92 21.1
Vasquez
2009
AS+MQ 0.75 12.53 8.87 -41.3 1.10 0.95 -15.8
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A P P E N D I C E S
Appendix 1. Search strategy
Search set CIDG SR1 CENTRAL MEDLINE2 EMBASE2 LILACS2
1 malaria MALARIA, FALCI-
PARUM/
DRUG THERAPY
MALARIA, FALCI-
PARUM/
DRUG THERAPY
MALARIA
FALCIPARUM/
DRUG THERAPY
Malaria AND falci-
parum
2 primaquine OR pa-
maquine OR plasmo-
quineORplasmochin
OR plasmocide OR
rhodoquine OR plas-
mocid OR quinocine
OR pentaquine OR
isopentaquine OR
bulaquine OR tafeno-
quine OR 8-amino-
quinoline*
Malaria AND falci-
parum ti, ab
Malaria AND falci-
parum ti, ab
Malaria AND falci-
parum ti, ab
primaquine OR pa-
maquine OR plasmo-
quineORplasmochin
OR plasmocide OR
rhodoquine OR plas-
mocid OR quinocine
OR pentaquine OR
isopentaquine OR
bulaquine OR tafeno-
quine OR 8-amino-
quinoline$
3 1 and 2 1 or 2 1 or 2 1 or 2 1 and 2
4 - PRIMAQUINE/
ADMIN-
ISTRATION AND
DOSAGE/ THERA-
PEUTIC USE
PRIMAQUINE/
ADMIN-
ISTRATION AND
DOSAGE/ THERA-
PEUTIC USE
PRIMAQUINE -
5 - primaquine OR pa-
maquine OR plasmo-
quineORplasmochin
OR plasmocide OR
rhodoquine OR plas-
mocid OR quinocine
OR pentaquine OR
isopentaquine OR
bulaquine OR tafeno-
quine OR 8-amino-
quinoline* ti, ab
primaquine OR pa-
maquine OR plasmo-
quineORplasmochin
OR plasmocide OR
rhodoquine OR plas-
mocid OR quinocine
OR pentaquine OR
isopentaquine OR
bulaquine OR tafeno-
quine OR 8-amino-
quinoline* ti, ab
primaquine OR pa-
maquine OR plasmo-
quineORplasmochin
OR plasmocide OR
rhodoquine OR plas-
mocid OR quinocine
OR pentaquine OR
isopentaquine OR
bulaquine OR tafeno-
quine OR 8-amino-
quinoline* ti, ab
-
6 - 4 or 5 4 or 5 4 or 5 -
7 - 3 and 6 3 and 6 3 and 6 -
8 - - Limit 7 to Humans Limit 7 to Human -
1Cochrane Infectious Diseases Group Specialized Register.
2Search terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Lefebvre
2011); Upper case: MeSH or EMTREE heading; Lower case: free text term.
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WH A T ’ S N E W
Last assessed as up-to-date: 10 February 2014.
Date Event Description
24 June 2014 New citation required and conclusions have changed We conducted a new search and added new studies. We
stratified the analysis by dose of primaquine
24 June 2014 New search has been performed We stratified the analysis by dose or primaquine and added
new studies. We clarified the excluded studies
C O N T R I B U T I O N S O F A U T H O R S
This edition: PMG and HG added the new studies. PG helped rewrite the review. All authors contributed to the interpretation of the
results and the conclusions drawn.
First edition: Two authors (PMG and HG) independently screened all abstracts, applied inclusion criteria, and extracted data. PG
helped structure the review, and contributed to the logic framework of the SOF tables. All authors contributed to the writing of the
review, the interpretation of the results and the conclusions drawn.
D E C L A R A T I O N S O F I N T E R E S T
We have no affiliations with or involvement in any organization or entity with a direct financial interest in the subject matter of the
review (for example, employment, consultancy, stock ownership, honoraria, expert testimony).
This review and the salary of PG is supported by a DFID grant aimed at ensuring the best possible systematic reviews, particularly
Cochrane Reviews, are completed on topics relevant to the poor in low- and middle-income countries. DFID does not participate in
the selection of topics, in the conduct of the review or in the interpretation of findings.
None of the authors are investigators on any of the included trials.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
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External sources
• Department for International Development, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1) After reading the trials, we added several new outcomes and modified some outcomes; we deleted two outcomes.
Changes to primary outcomes:
• Proportion of participants with gametocytes: we added: by microscopy and PCR.
• We added: Proportion of participants infectious.
• We included : Gametocyte density (by microscopy and PCR).
• ADDED: Gametocyte clearance time (also called duration of gametocyte carriage).
We arranged the primary outcomes to capture the three categories: transmission intensity, infectiousness and potential infectiousness.
Changes to secondary outcomes:
• We deleted AUC of asexual parasite density over time. We did not identify any relevant data.
• We added asexual clearance time.
Changes to Adverse events:
• We deleted: All adverse events (data reported was minimal and not in a form that was easily summarised. The main question is
whether there are serious adverse events).
• We modified haemolysis or drop in haemoglobin or PCV (as assessed/defined in each trial) by deleting reference to G6PD since
these outcomes occur in non-G6PD people too. We also added PCV since this was used in some trials as a measure of anaemia.
2) In the first version of the review, we deleted the objective: “To compare the effects of different doses and schedules of PQ given to
reduce infectiousness” and we modified the definition of control in comparisons accordingly. We only included controls without PQ.
We deleted the comparison of different doses of PQ with identical other treatment regimens since it does not answer the important
question of whether adding PQ is effective.We included one trial with two arms using different doses of PQ with same other treatment
regimens as two separate arms within the same comparison.
In the update, we reversed this decision.
3) We planned to use the following comparisons described in the protocol:
• CQ (with and without PQ, or with different doses of PQ)
• SP (with and without PQ, or with different doses of PQ)
• CQ plus sulfadoxine + pyrimethamine (with and without PQ, or with different doses of PQ)
• Artemisinin derivatives (with and without PQ, or with different doses of PQ)
• Other drugs (with and without PQ, or with different doses of PQ)
In the review, we changed the groups, added some, and combined some for the following reasons:
a) some trials combined two types of malaria treatment regimens, not distinguishing the patients who received each one (for example,
CQ or CQ plus SP).
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b) there were many different artemisinin derivatives and combinations tested, with few trials of each, so these were grouped within the
same comparison. We also grouped combinations of an artemisinin derivative with SP here.
3) There were no cluster-RCTs so we deleted how we would manage them from the Methods. If we include any cluster-RCTs in future
editions, we will check that trials have correctly adjusted for clustering and, if not, attempt to make this adjustment. When the analyses
have not adjusted for clustering, we will attempt to adjust the results for clustering by multiplying the standard errors of the estimates
by the square root of the design effect, where the design effect is calculated as DEff=1+(m-1)*ICC. This assumes that the necessary
information is reported, the average cluster size (m) and the intra-cluster correlation coefficient (ICC).
4) We intended a sensitivity analysis to investigate the robustness of the results to the quality (risk of bias) components, but were unable
to do so as there were insufficient trials. If appropriate and necessary, we will conduct sensitivity analysis on cluster-RCTs using a range
of estimates for the ICC to see if clustering could influence the individual trial’s result.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antimalarials [∗administration & dosage]; Artemisinins [therapeutic use]; Chloroquine [therapeutic use]; Drug Combinations; Glu-
cosephosphate Dehydrogenase Deficiency [diagnosis]; Malaria, Falciparum [∗prevention & control; transmission]; Mefloquine [ther-
apeutic use]; Plasmodium falciparum [∗drug effects]; Primaquine [∗administration & dosage]; Pyrimethamine; Quinine [therapeutic
use]; Randomized Controlled Trials as Topic; Sulfadoxine
MeSH check words
Humans
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